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Abstract
Consumption of n-3 long chain polyunsaturated fatty acids (n-3 LCPUFA) is associated
with higher n-3 LCPUFA status in the circulation, which has in turn has been
associated with a number of health benefits in humans. n-3 LCPUFA cardiovascular
health benefits are well known and there is emerging evidence for mental health
benefits. Limited studies have indicated that there is a positive correlation between an
improvement of Ultra-High-Risk (UHR) of developing psychosis symptoms and the
intake of n-3 LCPUFA; however there is a need for further studies involving larger
randomized-controlled studies since the previous work was conducted with low
numbers. These studies have also shown that people classified as UHR of developing
psychosis have reduced n-3 PUFA, n-6 PUFA and n-3 index. What is unknown is the
molecular phospholipid data and how that data may relate to developing psychosis and
also how this is affected by n-3 LCPUFA supplementation.

The first aim of this thesis was to develop an automated high-throughput technique for
the analysis of n-3 index, fatty acids and molecular phospholipid profile in human
erythrocytes. To achieve this a robotic liquid handling workstation (Hamilton Star) was
utilized for lipid extraction from erythrocytes that allows extraction of 186 samples per
day. Advances in mass spectrometry instrumentation have enabled increased
sensitivity in the detection, accurate characterization, identification, and quantitation of
membrane lipid species from human erythrocytes samples. The high throughput
method described here offers considerable advantages in terms of simplicity and
throughput compared to gas chromatography flame ionization method and provides
additional information on molecular phospholipid concentrations.

The second aim of this thesis was to compare n-3 index, fatty acids and molecular
phospholipid species from erythrocytes of people with UHR (n =285) with age-matched
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healthy controls (n =120). It was hypothesized that the n-3 index, erythrocyte fatty acids
and phospholipid molecular species differ between the UHR of developing psychosis
and the healthy groups (The UHR of developing psychosis group having a lower n-3
index than the healthy group). A significant decrease in levels of eicosapentaenoic acid
(EPA, 29.3%), docosahexaenoic acid (DHA, 27.2%), arachidonic acid (AA, 15.8%) and
n-3 index (26.9%) was found in the erythrocytes of the UHR group compared to healthy
controls. Additionally, at a lipid class level, the UHR group had higher concentrations of
sphingomyelin (16%) and lower concentrations phosphatidylethanolamine (46%)
compared to healthy group; these differences may represent a promising prodromal
risk biomarker in the UHR population to aid clinical diagnosis.

The third aim of this thesis was to evaluate the effect of n-3 LCPUFA supplementation
on erythrocyte membranes from individuals at UHR of developing psychosis. It was
hypothesized that n-3 LCPUFA supplementation would alter n-3 status in these
individuals. n-3 LCPUFA supplementation significantly increased the 20:5, 22:6 and
most of 22:5 fatty acid containing lipid species, with a range of increased levels of 12%50%. Furthermore, n-3 LCPUFA supplementation significantly decreased 18:2, 20:3,
20:4, 22:4 fatty acid containing lipid species, with a range of decreased levels of 7.4%43%. Additionally, the omega-3 index was significantly increased by 37% after 6
months of receiving n-3 LCPUFA capsules. The response of n-3 index to n-3 LCPUFA
supplementation was much lower than previous studies that administered EPA+DHA
for up to 12 months; this is likely a consequence of low compliance (< 44%) in both
groups.

People at UHR of developing psychosis have a 30% chance of developing the illness
within three years. The final aim of this thesis was to identify potential biomarkers, i.e.,
n-3 index, fatty acids and/or molecular phospholipid species that may be a predictor of
transition to psychosis for people at UHR. Results showed that there were no
3

differences in the omega-3 index, fatty acids or molecular phospholipid species
observed between those with UHR that did and did not transition to psychosis. This
suggests that the n-3 index, fatty acids or molecular phospholipid species are not
useful markers to predict transition to psychosis in people at UHR of developing
psychosis.

This thesis presents an optimized method that allows the identification and
quantification of the n-3 index, fatty acids and molecular phospholipid species in
erythrocytes; using automated extraction and ESI-MS analysis. The throughput ESI-MS
method does however, have limitation, the double bond location cannot be determined,
e.g., this method is unable to determine whether 22:5 DPA is 22:5n-3 or 22:5n-6 or if
18:1 is 18:1n-9 or 18:1n-7. A significant outcome of this thesis was identifying that
people at UHR of developing psychosis have lower n-3 index, fatty acids and
phospholipid levels compared to healthy subjects. However, none of the assessed
lipids i.e., n-3 index, fatty acids and molecular phospholipid species were able to
predict the transition to psychosis in those at UHR of psychosis. Given the numerous
differences in lipid levels between those at UHR of psychosis and healthy controls, it
could be argued that the lipid pathology commences prior to the development of
psychosis. The lack of lipid differences between those at UHR that transitioned to
psychosis and those at UHR that did not suggests that another trigger is required for
psychosis to develop.
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Chapter 1
Literature Review
1.1 Lipids
The term “Lipids” was initially defined as organic compounds that are soluble in organic
solvents but insoluble in water, and that are commonly present in or derived from the
living organisms (Christie & Han 2012). This chemical class covers a broad range of
molecules, such as fatty acids, triacylglycerols (TAG), phospholipids, sterols,
sphingolipids and terpenes. However, this definition does not cover all lipids in
biological systems, since several new classes (such as lipopolysaccharides) are now
widely regarded as lipids, even though they are not soluble in organic solvents
(Ivanova et al., 2007). The International Lipid Classification and Nomenclature
Committee on the initiative of the LIPID MAPS Consortium broadly define lipids as
“hydrophobic or amphipathic small molecules that may originate entirely or in part by
carbanion based condensations of ketoacyl thioesters (fatty acyls, glycerolipids,
glycerophospholipids, sphingolipids, saccharolipids, and polyketides) and/or by
carbocation-based condensations of isoprene units (prenol lipids and sterol lipids)”
(Fahy et al., 2011).
1.1.1

General lipid structures, classification and nomenclature

Lipids are characterized by structural diversity and complexity, with over 37,000 unique
structures currently stored in LIPID MAPS, the most comprehensive lipid structure
database, and up to 180,000 different structures of lipids in theory (Brugger, 2014).
Simple lipids (usually neutral) are defined as those yielding at most two types of
primary products per mole upon hydrolysis (such as acylglycerols, ether acylglycerols,
sterols and their esters and waxes); Complex lipids (usually polar) yield three or more
primary hydrolysis products per mole (such as phospholipids and glycolipids). In 2005,
The International Lipid Classification and Nomenclature Committee and The LIPID
MAPS Consortium established a comprehensive classification system for lipids that
17

covers both eukaryotic and prokaryotic sources. This commonly accepted system
classified lipids into eight well-defined categories (Fatty Acyls, Glycerolipids,
Glycerophospholipids, Sphingolipids, Sterol lipids, Prenol lipids, Saccharolipids,
Polyketides) (Fahy et al., 2009, 2011).
Considering the vast complexity of lipids (containing positional and conformational
isomers of fatty acids and/or double bonds), use of a uniform nomenclature is
essential. The “gold standard” for chemical nomenclature is provided by the
International Union of Pure and Applied Chemistry (IUPAC) and also includes lipids
(Anon 1967; Anon 1970; Moss 1978), although these recommendations are somewhat
outdated nowadays. The LIPID Metabolites And Pathways Strategy (LIPID MAPS)
consortium, founded in 2003, has provided a widely accepted lipid nomenclature for
lipidomics (Fahy et al. 2005; Fahy et al. 2009), describing lipids on various levels. On
the simplest level, a lipid is only identified with its class and monoisotopic molecular
mass. In contrast, for the most precise and unambiguous identification, the positions of
the fatty acyls need to be known, as do the positions and conformations of the double
bonds. The entire complexity however cannot always be deduced from lipidomic
analyses. For example, the identities of fatty acyl constituents of phospholipids can
never be deduced from single stage mass spectrometry. Further elucidating the
structure of fatty acyls, especially the location or the conformations of double bonds, is
tremendously difficult and requires specialized techniques such as ozonolysis (Sun et
al. 2013; Batarseh et al. 2018).
It is essential that lipidomic results are reported at the correct identification level, and
that as few assumptions as possible are made concerning the structure. In particular,
automated tools used for data analysis of large-scale untargeted lipidomics or
metabolomics studies often erroneously assume a deeper level than is actually
reached and their matching algorithms may for example report results at the fatty acyl
structure level, although the method is based only on full scan or tandem mass
spectrometric measurement (Liebisch et al. 2015).
18

1.2 Membrane bilayer & Phospholipids
Biological membranes provide a barrier within and around the cells of all living
organisms. These membranes primarily consist of a lipid bilayer and embedded
proteins. The lipid bilayer includes both phospholipids and cholesterol, but the
phospholipids are the most important structural component of the membrane (Figure
1.1). The basic structure of lipid membranes was described in 1972 as the fluid mosaic
model (Singer & Nicolson, 1972). The hydrophobic hydrocarbon tails of the
phospholipids face each other to form an oily centre and the polar head groups face
outwards towards the aqueous solutions on either side of the membrane. Only small
hydrophobic solutes are able to pass through this barrier and there is low permeability
for polar inorganic compounds and ionic molecules, giving the cell control over
processes occurring across the cellular membrane (Singer & Nicolson, 1972).

Phospholipid

Figure 1.1: structure of a typical biological membrane_modified from
http://fig.cox.miami.edu/faculty/dana/membrane.jpg; visited 12/04/2017
The physical properties of the lipid bilayer are affected by its lipid composition, as well
as the temperature and membrane pressure (Williams, 1998). Temperature affects a
lipid membrane, the acyl moieties of membrane phospholipids change from a solid,
hexagonal close packing to a fluid as the temperature is increased (Cronan &
Gelmann, 1975). Increasing the length of the fatty acyl hydrocarbon chain and the
19

degree of unsaturation (i.e. number of double bonds) will affect the fluidity of the lipid
bilayer (Leekumjorn et al., 2009). The presence of a double bond in the acyl chain
creates more freedom of movement at the carbon next to the double bond, thus
increased desaturation results in the hydrocarbon chain are more loosely packed than
those of saturated fatty acids in the lipid bilayer (Lee, 2003).
Phospholipids and specific fatty acids within phospholipids play important structural
and functional roles in the membrane bilayer. One type of phospholipid class is the
glycerophospholipid, consisting of a 3-carbon glycerol backbone with each of the three
carbons denoted as sn-1, sn-2 or sn-3 in terms of position and a phosphate group is
attached at the sn-3 position and two fatty acyl chains are attached at the sn-1 and sn2 positions. Another type of phospholipid is sphingomyelin, part of a class of lipids
named sphingolipids; this lipid contains a sphingosine backbone instead of a glycerol
backbone and has only one attached fatty acyl chain.
The differences in the structure of the head group determine the classes of
phospholipids. The following are the most abundant phospholipids in human red blood
cell membranes: phosphatidylcholine (PC), phosphatidylethanolamine (PE),
phosphatidylserine (PS), sphingomyelin (SM) and phosphatidylinositol (PI) (Belhocine
& Prato 2011; Hussein, 2013). PC and SM are primarily found in the outer monolayer,
the amino phospholipids, PE, PS and PI are mainly to be found in the inner monolayer
(Butikofer et al. 1990; Srinivasan et al., 1999). The type of head group is known to not
only affect its position in the membrane bilayer (Tresset, 2009), but it also affects its
distribution between tissues (Veloso et al., 2011) and its interaction with protein (Lee,
2003).
Membrane phospholipids typically consist of at least 50% unsaturated fatty acids, with
the sn-1 position usually saturated fatty acids (SFA) or monounsaturated fatty acids
(MUFA) and the sn-2 position commonly taken up by an unsaturated acyl chain usually
polyunsaturated fatty acids (PUFA) (Lands, 2000). In some tissues, however there is a
higher proportion of unsaturated fatty acids present in the phospholipid, which
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increases the fluidity of the membrane; for example, in the eye and brain (Geiser,
1990).
1.3 Fatty Acids
The basic composition of fatty acids involves a hydrocarbon chain with a carboxylic
acid (-COOH) moiety. Two structural characteristics determine how specific fatty acids
are named: the length of the hydrocarbon chain and the number / position of double
bonds.

The three types or families of fatty acids are those that are saturated (SFA),
monounsaturated (MUFA) and poly unsaturated (PUFA) - depending on the number of
double bonds occurring between carbon atoms. They also are classified by length
within the carbon chain, with the short-chain fatty acids containing less than eight
carbons, the medium-chain fatty acids having between 8 and 12 carbons (Huang et al.,
2011; Schmalz & Kerrigan, 2003) and the long-chain fatty acids, consisting of 16 or
more carbons (Schonfeld & Wojtczak, 2016). From a nutritional perspective, however,
the classification changes. In terms of essential fatty acids (described below), they are
labeled as short-chain when having 18 carbons and are considered as long-chain when
containing 20 or more carbons (Nichols et al., 2010).
1.3.1 Saturated Fatty Acids
SFA are those whose chain contains only carbon-carbon single bonds. These carbons
are saturated completely with hydrogen atoms, thus the name SFA. SFA provide
rigidity because their physical properties allow them to be stacked tightly. They become
solid at room temperature when used to make a food fat such as butter.
These fatty acids also have important structural properties which provide a useful
energy source. Stearic acid, (containing 18 carbons) and palmitic acid (containing 16
carbons) are the most common SFA found in animal product (Schmalz & Kerrigan,
2003). Vegetable derivatives of SFA are also found, including palm oil, coconut oil, and
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palm kernel oil, all produced from vegetables that are normally found in locations with
tropical climates (Johnson & Sanders, 1994).
1.3.2 Unsaturated fatty acids
In cases where one or more double bonds are present in the carbon chain, the fatty
acid is referred to as unsaturated fatty acids. Examples of unsaturated fatty acids
include MUFA and PUFA (Table 1.1). When one or more pairs of hydrogen atoms have
been removed, this causes the formation of a double bond, which results in a kink or
bend developing in the fatty acid molecule. Because the unsaturated fatty acids
containing several double bonds usually occupy more space, thereby making a fat
containing them liquid (an oil) and cell membranes more fluid (Schmalz & Kerrigan,
2003).
Table 1.1: Examples of unsaturated fatty acids
Common Name
Vaccenic Acid
Oleic Acid
alpha-linolenic acid
Stearidonic acid (SDA)
Eicosapentaenoic acid
Docosapentaenoic acid
Docosahexaenoic acid
Linoleic acid
Gamma-linolenic acid
Arachidonic acid
Docosapentaenoic acid

Scientific Name
Monounsaturated Fatty Acids
11-octadecenoic acid
9-octadenoic acid
n-3 Polyunsaturated Fatty Acid
9,12,15-octadecatrienoic acid
6,9,12,15-octadecatetraenoic acid
5,8,11,14,17-eicosapentaenoic acid
7,10,13,16,19-docosapentaenoic acid
4,7,10,13,16,19-docosahexaenoic
n-6 Polyunsaturated Fatty Acid
9,12-Octadecadienoic acid
6,9,12-Octadecatrienoic acid
5,8,11,14-eicosatetraenoic acid
4,7,10,13,16-docosapentaenoic acid

Molecular
Name
Abbreviation
18:1 n-7
18:1 n-9

VA
OA

18:3 n-3
18:4 n-3
20:5 n-3
22:5 n-3
22:6 n-3

ALA
SDA
EPA
n-3 DPA
DHA

18:2 n-6
18:3 n-6
20:4 n-6
22:5 n−6

LA
GLA
AA
n-6 DPA

Fatty acids that contain one double bond are MUFA. Typical examples of MUFA
include palmitoleic acid (16:1 n−7), cis-vaccenic acid (18:1 n−7) and oleic acid (18:1
n−9, OA). MUFA are found in vegetable oils such as olive oil and canola oil (Schmalz &
Kerrigan, 2003). MUFA is also found in beef fat and lard fats. Additional sources of
MUFA include avocado, grape seed oil, peanut oil, macadamia nut oil, tea oil and also
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whole grain wheat, popcorn, cereal, oatmeal, and camellia (Schmalz & Kerrigan, 2003).

The name given to fatty acids containing more than one double bond is PUFA. For
example, n-3 and n-6 fatty acids indicate fatty acids in which the first double bond
begins at 3 and 6 carbons from the methyl end, respectively. The fatty acid with the
symbol 18:3 n-3 is identified by 18 carbon atoms and 3 double bonds with the first
double bond at the third carbon atom from the methyl end (Gurr et al., 2002).
Linoleic acid (LA) is classified as an essential fatty acid and is the primary PUFA found
in western diets (Meyer et al., 2016). High proportion of LA found in vegetable oils,
such as, corn, safflower, sunflower and soybean oils (Schmalz & Kerrigan, 2003).
Other sources of high levels of LA include evening primrose and borage oil. Muscle
and organ meats are animal products that provide a major source of n-6 PUFA in the
form of arachidonic acid (ARA) (Sinclair, 1991).
The n-3 polyunsaturated fatty acids (n-3 PUFA) can be found in both short and longchain varieties. Alpha-linolenic acid (ALA) contains 18 carbons and 3 double bonds.
Classifying ALA as essential means that all vertebrates are incapable of
biosynthesizing it denovo. n-3 LCPUFA are eicosapentaenoic acid (EPA),
docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA). Comparing them to
ALA, these fatty acids have an elongated and highly unsaturated content. To be
specific, EPA contains 20 carbons and 5 double bonds, while DPA has 22 carbons with
5 double bonds and DHA has 22 carbons 6 double bonds.
The dietary source of n-3 LCPUFA mainly comes from fish and seafood (Oken, 2015;
Gil & Gil, 2015). The initial production of n-3 LCPUFA occurs from small aquatic plants
- marine micro-algae that is found and consumed within the bottom of the marine food
chain, and then accumulated in the fish and other seafood thereby bioaccumulating in
the seafood chain (Nichols et al., 2010). Marine fish, most particularly oily fish such as
sardines, mackerel, tuna, salmon, herring, anchovies and oysters, provide the richest
food sources of n-3 LCPUFA (Nichols et al., 2010). Lower amounts can be found in
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meat (Howe et al., 2006) especially lean meat and eggs (Meyer et al., 2003). Foods
that have been enriched with n-3 LCPUFA such as bread, eggs, margarine and other
spreads, milk products, and any infant formula also provide a small amount of n-3
LCPUFA (Whelan & Rust 2006). Likewise, meat products or meat may be enriched
with n-3 LCPUFA by the animals’ diet (Kitessa et al., 2004; Wood et al., 1999). Another
possible source of n-3 LCPUFA is obtained by genetic modification, which transfers the
genes responsible for the production of n-3 LCPUFA to plants that are land-based
(Wood et al., 1999; Truksa et al., 2006; Nichols et al., 2010).
1.4 n-3 LCPUFA Metabolism
The process of converting dietary ALA into EPA and DHA primarily takes place in the
endoplasmic reticulum of the cells of the liver by a series of enzymatic processes (Scott
& Bazan, 1989). The processes involve a range of elongation enzymes that will add
carbon units, along with desaturation enzymes e.g. Δ-5 and Δ-6 desaturases which
insert double bonds in the fatty acid molecules (Burdge, 2006) (Figure 1.2).
The low n-3 fatty acid conversion rate in humans is brought about because only a small
percentage of ingested fatty acids are subjected to elongation in the process of
creating the long-chain PUFA (Barceló-Coblijn & Murphy, 2009) and the same
enzymes are used by both ALA and LA fatty acids and this result in significant
competition (Brenna et al., 2009). To explain it in more detail, in the human body
(including the brain), large quantities of ALA and LA undergo degradation by way of
processes of β- oxidation (Barceló-Coblijn & Murphy, 2009). The products that come as
a result of this are used to produce adenosine triphosphate (ATP), a highly essential
source of energy for cellular activities (Burdge & Calder, 2006; Russo, 2009). The
percentage of fatty acids that remains is either stored in adipose tissues or is used to
produce neutral and polar lipids such as phospholipids, sphingolipids and triglycerides
in tissues and organs such as the brain and liver (Barceló-Coblijn & Murphy, 2009;
Russo, 2009).
n-3 DPA is an elongated metabolite of EPA. It plays an intermediary role in the
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conversion process of EPA and DHA (Voss et al., 1991). The enzyme fatty acids
elongase-2 (Elovl-2) and Elovl -5 (Wang et al., 2005) are responsible for mediating the
conversion of EPA to DPA. During this process, an active interchange of EPA and DHA
takes place in the endothelial cells, which then results in the accumulation of DPA n-3
(Rosenthal & Hill, 1986).
The conversion process shown in (Figure 1.2) is inefficient and highly variable
(Breslow, 2006). Isotope-labelled ALA feeding trials indicate that roughly 0.2 to 21% of
ALA that is consumed is then converted into EPA (Emken et al., 1994; Gerster, 1998;
Burdge, 2006). Another influence on this conversion process is the fact that the gender
also plays a role, since it has been established that there is a higher conversion rate in
women (Burdge & Calder, 2006). In a study focusing on adult males, the conversion
rate of ALA to EPA was indicated as roughly 8%; while in the case of DHA, the range
was from 0 - 4% (Emken et al., 1994). This suggests that men rely more on pre-formed
DHA while in the case of women, the conversion of ALA to DHA is shown to be
considerably greater. In addition plasma conversion of EPA and DHA from ALA has
been shown to be 21% and 9.2% higher in women than men (Burdge & Wootton,
2002). It would seem that a possible explanation for the apparent synthesis of DHA in
women is due to an up-regulation of the desaturation and elongation pathway due to
the presence of estrogen (Jeong & Yoon, 2007).
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Figure 1.2: Metabolism of n-3 LCPUFA (Modified from SanGiovanni & Chew, 2005,
Ratnayake & Galli, 2009).

1.5 Biomarkers for n-3 LCPUFA status
A biomarker is generally referred to a measurable indicator of some biological state or
condition. There are several tissues that are potential suitable biomarkers of n-3
LCPUFA status. These include cheek cells, adipose tissue biopsies, plasma, whole
blood and erythrocyte membranes (Hirsch et al., 1960; McMurchie et al., 1984a; Arab,
2003; Guallar et al., 1999; Ogura et al., 2010; Sullivan et al., 2006; Rise et al., 2007).
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In table 1.2, the typical n-3 fatty acid composition of adult human body tissues are
shown.
Table 1.2: proportions of n-3 fatty acid composition in blood, cell and tissue lipid
fractions from adult human tissues. Table adapted from (Burdge & Calder, 2006).
% of Total fatty acids
Lipid fraction
ALA
EPA
DHA
Plasma phosphatidylcholine
0.1
0.8
2.9
Plasma cholesteryl ester
0.4
0.8
0.5
Plasma TAG
0.3
0.2
1.1
Platelet phosphatidylcholine
0.3
0.2
1.1
Platelet phosphatidylethanolamine
0.2
0.6
6.3
Mononuclear cell phospholipid
0.1
0.3
2.3
Neutrophil phospholipid
0.6
1.3
Erythrocytes phospholipid
0.8
3.5
Liver phosphatidylethanolamine
0.2
1.6
7.7
Brain grey matter phosphatidylethanolamine

0.1

-

24.3

Brain grey matter phosphatidylserine

-

-

36.3

Brain grey matter phosphatidylcholine

-

-

3.1

Brain white matter phosphatidylethanolamine

-

-

3.4

Retina phosphatidylcholine
Retina phosphatidylethanolamine
Retina phosphatidylserine
Testis total lipids
Sperm phospholipid
White adipose tissue

0.7

-

22.2
18.5
4.6
8.5
35.2
0.1

ALA, alpha-linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; TAG, triglycerides

1.5.1 Cheek cells
An analysis of fatty acids in cheek (buccal epithelial) cells by McMurchie et al., (1984a)
showed that this type of analysis delivered an appropriate measure of dietary lipids in
human body. The examination consists of an initial collection of cheek cells by
vigorously rinsing the mouth using 40ml of distilled water this following by centrifugation
for 10min and the pellet of cells resuspended in 1 ml distilled water. In the presence of an
antioxidant, the total lipids are then extracted from the cheek cell and the phospholipids
methylated in 1% (v/v) H2SO4 in methanol, and separated by thin-layer
chromatography (TLC) from the other lipid classes. Fatty acid methyl esters (FAME) are
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then assessed by gas-liquid chromatography (McMurchie et al., 1984a).
The composition of cheek cell fatty acid gave a sensitive marker of human fatty acids
and reflect the dietary LCPUFA consumption in preterm infants (McMurchie et al.,
1984a; Koletzko et al., 1999). Moreover, the DHA content in newborn infants cheek cell
phospholipids was highly correlated with that of both plasma phospholipids r=0.53 and
0.83 at 36 weeks and at 57 weeks respectively and erythrocytes lipids r=0.46 and 0.72
at 36 weeks and at 57 weeks respectively (Hoffman et al., 1999). Nevertheless, in 12
week period diet intervention study showed interesting results, the level of LA in the
cheek cell phospholipids responded to an alteration from a low to a high PUFA/ SFA
diet but not to the opposite manipulation (McMurchie et al., 1984b). This demonstrated
that cheek cell phospholipids’ response to the alterations in dietary intake of various
fatty acids is not the same. Hence, the validity of using check cells for examining the
fatty acid status remains unclear in dietary research. In summary, cheek-cell lipid
evaluation is of possible value in nutrition research investigations and of beneficial use
in epidemiological research on fatty acid assessment mainly from children (Laitinen et
al., 2006; Koletzko et al., 1999; McMurchie et al., 1984 a, b; Abraham et al., 2013). Yet,
the amount of assessment material is very small and there is high threat of
contamination of sample by food particles.
1.5.2 Adipose tissue
Fatty acids from subcutaneous adipose tissue has been used since the 1960s to
measure the habitual long-term dietary fatty acid intake of human beings
(Hirsch et al., 1960).The adipose tissue biopsy is mostly taken using a needle and
disposable syringe from the upper buttock (Hirsch et al., 1960). In weight stable
individuals adipose tissue fatty acids provide the best choice for the study of long- term
fatty acid intake (> 6 months) because of their absence of response to acute disease
and slow turnover 2-3 years (Dayton et al., 1966). However, the fatty acid composition
can be affected by the tissue-sampling site (Phinney et al., 1994; Malcom et al., 1989).
Research comparing fat from outer and inner thighs and abdominal areas has shown
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that there is greater levels of SFA in abdominal fat (Phinney et al., 1994), whereas
PUFA levels were lowest in the abdomen, moderate in the inner thigh, and the greatest
in the outer thigh. The observed differences were as high as 17% for PUFA and 30%
for SFA (Phinney et al., 1994). A comparison of fatty acid patterns from two
subcutaneous sites (abdomen and buttocks) and a deep-seated site (perirenal) from
autopsies of a group of adults belonging to different ethnicities showed that the
proportion of SFA were lowest in the gluteal depot and greatest in the perirenal adipose
tissue. While MUFA were greatest in the gluteal depot, PUFA profiles, however, were
not significantly different across these three tissue sites (Malcom et al., 1989). The
differences in fatty acid composition from subcutaneous adipose tissues in the
abdominal area are more evident than adipose tissue from gluteal pool in
demonstrating the dietary n-3 LCPUFA intakes (Katan et al., 1997). As a result, the
sampling of adipose tissue should be conducted carefully and accurately to make sure
that the results between subjects are comparable. Even though adipose tissue is
usually considered by most researchers as a gold standard biomarker for long-term
dietary fatty acid alterations (>6 months), because of the complications in collecting the
tissue specimens, adipose tissue is not a practical option for usage in routine
population screening or large clinical research (Beynen & Katan, 1985).
The investigation of the composition of human adipose tissue as a dependable
biomarker of dietary fat intake was carried out in six research studies, which all chose
Dietary assessment by Food Frequency Questionnaire (FFQ) and Gas
chromatography (GC) to assess the fatty acid composition of human tissues. One
research study evaluated habitual fish intake by assessing marine n-3 LCPUFA
composition of adipose tissue only (Marckmann et al., 1995); Trans fatty acid (TFA)
was measured in another (Clifton et al., 2004), and ALA and the risk of nonfatal acute
myocardial infarction (MI) were evaluated in two research studies (Baylin et al., 2003;
Campos et al., 2008). The reliability of adipose tissue as biomarker for a number of
fatty acids was assessed by further (Baylin et al., 2002; Craig et al., 2009). All the six
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research studies found that there was a relationship between adipose tissue
composition and dietary fat intake as evaluated by FFQ. Case control studies on
Australian groups indicate that adipose tissue TFA composition is associated with
consumption of TFA from the diet (18:1n-9, r=0.66, 18:1n-10, r=0.66) (Clifton et al.,
2004). Interestingly, in mid-1996 TFA was removed from margarine, and levels of TFA
(18:1n-9 and 18:1n-11) were higher in cases biopsied before mid-1996 (P< 0.03, P<
0.001 respectively). It was established in the research that adipose tissue TFA levels
(18:1n-9 and 18:1n-10) were correlated to TFA in the diet, suggesting that adipose
tissue is a good biomarker of dietary TFA consumption (Clifton et al., 2004). Higher
levels of ALA were found in the adipose tissue of controls in comparison to patients
who had experienced a MI (Baylin et al., 2003). Consequently, Campos et al., (2008)
conducted a follow-up of this research, assessing the relationship between the
consumption of ALA and the risk for myocardial infarction MI on 1819 subjects and the
same number of controls, showing that approximations of the proportion of ALA in
adipose tissue correlated with dietary ALA consumption. Interesting results were
obtained when using adipose tissue as a biomarker of habitual fish consumption,
where the outcomes demonstrated that the marine n-3 PUFA (r=0.58) and fish
consumption (r=0.55) were considerably associated with adipose tissue DHA content
(P< 0.001), but were not considerably associated with EPA and DPA levels
(Marckmann, 1995). The other two studies (Baylin et al., 2002; Craig et al., 2009)
compared the reliability of the use of adipose tissue as a biomarker of different fatty
acids. The first demonstrated that adipose tissue is appropriate for the evaluation of
TFA (r=0.58) and n-6 PUFA (r=0.58), n-3 PUFA (r=0.34) consumption from dietary
intake (Baylin et al., 2002), while the other reported the reliability of adipose tissue to
considerably reflect EPA (r=0.41) and DHA (r=0.36) (Craig et al., 2009). In conclusion,
the findings proposes that adipose tissue is appropriate to estimate intake of TFA and
PUFA so long as sampling sites are similar within the study. The reliability for
evaluating intake of MUFA and specific SFA remain unclear.
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1.5.3 Plasma
Since the 1950s plasma has been in use widely for evaluating human fatty acid status,
(Bronte-Stewart et al., 1956; Ahrens et al., 1957). Plasma contains lipoproteins which
contains fatty acids as well as free fatty acids bound to albumin; when measuring
plasma fatty acids the level of phospholipids, cholesterol ester and triglycerides are
highly variable. Plasma fatty acid levels have also provided a sensitive indicator of
alterations in dietary consumption of LCPUFA (Dougherty et al., 1987). However, the
strength of the relationship between the amount of LCPUFA in plasma and estimated
dietary consumption of certain fatty acids differ for various fatty acids (Glatz et al.,
1989; Vessby, 2003). There are relatively strong relationships between the amount of
n-3 PUFA (r=0.31), EPA (r=0.34) and DHA (r=0.41) in the diet and the proportions of
fatty acids in plasma phospholipids (Warensjo Lemming et al., 2015). The
relationships between the levels of fatty acids in plasma phospholipids and SFA in the
diet are weak (r=0.15) and the relationships for MUFA are are almost nonexistent
(r=0.05) (Ma et al., 1995). This may reflect the point that while the amounts of PUFA in
blood lipids and human tissue are ultimately resulting from the diet (Riboli et al., 1987;
James et al., 1993), considerable amounts of SFA and MUFA are endogenously
synthesized in the human body (Ma et al., 1995). The short lifetime of circulating fats
in plasma is a limitation for using plasma fatty acids as a biomarker of fatty acid status
in human body. The levels of fatty acids in plasma only reflect the dietary fat
composition over the last few days meals (plasma triglyceride) or (plasma
phospholipid fatty acids and serum cholesterol ester) (Kohlmeier & Kohlmeier, 1995).
Hence, plasma fatty acid status does not have the capability to deliver information on
long-term dietary fat consumption.
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1.5.4 Whole blood
For a fatty acid biomarker whole blood is an attractive alternative option when
conducting epidemiologic studies compared with erythrocytes or plasma samples,
because of its easier processing requirements. It was validated in a research
conducted by Baylin et al., (2005) that fasting whole blood reflects dietary intake of LA
and ALA, high correlations were observed between whole blood ALA and LA and
plasma (r=0.96 and r=0.88) and adipose tissue (r=0.59 and r= 0.67) respectively
(Baylin et al., 2005). However, whole blood fatty acid concentration is more difficult to
interpret because the blood volume proportion that is occupied by erythrocytes
changes with age and gender (Cirillo et al., 1992) and can be affected by factors such
as pregnancy, cardiac and pulmonary diseases (Belo et al., 2002) and hypertension
(Cirillo et al., 1992). Thus, the likelihood for differences in the percentage of whole
blood composed of erythrocytes and plasma needs to be considered cautiously to
avoid the misinterpretation the results of whole blood fatty acid (Rise et al., 2007).
1.5.5 Erythrocytes
Many investigators consider erythrocyte lipids as a reliable indicator of relatively longterm (few weeks to few months) dietary fatty acid consumption as compared to
plasma lipids, this is because the turnover of fatty acid status in erythrocytes is much
slower compared to plasma (Glatz et al., 1989; Siscovik et al., 1995; Poppitt et al.,
2005). Erythrocyte fatty acid profile was not significantly affected by alterations in
short-term (a few days) dietary consumption of EPA and DHA, when compared to the
fatty acid profiles of plasma or platelet phospholipids or plasma free fatty acids (Von
Schacky et al., 1985; Harris et al., 2007). The average lifespan of erythrocytes is 120
days (Franco, 2012) significantly longer (Ebaugh et al., 1953; Prisco et al., 1991),
less brief as compared to that of the platelets (7-10 days) (Harker et al., 2000;
Andreoli et al., 1973) and less variable than white blood cells (hours to years).
The mature erythrocyte does not comprise any intracellular membrane compartments
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other than its plasma membrane component (Mikhalyov et al., 2001). Consequently,
any lipids that may be established from the erythrocyte must originate from its lipid
bilayer.
The n-3 LCPUFA concentration in erythrocytes provides a good biomarker that can be
used to measure n-3 fatty acid (Harris et al., 2004; Sullivan et al., 2006), erythrocytes
contain a substantial concentration of n-3 LCPUFA (Arterburn et al., 2006; Burdge &
Calder, 2006), and there is no significant fluctuation unless dietary intake of n-3
LCPUFA is increased (Arab, 2003; Di Marino et al., 2000). Also, erythrocyte n-3
LCPUFA levels have less inter-individual variability than plasma (Harris et al., 2004),
reflects intake that has occurred during the past 120 days (Arab, 2003) and maintain a
level of stability at -80°C for several years (Arab, 2003). There is evidence that a linear
relationship can be seen between erythrocyte EPA, DHA and total n-3 LCPUFA r=0.92,
r=0.69 and r=0.78 respectively and the intake of EPA, DHA and total n-3 LCPUFA
(Swierk et al., 2011). Also, there is a strong relationship between the total levels of
DHA+EPA in erythrocytes and cardiac tissues (r=0.82) (Harris et al., 2004). This makes
extraction of fatty acids from erythrocyte membranes suitable for long-term evaluation
of fatty acid status.
1.6 Lipidomics
1.6.1 Introduction
With the rapid development of lipid research, the concept of “lipidomics” was
introduced in the early 2000s. Lipidomics focuses on the global study of molecular
lipids in biological systems and aims at the “full characterization of lipid molecular
species and of their biological roles with respect to expression of proteins involved in
lipid metabolism and function, including gene regulation” (Spener et al.,2003).
Advances in mass spectrometry instrumentation and computational methods have
greatly promoted the development of the lipidomics field, enabling precise identification
and quantification of the lipidome in cells and tissues. Through the incorporation of
multiple lipidomics techniques, lipidomics have provided insight into the functional roles
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of subcellular membrane compartments in mammalian cells and have expanded our
knowledge on human health and diseases (Han & Gross, 2003).
Over past decades, the relationship between blood lipids and n-3 intake has been
examined extensively. This has been greatly influenced by early associations between
the consumption of fish and positive health outcomes, such as reducing the risk of
developing heart disease (Dyerberg & Bang, 1979; Chowdhury et al., 2014). Most of
this research has used fatty acid compositional data derived from gas chromatography
analyses, resulting in specific parent acyl lipid species information being lost and
limited to the fatty acid composition of lipid classes (Xu et al., 2007). Lipidomics can
allow us to identify relationships between lipids, diet and health at the level of individual
molecular species of complex lipids. Therefore, the metabolism of these very specific
lipid molecules can be better characterized. The emerging literature on analysis of
native lipids containing n-3 in biological samples include the analysis of single lipid
classes of cell cultures (Ramanadham et al., 2000; Rucker et al., 2013), isolated
tissues (Lamaziere et al., 2011; Murthy et al., 2002; Sjovall et al., 2015), plasma,
erythrocytes and other circulating blood cells (Ottestad et al., 2012; Pacetti et al., 2004;
Stanke-Labesque et al., 2008; Uhl et al., 2013).
1.6.2 Erythrocyte lipid extraction
There have been several popular methods for total lipid extraction including Folch et
al., (1957), Bligh & Dyer (1959) or Rose & Oklander (1965) methods. Lipid extraction
has been performed by using chloroform: methanol (2:1) in the Folch's method, this
method shows high efficiency of lipid extraction however, it poses some disadvantages
such as formation of highly pigmented (Folch et al., 1957). Bligh and Dyer have used
chloroform, methanol and water, where the chloroform layer contained lipids and the
methanol-water layer contained non-lipids. This method attempted to eliminate the
centrifugation step in the lipid extraction and instead create a spontaneous phase
separation, the proposed system seems to be more effective and time saving
compared to Folch et al., (1957) method.
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Alternative chloroform: methanol extractions have been discussed by Reed et al.,
(1960) and Ways & Hanahan (1964) these extraction procedure have found wide
application with reliable results. However, there is still an issue that heme pigment is
often extracted as well, this pigment is difficult to remove and may have catalytic
effects on auto oxidation processes. Therefore, Rose & Oklander (1965) advised to use
of isopropanol instead of methanol and proposed a simpler procedure employing
chloroform: isopropanol (7:11). It is reproducible and simple method, uses a single
extraction tube and yields an extract with slightly heme contaminated.
At the present time, procedure allowing both hydrolysis and esterification of bound fatty
acids are being more popular for saving the time and commonly used. Lepage & Roy
(1986) have proposed the one-step direct transesterification and extraction procedure
suitable for total fatty acids as well as fatty acid classes. The advantage of the method
is no addition of antioxidants to protect unsaturated lipids (Lepage & Roy, 1984) and an
acidic catalyst (acetyl chloride) are required. The procedure provides higher recovery of
fatty acids compared to the Folch's method (Rodrıg
́ uez-Palmero et al., 1998).
Therefore, it is preferable and common method used for the analysis of biological
samples such as erythrocytes and plasma (Ridges et al., 2001; Rodrıg
́ uez-Palmero et
al., 1998; Stewart et al., 2007; Goozee et al., 2017; Masood et al., 2005, Masood &
Salem, 2008). However, whilst this method provides consistent and reliable
measurement of fatty acids, it has a number of disadvantages. It utilises manual
sample preparation and as such is time consuming (6 hours to prepare only 24
samples a day). A relatively large amount of sample (400ul of erythrocytes) is required
and this method cannot generate molecular phospholipid data as the fatty acids are
removed from the glycerol backbone during the derivatisation steps. Furthermore, this
method uses an extremely toxic solvent (benzene). Considerable research effort has
been focussed on the development of efficient analytical techniques in order to reduce
time and labour involved in the estimation of fatty acids (Masood et al., 2005; Masood
& Salem, 2008). Thus far the focus of development has primarily been on modification
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of the original techniques of Lepage & Roy (1986) and still using gas chromatography
for analysis.
The technique for lipid extraction using methyl-tert-butyl ether (MTBE) (Matyash et al.,
2008) simplifies the handling of samples and allows for automated processing of small
amounts of biological samples. Studies have demonstrated that the use of MTBE in the
recovery of lipid species for almost all the fundamental categories is similar to, or even
more efficient than the Folch’s (1957) or Bligh & Dyer's (1959) methods (Matyash et al.,
2008).
The Matyash et al., (2008) technique that substitutes the use of chloroform with MTBE
has similar steps as those in Folch method, particularly considering that the two revolve
around two fundamental steps. First, is the single phase lipid homogenisation of the
biological matrix in which they are found. Second, is the solubilisation of the lipids in
the distinct ‘organic” phase. The key distinction between the Folch et al., (1957) and
the Matyash et al., (2008) method is that in the latter technique, the separation of the
two phases is spontaneous once the aqueous agent has been added. Extraction of the
layer containing the organic lipid is also much simpler, as MTBE is much less dense
than methanol/water mixture. The organic layer containing the lipids forms at the top
layer, thus reducing the possibility of cross-contamination with the insoluble and nonlipid materials that often fall to the bottom layer.

Matyash et al., (2008) devised extraction protocols specifically aimed at being used
alongside automated robotic platforms combined with a shotgun-lipidomics approach to
mass spectrometry. The main purpose of this was to produce techniques on the basis
of a standard 96-well format that makes use of a two-phase solvent system similar to
the Folch technique (Folch et al., 1957), with the only difference being that there would
be a spontaneous separation of phases, in which case it would not be necessary to
undertake centrifugation. Similarly, the technique comes with the use of MTBE, which
is a much less toxic reagent, with chloroform being replaced by MTBE and methanol as
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the primary reagent in the extracted phospholipid and fatty acids solubilisation
(Matyash et al., 2008).

1.6.3 Electrospray ionization mass spectrometry (ESI-MS) and lipid analysis

The development of electrospray ionization (ESI) has revolutionized the mass
spectrometric analysis of biomolecules, including lipids. In 1994, the first combination
of LC and ESI-MS for phospholipids analysis was published (Kim et al., 1994). Since
then, ESI has become the most frequently employed ionization technique in the
lipidomics field. ESI is a soft ionization technique with minimal in-source fragmentation.
In an ESI experiment, the liquid sample is introduced from an LC column or infusion
pump to the probe near the orifice of a mass spectrometer. The high potential
difference between the probe tip and the sample cone causes electroionization of the
liquid sample. Charged droplets are generated with the help of a drying gas. The
surface of the droplets that contains the ionized compounds will become charged,
either positively or negatively. As the solvent evaporates, the size of the droplets is
reduced, and, consequently, the density of charges at the droplet surface increases.
The repulsion forces between the charges increase until there is an explosion of the
droplet. This process repeats until analyte ions are ejected from the droplet (Kim et al.,
1994; Cole, 2000). The ESI technique allows rapid, accurate and sensitive analysis of a
wide range of analytes from low molecular weight (less than 200 Da) polar compounds
to biopolymers larger than 100 kDa. Generally, compounds of less than 1000 Da
produce singly charged molecules and compounds of high molecular weight produce a
series of multiple charged ions. The typical sample flow rates of the ESI ranges from 5
to 20 μL/min. Nanoelectrospray today supports stable flow rates as low as 20 nL/min,
which further increases sensitivity (Brugger, 2014).
The use of neutral loss (NL) and precursor (PIS) scanning technology was improved
the reliability and specificity of this methodology (Brugger et al., 1997). The use of this
type of technology contributed to the specific identification of molecular ions (precursor
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ions) that upon collision-induced dissociation release characteristic fragment ions. In a
positive ion mode, the PC and SM can be easily detected and recognized as
protonated molecular cations which upon collision-induced dissociation these ions
generate a characteristic fragment ion of the phosphorylcholine head group having m/z
184.1. A triple quadruple mass spectrometer using PIS m/z 184.1 allowed the
quantitative profiling of molecular PC and SM classes at the lowest nM levels (Brugger
et al., 1997).
The collision-induced dissociation of cationic molecular PS and PE classes the
particular NL of their head group moiety (e.g. neutral loss of 141 by PE species) which
prompted their quantitative profiling by NL scanning (Brugger et al., 1997); despite the
fact that, glycerophospholipids except PC are always negatively charged molecular
anions. Therefore upon collision-induced separation in negative ion mode, anionic
glycerophospholipid species generate acyl anions that relate to the fatty acid moieties
which are attached to the glycerol phosphate backbone (Hsu & Turk, 2000a; 2000b;
2000c; 2001). Hence, encouraging the use of PIS technology for direct profiling and
quantitative of the fatty acid that consists of molecular glycerophospholipid classes
(Beckedorf et al., 2002; Ekroos et al., 2002; Han et al., 2004). Furthermore, the same
methods have been used for the molecular quantification and characterization of
sphingolipids (Gu et al., 1997; Han, 2002; Liebisch et al., 1999).

Recent advances in ESI-MS have enabled increased sensitivity in the detection, and
accurate characterization, identification, and quantitation of membrane lipid species
from biological samples. These techniques have been applied in several studies of lipid
metabolism (Boumann et al., 2003; Boumann et al., 2004; Brooks et al., 2002; DeLong
et al., 1999; Hunt et al., 2002), lipid trafficking (Heikinheimo & Somerharju, 2002) and
lipid composition (Blom et al., 2001; Brugger et al., 1999; Brugger et al., 2006; Brugger
et al., 2004; Fridriksson et al., 1999; Rodemer et al., 2003; Schneiter et al., 1999) but
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have yet to be applied to studies in people who are at UHR of developing psychosis
and the effect of n-3 supplementation in this population.

1.7 n-3 index
The n-3 index defined as the sum of EPA and DHA levels in erythrocytes membranes
expressed as percent of total fatty acids was first postulated by Von Schacky & Harris
(2004), for consideration to be used as a new risk factor to determine risk for sudden
cardiac death.
There have been several studies done examining which of the n-3 LCPUFA shows the
most benefit for cardiovascular-related end-points such as nonfatal MI or even sudden
cardiac death (Sun et al., 2008, Lee et al., 2009). It has been shown in the
epidemiological studies and large randomized controlled clinical trials (RCTs) including
the JELIS (Japan EPA Lipid Intervention Study), DART (diet and reinfarction trial) and
GISSI (Gruppo Italianoperlo Studio della Sopravvivenzanell Infartomiocardico)Prevenzione trial), that EPA and DHA supplementation is a favourable treatment for
both primary and in specific secondary prevention of cardiovascular disorders,
including heart attack, atherosclerosis, cardiac arrhythmias and stroke (Kromhout et al.,
1985; Burr et al., 1989; GISSI-P, 1999; Marchioli et al., 2002; Yokoyama et al., 2007;
Lavie et al., 2009). However, currently, the efficiency of n-3 LCPUFA in preventing
cardiovascular disease (CVD) in adult humans has been doubted by the results of
some RCTs, which have mentioned that low dose daily intake of DHA and EPA did not
significantly reduce the rate of major CVD in patients with dysglycemia (Bosch et al.,
2012) and in post MI patients (Kromhout et al., 2010). In addition, the most recent
meta-analysis (Abdelhamid et al., 2018) showed that the RCTs showed no effect of n-3
LCPUFA on CVD mortality. However, this meta-analysis included studies with primary
outcomes not being CVD mortality; there were lower than expected rates of death from
CVD, most likely due to increased CVD care; and the dose of n-3 LCPUFA (particularly
DHA) may not have been sufficiently high to demonstrate the efficacy (Meyer & Groot,
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2017). Furthermore, not all of these studies measured the levels of n-3 LCPUFA in the
blood. Of these studies that did measure n-3 LCPUFA in the blood, their levels only
increased by approximately 1% which is not enough of a change to see a difference.
Further research in this area is necessary with high enough dose of n-3 LCPUFA and
studies should also check the n-3 LCPUFA at baseline and exclude participants with
high levels of n-3 LCPUFA status (James et al., 2014).
Recently, there is emerging evidence that suggests a relationship between an n-3
index of less than 4% as an independent risk marker for major depressive disorder
(MDD) in adults (Baghai et al., 2011; Grant et al., 2013), schizophrenia and depression
(Parletta et al., 2016; 2017). In addition, n-3 index is starting to be utilized in other
areas such as obesity, depression and diet quality (Burrows et al., 2011; Baghai et al.,
2011; O’Sullivan et al., 2011). However, the research available in these areas is fairly
limited. Whilst the n-3 index has been used in cardiovascular health applications (Von
Schacky & Harris 2007; Harris, 2008a) the use of the n-3 index as it applies to mental
health is still novel and requires further investigation.
1.8 n-3 LCPUFA and mental health
Several studies have investigated the n-3 LCPUFA (EPA and DHA) ‘status’ of
psychiatric patients. These studies have found that patients with major depressive
disorder (MDD) (Assies et al., 2010; Edwards et al., 1998; Maes et al., 1996; Peet et
al., 1998; Riemer et al., 2010; Mcnamara et al., 2010), bipolar disorder (Mcnamara et
al., 2010; Chiu et al., 2003; Ranjekar et al., 2003), schizophrenia (Ranjekar et al., 2003;
Evans et al., 2003; Khan et al., 2002; Reddy et al., 2004; Parletta et al., 2016), anxiety
disorders (Green et al., 2006) and attention deficit hyperactivity disorder (ADHD) (Chen
et al., 2004; Colter et al., 2008; Stevens et al., 1995; Young et al., 2004) exhibit
significant EPA and DHA deficits in erythrocytes compared with demographically
similar healthy subjects.
n-3 LCPUFA, particularly EPA and DHA are capable of playing a role and are seen to
be related to brain activity (Markrides et al., 1994) as they induce electrical signals from
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the brain cells to other parts of the body (Bourre et al., 1991; 1992). Studies have been
conducted confirming the fact that a diet that is low in n-3 LCPUFA could quite possibly
impair neuron growth and function (Neuringer, 1988). As a result low levels of n-3
LCPUFA is thought considered to play an important role in mental disorders such as
depression and dementia (Hibblen & Salem, 1995).
By incorporating DHA into brain cell membranes, there is also an improvement in the
fluidity of membranes, which might affect brain function because of its capability to bind
ligands and initiate a series of signal transduction processes (Michell et al., 2003).
Brain function is also influenced by DHA and EPA by effecting the working of
neurotransmitters like dopamine and serotonin (Du Bois et al., 2006), where deficiency
of n-3 LCPUFA alters the internalization of dopamine in the storage pool of the frontal
cortex (Zimmer et al., 1998). Also, low levels of n-3 LCPUFA result in changes in the
vesicular pool of serotonin as well as dopamine, thus inducing several regulatory
processes such as modification of cerebral receptors in specific brain areas (Chalon,
2006).
The presence of n-3 LCPUFA has a critical impact on the function of the brain. DHA is
a prime structural component of phospholipids within the neuronal cell membranes
(Horrobin et al., 1991). Altering the lipid environment of the phospholipid bilayer can
result in changes in the function within the activity of the receptor as well as the activity
of other proteins embedded in the membrane (Rudin, 1981). Although EPA is not found
in neuronal cell membranes, it still has several significant physiological functions it can
perform, such as acting as a precursor for eicosanoids, or as acting as modulator of
cytokines which have neurotransmitter and neuromodulatory activity (Fenton et al.,
2000). Therefore, there are numerous potential mechanisms where the presence of n-3
LCPUFA can cause a modulation in brain function.
It was first suggested by Rudin (1981) that n-3 LCPUFA showed potential for use in
treating mental disorders. He suggested that the cause of mental health problems
could be linked to a deficiency in n-3 LCPUFA, and reported that a number of patients
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had been successfully treated with the use of flaxseed oil which is high in levels of
ALA. Western diets since that time often show a major deficiency in n-3 LCPUFA
intakes (Leaf & Weber, 1987; Meyer et al., 2003; Howe et al., 2006; Meyer et al.,
2016). This could possibly be linked to the increasing rate of several psychiatric
illnesses (Weissman et al., 1996).
People with schizophrenia were the first to take part in studies involving fish oil
derivatives. Soon afterward, studies were done on patients exhibiting mood disorders.
In the first study (a 3-month pilot study), a comparison was made between the effects
of EPA-enriched oil, DHA enriched oil and corn oil when they are added to an existing
dosage of antipsychotic medication, the patients who were studied were already
symptomatic of schizophrenia (Peet et al., 2001). This study showed that those
patients on high levels of EPA treatment all showed clinical improvement, while
patients receiving treatment with DHA showed no difference in therapeutic response
from those offered the placebo (Peet et al., 2001). Since then, studies focusing on
schizophrenia have been directed toward effects of EPA (Emsley et al., 2002; Peet &
Horrobin 2002; Fenton et al., 2001; Berger et al., 2004) or in some cases, on the effect
of a mixture of EPA and DHA (Arvindakshan et al., 2003; Sivrioglu et al., 2007). No
further studies have been done using pure DHA. An improvement in psychotic
symptoms was found when an add-on treatment with EPA was incorporated into the
daily lives of patients suffering from schizophrenia (Peet et al., 2001; Emsley et al.,
2002; Mellor et al., 1995; Arvindakshan et al., 2003; Sivrioglu et al., 2007). Another two
trials showed no improvement following the use of n-3 LC-PUFA. In one trial, patients
known to have schizoaffective disorder and those with a definitive diagnosis of
schizophrenia were examined (Fenton et al., 2001) and one trial assessed patients with
first episode psychosis (FEP) (Berger et al., 2007). It is not clear whether the
differences in terms of the analysed population, dose intake or study duration time had
an effect on the results. In a recent meta-analysis of those who clearly manifest
schizophrenia, the addition of PUFA as a supplement to existing antipsychotic therapy
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has shown evidence that there is no sufficient effect (Fusar-Poli & Berger, 2012). On
the other hand, when a review of epidemiological data (Hedelin et al., 2010) was done,
combined with a recent RCT of an emerging psychosis, the hypothesis that n-3
LCPUFA may in fact show potential effects for prevention of the very early stages of
psychotic disorders was supported (Amminger et al., 2010). The results of these
findings points to the potential neuroprotective properties of n-3 LCPUFA (Berger et al.,
2007). Studies have indicated that there is a valid, positive correlation between an
improvement of symptoms and the intake of n-3 LCPUFA; however there is a need for
further studies involving larger and more randomized-controlled studies since the
previous work was generally conducted with small groups. Currently, there is limited
knowledge and only two studies investigating the relationship between those with ultra
high risk (UHR) of developing psychosis and n-3 LCPUFA supplementation (McGorry
et al., 2017; Amminger et al., 2010). Most of the knowledge of n-3 concentration in
human erythrocytes comes from experiments performed using methods that are far
less comprehensive than those currently available (Han & Gross, 2003). What remains
unclear, however, is the molecular phospholipid data and n-3 index which relates to
individuals with an UHR of psychosis and how this is affected by n-3 supplementation.
1.9 The ultra high risk of psychosis period
“Prodromal syndrome” is technical term used to describe the specific group of
symptoms that are characteristic during UHR period (Simon et al., 2007), and the
appearance of this syndrome does not qualify as a psychological or psychiatric
diagnosis. The UHR period that precedes actual psychosis is often characterized by
attenuated positive symptoms and a decrease in social and role function (Yung et al.,
2004; 2005; Yung & McGorry, 1996). These attenuated positive symptoms have not yet
reached the level of conviction and impairment generally seen in the case of a formal
psychosis diagnosis, but feelings do emerge that indicate a sense that something is
“off” or there may also be an increase in overall suspicion. These feelings don’t occur
with the severity exhibited in a case of formal psychosis; however these positive
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symptoms are cause for concern and can still be jarring (Yung et al., 2004). An
examination of UHR individuals during this time period is critical toward efforts in
prevention and intervention. It is a fact that with early intervention, there is potential for
help in preventing or decreasing the impact of an episode (Yung et al., 2004). During
the mid-1990s, the suggested criteria for use in identifying individuals thought to be at
UHR of psychotic disorder has been established (Miller et al., 2003; Miller et al., 2002;
Yung et al., 1996; Yung et al., 2003; Yung et al., 2004). Since that time, several studies
have offered validation of the UHR criteria, determining that young people who were
seeking help and met the criteria went on to have a high risk of developing psychosis
over 1–2 years (Cannon et al., 2008, Mason et al., 2004; Yung et al., 2003).
In more recent studies, there is evidence suggesting that 36% of individuals
categorized as UHR will progress to the point of developing a psychotic disorder within
3 years after follow up (Fusar-Poli et al., 2012; Cannon et al., 2008; Mittal et al., 2007;
Mittal et al., 2008). Research should be done on the biological mechanisms involved in
psychosis, information may come forward to provide better understanding of etiological
processes during the UHR period. Along with brain changes characteristic of healthy
adolescence (Mittal et al., 2008; Bernard, 2014), but various environmental stressors
can interact with these biological vulnerabilities and potentially lead to a formal
diagnosis of psychosis. Particular environmental stressors include sexual trauma
(Thompson et al., 2014), drug use (Carol & Mittal 2014), and problematic family
environments (Meneghelli et al., 2011), among others.
The uses of psychosocial (Morrison et al., 2012) and cognitive-based (Hooker, 2014)
therapies have proven effective as early interventions during the UHR period. Very
recent evidence indicates that interventions involving exercise may also be helpful in
prevention, since exercise is known to help stimulate hippocampal neurogenesis, which
has been shown a positive effects in cognitive deficits (Mittal et al., 2013).
Several interventions using both pharmacological and psychological techniques have
been suggested in an effort to either delay or perhaps even prevent the onset of
44

psychosis in the UHR population (Preti & Cella 2010). There is value to the use of
antipsychotics, but their risk-benefit profile is currently unclear (McGorry et al., 2002).
During a 12-week randomized, placebo-controlled trial that followed 81 individuals
aged 13 to 25 years who had been diagnosed with UHR of developing psychotic
disorder, a 12-week intervention using 1200 mg/day n-3 LCPUFA or placebo was
followed by monitoring for a period of 40 weeks (Amminger et al., 2010). Study results
showed a 4.9% (2 out of 41) rate of transitioning to acute psychosis in the UHR
patients who had been treated with n-3 LCPUFA in compared to a much higher
psychosis transition rate of 27.5% (11 out of 40) in the individuals who had received
placebos in addition to their standard care. A follow-up of the same subjects conducted
seven years later indicated that even the brief intervention with n-3 LCPUFA had
caused a reduction both in the risk of progression to psychotic disorder and in actual
cases of psychiatric morbidity (Amminger et al., 2010; 2015). No severe functional
impairment was found in the majority of the individuals from the n-3 LCPUFA group,
and in addition, they no longer experienced attenuated psychotic symptoms when the
follow-up occurred (Median 6.7 years) (Amminger et al., 2010; 2015). This indicates
that a supplementation of n-3 LCPUFA could possibly reduce the risk of a transition to
psychosis in those at risk. In contrast, the first randomized, placebo controlled
multicentre study for individuals aged 13 to 40 years who had been diagnosed with
UHR of developing psychotic disorder, using 1400 mg/day n-3 LCPUFA did not
demonstrate an advantage over placebo in the prevention of psychosis at 6 month
(5.1% of placebo group and 6.7% of the n-3 LCPUFA group transitioned to psychosis)
or 12 month (11.2% of placebo group and 11.5% of the n-3 LCPUFA group transitioned
to psychosis) follow up evaluations (McGorry et al., 2017). This lower transition rate
compared to the previous study could be due to insufficiently enriched for risk of
transition and a high level of antidepressant treatment received by both groups
(McGorry et al., 2017).
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1.10 The NEURAPRO-E randomized clinical trial
The NEURAPRO-E study is a multicentre, randomised, controlled trial of n-3 LCPUFA
supplementation and cognitive behavioural case management (CBCM) for patients at
UHR of psychosis.
A total of 304 participants meeting the ‘at-risk’ criteria were randomized to treatment
with either n-3 LCPUFA plus CBCM or to treatment with placebo plus CBCM (see
appendix (A) Flow chart for participant distribution). The total length of treatment was 6
months with a follow-up assessment at 6 and 12 months post study entry. This study
involving 10 research centres around the world Australia (Sydney, Melbourne),
Switzerland (Basel, Zurich), Germany (Jena), Denmark (Copenhagen), Austria
(Vienna), Singapore, Hong Kong (Pokfulam), and The Netherlands (Amsterdam).
Inclusion and exclusion criteria for these participants has been reported previously
(Markulev et al, 2015; McGorry et al., 2017) (See appendix (B) for more details).
At study entry, participants were randomly assigned into either the n-3 LCPUFA plus
CBCM group, or the placebo plus CBCM group by way of an online electronic data
management system. Randomization was stratified based on site and total score
according to the Montgomery- Åsberg Depression Rating Scale (MADRS) (total score
range 0-60) (Montgomery & Asberg, 1979) since both antidepressants and depression
may affect illness progression and UHR symptoms (McGorry et al., 2009; McGorry et
al., 2012; Cornblatt et al., 2007; Fusar-Poli et al., 2015).
Participants received either n-3 LCPUFA (2600 to 3000 mg of concentrated marine fish
oil active intervention containing: 560mg of (DHA) and 840mg of (EPA) or placebo
(2600 to 3000 mg of paraffin oil) together with clinical care with up to 20 sessions of
CBCM for the 6-month intervention phase, after which administration of both the n-3
LCPUFA and placebo were ceased, although patients could continue to access CBCM
on the basis of need throughout this 6-month follow-up (Markulev et al., 2015). A total
of 125 participants (41.1%) continued to receive CBCM after the 6-month follow-up
visit. During the study’s first 12 months, benzodiazepine therapy was permitted for
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anxiety and therapy using selective serotonin reuptake inhibitors was allowed for
treatment of depression at a moderate or even severe and major level. Using any form
of mood stabilizers or antipsychotics was not allowed at any point while the trial was
underway, unless the withdrawal of a participant from the study took place before 12
months and it was determined that the treatments were considered to be necessary in
accordance with clinical guidelines (Markulev et al., 2015).
To date, there is no data available for erythrocytes molecular phospholipids species in
UHR cohort. In this PhD research project the aim is to investigate the UHR cohort
erythrocytes n-3 index, fatty acids and molecular phospholipids species and this will
certainly enable a better understanding and deep knowledge of these parameters in
UHR population.
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1.11 Aims and Hypothesis
1.11.1 Hypothesis:
 The automated extraction method coupled up with mass spectrometry will show
no difference from the Lepage and Roy’s GC method and it will be a valid highthroughput method for assessing n-3 index in erythrocytes.
 The erythrocyte n-3 index, fatty acids and phospholipid molecular species will
differ between the UHR of developing psychosis and the healthy groups. (The
UHR of developing psychosis group will have a lower n-3 index than the healthy
group).
 n-3 supplementation will alter n-3 status in UHR of developing psychosis group.
 Erythrocytes n-3 index, fatty acids and/or phospholipid molecular species, will
predict the transition of UHR to psychosis.
1.11.2 Research Aims
The aims of this project were to:
 Develop and validate a highly-automated, high-throughput technique for the
analysis of n-3 index and molecular phospholipid profile in human erythrocytes.
 Compare human erythrocyte n-3 index, fatty acid and phospholipids molecular
species of individuals at high risk of developing psychosis to healthy agematched individuals.
 Determine the effect of n-3 supplementation on n-3 index, fatty acids and
phospholipid molecular species to those at high risk of developing psychosis.
 Identify any n-3 index, fatty acids and/or phospholipids molecular species that
may predict the transition of UHR to psychosis.
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Abstract
n-3 long chain polyunsaturated fatty acids (n-3 LCPUFA) have several health benefits. In
particular, low n-3 LCPUFA status is associated with cardiovascular disease (CVD) and led
to the development of the n-3 index which is the proportion of eicosapentaenoic acid and
docosahexaenoic acid in the erythrocyte membranes, as a marker of CVD risk. Most
methods used to measure the n-3 index are laborious and time consuming. Therefore, the
aim of this study was to develop a high-throughput method for the extraction and
measurement of erythrocyte fatty acids and the n-3 index. For sample extraction and
quantification two methods were used; a single-step extraction, degradation and
derivatisation method by Lepage and Roy, followed by gas chromatography flame ionization
(GC-FID) which is commonly used and a high throughput method using an automated
methyl tert-butyl ether extraction followed by electrospray ionization mass spectrometry.
Both methods were first applied to the analysis of known concentrations of synthetic
phospholipid mixtures to determine recovery and precision prior to their application in the
analysis of human erythrocytes. The range of recoveries over five synthetic PL mixtures
were 86.4% - 108.9% and the coefficient of variation was < 10% (within-run) and ≤ 15.2%
(between-run). Both methods showed high correlation (R=0.993) for the n-3 index and there
was no systematic bias in the detection of n-3 index using either method. The new high
throughput method described here offers considerable advantages in terms of simplicity and
throughput compared to GC-FID method and provides additional information on molecular
phospholipid concentrations.

Abbreviations CerPCho Sphingomyelin, PtdSer Phosphatidylserine, PtdEtn
Phosphatidylethanolamine, PtdCho Phosphatidylcholine
Key words Mass spectrometry, n-3 index, Gas chromatography, Docosahexaenoic acid,
Eicosapentaenoic acid.
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Introduction
n-3 long chain polyunsaturated fatty acids (n-3 LCPUFA), particularly eicosapentaenoic acid
(20:5n-3, EPA) and docosahexaenoic acid (22:6n-3, DHA), provide several health benefits
including enhanced cognitive function, CVD prevention and treatment of arthritis and other
inflammatory and autoimmune disorders (Salem, 1989; Simopoulos,1999; Bakker et al.,
2003; Hibbeln et al., 2007; Marchioli et al., 2002). Conversely, insufficient n-3 LCPUFA
intake (Meyer, 2016) has been implicated in increased risk of CVD (Mozaffarian, 2008),
suboptimal neural development (Salem, Kim, & Yergy, 1986), psychiatric disorders (Hibbeln
& Salem, 1995) and neurodegenerative diseases (Calon et al., 2005).
The ‘n-3 index’ is defined as the sum of EPA and DHA levels in erythrocyte membranes
expressed as percent of total fatty acids (Harris & Von Schacky, 2004; Harris, 2008; Von
Schacky & Harris, 2007; Block et al., 2008). The n-3 Index in the western countries, the
Middle East, Africa and Southeast Asia is believed to be ≤ 4%. In countries where fish
consumption is high such as Korea, Japan and Scandinavia the average n-3 Index is ≥ 8%
and coronary artery disease is less common (Stark et al., 2016). Most notably, it has been
observed that an n3 index of 5% or more was associated with a 70% reduction in the risk of
primary cardiac arrest (Siscovick et al., 1995). Also, similar results suggest that whole blood
EPA and DHA concentration is strongly associated with a reduced risk of sudden death
among men without evidence of prior cardiovascular disease (Albert et al., 2002). Based on
this foundation, the n-3 index was proposed in 2004 as a marker of risk of death from CVD
(Harris & Von Schacky, 2004; Harris, 2008) and the n-3 index has now been widely
measured in different studies that examined not only CVD but also schizophrenia and
depression (Parletta et al., 2016) .
Erythrocytes have advantages over plasma since the former reflects the last few months of
food intake (Sullivan, Williams, & Meyer, 2006; Katan et al., 1997), while plasma EPA and
DHA status is representative of food intake over the previous few days (Arab, 2003).
Therefore, erythrocyte fatty acids are a more reliable biomarker of long-term EPA and DHA
status (Arab, 2003; Harris & Thomas, 2010). Specialized methods for extraction of lipids
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from erythrocyte membranes have been developed in the past (Reed, Swisher, Marinetti, &
Enen, 1960; Rose & Oklander, 1965) and these two methods have noted the difficulty of
extracting lipids from erythrocytes. The MTBE method (Matyash et al., 2008) has been
performed manually for the extraction of lipids from erythrocyte membranes (Turcot et al.,
2015, Tran et al., 2016). An automated plasma lipid extraction using the Hamilton STAR
robotic platform has also previously been published (Surma et al., 2015). However, the
previous MTBE methods were done manually and the automated method used plasma as
the sample, the novelty in this thesis is the use of the automated Hamilton STAR robotic
platform being applied to erythrocytes. Doing plasma samples on Hamilton STAR robotic
platform is easier than erythrocytes because erythrocytes need to be lysed to be able to
extract erythrocyte membrane lipids.
A common method used for measuring erythrocyte membranes fatty acid concentrations
including EPA and DHA (Ridges et al., 2001; Rodriguez-Palmero et al., 1998; Stewart et al.,
2007; Goozee et al., 2017) is the gas chromatography-based method of Lepage & Roy
(1986). The development of efficient analytical techniques, to improve recovery of all lipid
species, to reduce the time and amount of labour that is involved in the estimation of fatty
acids would improve the utility of measuring the n-3 index. Accordingly, several recent
studies have improved the throughput of gas chromatography-based fatty acid analysis
(Masood, Salem, & Stark, 2005; Masood & Salem 2008; Glaser et al., 2010).
The aims of this study were 1) to develop high throughput method for measuring erythrocyte
fatty acids and n-3 index utilizing an electrospray ionization mass spectrometry (ESI-MS)based method and 2) to compare this new method to the commonly used Lepage and Roy
method (GC-FID method) in terms of time, sample volume and overall cost.
Material and Methods
Chloroform, methanol and methyl tert-butyl ether (MTBE), were purchased from VWR
International (QLD, Australia) and were high performance liquid chromatography grade or
higher. Analytical grade ammonium acetate was obtained from Crown Scientific (New South
Wales, Australia). Ethylenediaminetetraacetic acid (EDTA), butylated hydroxytoluene (BHT),
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acetyl chloride, toluene and potassium carbonate (K2CO3) were all purchased from Sigma
Aldrich (NSW, Australia). Synthetic phospholipids (PL): 1-palmitoyl-2-oleoyl-sn-glycero-3phosphocholine (PtdCho 16:0/18:1), 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine
(PtdCho 16:0/18:2), 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (PtdCho
16:0/20:4), 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine (PtdCho
16:0/22:6), 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine (PtdEtn 18:0/20:4),
1-stearoyl-2- docosahexaenoyl –sn-glycero-3-phosphoethanolamine (PtdEtn 18:0/22:6), 1palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (PtdEtn 16:0/18:1) were purchased
from Avanti Polar Lipids through Auspep (Victoria, Australia).
Disposable tips used on the Hamilton-star liquid handling workstation were purchased from
Hamilton Robotics (Reno NV, USA). 50 uL and 300 uL sizes of conductive CO-RE tips
(without filter) were used. Twin-tec PCR (Polycarbonate) clean plates and 96-well plates
were purchased from Eppendorf (POCD scientific, Australia).
Preparation Synthetic PL mixtures
The seven synthetic PL listed above were mixed in concentrations designed to mimic human
erythrocyte membranes lipid levels (additional information is available in supplementary
materials). The concentrations of PtdCho (16:0/22:6) and PtdEtn (18:0/22:6) were varied in
order to create five synthetic PL mixtures with a range of n-3 indexes (2, 4, 6, 8 and 10 %).
The synthetic PL stock solutions were stored at -80oC in 10 mL glass vials containing 2:1
methanol: chloroform with 0.01 % BHT as an antioxidant. To the best of the authors’
knowledge, there are currently no commercially available synthetic PL species containing
EPA and hence EPA was not used in these synthetic PL mixtures. Nevertheless, EPA is
present at < 1% of total erythrocyte fatty acids. In comparison, DHA is usually present at ≥ 4
% (Jackson et al., 1997) and therefore in the synthetic PL mixtures DHA was used to
represent the n-3 fatty acids in the n-3 index. Synthetic PL mixtures were first analysed in
order to a determine recovery and accuracy of both methods. Analysing erythrocytes with
unknown fatty acid concentrations does not allow these parameters to be determined
accurately.
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Human Erythrocytes
This study was approved by the human research ethics committee at the University of
Wollongong (HE16/016) and written consent was obtained from all participants. Participants
were recruited from the University of Wollongong staff and students. Blood samples were
collected into vacutainers coated with EDTA to prevent clotting and platelet clumping. This
followed by centrifugation at 3000 rpm at 4 oC for 10 minutes and the remaining plasma and
white blood cells removed. Aliquots 1.5 ml of erythrocytes were stored at -80 oC until
required for analysis.
Lipid extraction & direct transesterification
The method for fatty acid extraction has been described previously (Ridges et al., 2001).
Briefly, frozen (-80°C) packed erythrocytes (n=25) were thawed and 400 uL resuspended at
room temperature in a Tris buffer, which contained 10 mM Trizma Base and 2 mM EDTA
Na2 (pH 7.2) in polycarbonate ultracentrifuge tubes (16 × 76mm). The samples were
capped, gently mixed and left at room temperature for 30 minutes to induce erythrolysis.
Erythrocyte membranes were pelleted by ultracentrifugation at 49000 rpm at 4°C for 30
minutes using a 70.1 TI rotor in a Beckman L-8 ultracentrifuge (Beckman, USA). The
supernatant was discarded and removed, and the pelleted erythrocyte membranes were
resuspended in 200 μL of distilled water. Aliquots (150 μL) of resuspended erythrocytes or
synthetic PL mixtures were subjected to direct transesterification according to the method of
Lepage and Roy (1986). Briefly, 2.2 mL of a stock solution methanol: toluene (4:1) and
0.01% BHT with the internal standard heneicosaenoic acid 0.2 mg/ml) was added to the 150
μL aliquots of erythrocyte membranes resuspension or synthetic PL mixtures. Following this,
200 uL of acetyl chloride was added while vortexing at low speed. The tubes containing this
solution were tightly sealed and heated on a heating block at 100oC for a period of 60
minutes. The tubes were cooled to room temperature in a water bath for 15 min and 6%
K2CO3 was added prior to centrifugation for 10 min at 3000 rpm at 4 oC. The extracted upper
toluene phase containing fatty acid methyl esters (FAME) was then transferred into glass GC
vials for analysis by GC-FID.
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Gas chromatography-flame ionization detection (GC-FID)
The gas chromatograph (GC-2010 plus, Shimadzu, Rydalmere, NSW, Australia) was fitted
with a fused silica capillary column with 50 m x 0.25 mm internal diameter x 0.25 um film
thickness from Agilent J & W GC Columns with the following temperature program: 150oC
initial temperature, 10oC/min to 162.5oC, 0.4oC/min to 172.5oC and 10oC/min to 211oC, the
injector and detector temperature were set at 250oC. The carrier gas was ultra-high purity
hydrogen and the column flow rate was 2.0 mL/min. Column pressure was maintained at
157.1 kPa. The split ratio was set at 20:1. One microliter of each sample was injected onto
the column using an auto injecting unit (Shimadzu AOC-20i) and the fatty acids were
detected using FID. The total analysis time was approximately 30 minutes per sample with
fatty acids eluting between 2.5 and 25 minutes. The fatty acids were identified by comparing
their retention time with known fatty acid standards (Nu-chek and Sigma, Sydney, NSW,
Australia). After analysis, each fatty acid was quantified by comparing their peak area to the
peak area of internal standard.
Adaptation of a lipid extraction protocol to a robotic platform
To assess the suitability of existing protocols to a robotic platform several key properties
were evaluated. They were: 1) the ability of the homogeising solvent to lyse erythrocytes, 2)
the impact of the solvent on erythrocyte clotting, 3) the ability to convert the protocol to small
volumes (<2000 μL) to fit a 96-well plate configuration, 4) an organic phase with a lower
density than water to allow removal of lipids from the top layer of the two-phase system, and
5) spontaneous phase separation (removing the need to centrifuge samples). The protocol
described by Matyash et al., (2008) appeared to fulfil many of these criteria and was chosen
as the method used in the current investigation.
The MTBE extraction protocol was initially tested manually using packed erythrocytes. The
first observation made was the difficulty of pipetting packed erythrocytes from the eppendorf
tubes in which they were stored. The second notable observation was the tendency of
erythrocytes to form an insoluble mass upon the addition of combined MTBE and methanol.
This was quite different from what occurs with the Lepage & Roy (1986) method where the
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addition of Tris buffer to the packed erythrocyte causes the cellular membranes to
immediately lyse with no sedimentation of the celluar membranes upon standing. The
clumping suggested that the membrane bound proteins had become denatured in the
presence of the organic solvents used. Furthermore, it was also unclear if the erythrocyte
membranes had been effectively lysed by the addition of solvents. This was an important
consideration as without the membrane being properly lysed, the lipids contained within the
membrane bi-layer would not be exposed to the solvents and it would not be possible to
solubilise the lipids in the following steps thus making the protocol ineffective for its proposed
means. The focus of refining the MTBE protocol thus turned to how the erythrocyte
membranes could be effectively lysed as well as preventing the “clotting”.
After testing several solvent systems (see supplementary material), we decided to use a 150
mM ammonium acetate solution due to its ability to lyse erythrocytes, prevent clotting and is
compatible with MS analysis. The Matyash et al., (2008) method reports the use of large
volumes of both the sample to be analysed and the reagents used in the protocol (matyash
et al., 2008). The starting volume of plasma used was 200 uL to which 1.5 mL of methanol is
added. Upon the addition of 5mL of MTBE this far exceeds the 2mL of the standard format
96-well plates. Hence, the first amendment made to the protocol was to reduce the volumes
used. To begin with, 10 uL was arbitrarily assigned as the volume of packed erythrocytes on
which the extraction would be performed. It was then calculated that the ratio of specimen to
methanol used by matyash et al., (2008) was 1:7 (sample: methanol v/v) and that the solvent
system used comprised of MTBE: methanol: aqueous reagents in the ratio 10:3:2.9 (v/v/v).
Applying these ratios to the new starting amount of 10 uL packed erythrocytes created a
protocol where the highest volume reached was 1600 μL. This is in line with the proposed
requirement for robot extraction that the highest volume reached is ≤2000 μL. This protocol
was then applied to the automated extraction as described below.
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Automated Lipid Extraction
For ESI-MS analysis, lipids where extracted from erythrocytes (n=25) and synthetic PL
mixtures (n=5) using the method of Matyash et al., (2008), with some modifications. In the
automated extraction method, 290 uL of an aqueous mixture containing 150 mM Ammonium
acetate and 2 mM EDTA was added to the wells of a 2.0 mL 96-well plate on ice. Aliquots of
10 μL taken from the synthetic PL mixtures or erythrocytes were then added to the wells
prior to vortexing at 800 rpm for 10 minutes. Robotic procedures were then started with all
plates, solvents and reagents loaded onto the automated liquid handling workstation
(Hamilton, Nevada, USA). A 300 μL aliquot of an internal standard mixture in methanol [500
uM (PtdCho 19:0_19:0); 166.7 uM (PtdEtn 17:0_17:0); 100 uM (PtdSer 17:0_17:0); 500 uM
(CerPCho 18:0_12:0)] was added to the wells prior to mixing and standing for 10 minutes.
Then 1 mL of MTBE was added to the wells and mixed for 30 minutes before the mixture
was allowed to stand for 15 minutes to allow phase separation. To ensure optimal lipid
extraction efficiencies the sample mixing was performed by repeated aspiration and
dispensing. Following this, 500 μL of the MTBE top phase was removed to the extraction
plate (containing the extracted PL) and 40 μL of this extract was transferred to another 96well plate and diluted with 760 μL of a 2:1 (v:v) methanol: chloroform solution containing 5
mM Ammonium acetate. A 40 μL aliquot of the diluted extract was transferred to another 96well plate, which was sealed with aluminum foil prior to analysis by mass spectrometry.
Electrospray ionization mass spectrometry (ESI-MS)
Mass spectrometry was performed utilizing a hybrid triple quadrupole linear ion trap mass
spectrometer (QTRAP 5500 ,Sciex, MA, USA) with an automated chip-based
nanoelectrospray source (Triversa NanoMate, Advion Biosciences, New York, USA) as
previously described (Brown et al., 2013; Norris et al., 2015). A 10 uL aliquot of lipid extract
diluted in methanol: chloroform (2:1 v/v) containing 5mM ammonium acetate (approximately
10 uM) was infused into the nano-electrospray ion source. Spray parameters were a voltage
of 1.1 kV for negative ion acquisition and 1.2 kV for positive ion acquisition and a nitrogen
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gas pressure of 0.40 psi (Brown et al., 2013; Norris et al., 2015). Lipids were identified using
precursor ion and neutral loss scans as show in Supplementary Table S7. Specifically,
precursor ion scans for phosphocholine ctaions (m/z 184.1) were used to detect PtdCho and
CerPCho species while neutral loss scans were used to detect PtdEtn species
(phosphoethanolamine loss, 141.0 Da) and PtdSer species (phosphoserine loss, 185.0 Da)
(Brugger et al. 1997). The identitiy of the FA component of each PL was determined using
precursor ion scanning for each FA in negative ion mode (Supplementary Table S7).
Ionized lipids identified with a minimum signal-to-noise ratio of 10 were included in the
analysis. Identification and quantification was accomplished using LipidView software
(version 1.2, Sciex, MA, USA) this included smoothing, identification, removal of isotope
contribution from lower mass species, and correction for isotope distribution, as described
(Brown et al., 2013; Norris et al., 2015). Quantification was performed using LipidView
software by comparing the spectral peak area of individual lipids to their class specific
internal standards following isotope correction. Fatty acid concentrations were then
determined directly from PL concentration i.e. the concentration of each fatty acid is
equivalent to the parent. For example if PtdCho 16:0_18:0 is 1.5 nmol/ml then the fatty acid
16:0 and fatty acid 18:0 are both 1.5 nmol/ml. Isobaric phospholipids e.g. PtdCho 16:0/22:6
and PtdCho 18:1/20:5 were resolved using fatty acid precursor ion scans. The concentration
obtained from the head group scan was multiplied by the ratio of the relative abundance of
each fatty acid pair to obtain the concentration of each molecular PL as described previously
(Nealon, Blanksby, Mitchell, & Else, 2008). An excerpt (plus explanatory comments) from the
spreadsheet where these calculations were performed is show in Supplementary Figure S1.
A quality control (QC) sample was produced using pooled erythrocytes from healthy
volunteers (n = 10, 5 male and 5 female) aged between 13 and 40 years. The QC aliquots
were stored frozen at (−80 °C). With each full plate prepared (96 well plate) in the highthroughput ESI-MS method 3 QC samples distributed in positions (2, 49 and 95) to monitor
instrument performance and assay precision. To assess contamination and interference 3
blank samples were processed side-by-side with analytical samples and placed in positions
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(1, 48 and 96) of each 96-well plate. Additionally, blanks were used to correct the data by
subtracting blank readings from sample readings.

Statistics
Statistical analyses were performed using Microsoft excel and SPSS statistics. Pearson’s
correlation coefficient (r) was determined and tested for significance via two-tailed analysis.
A Bland-Altman plot was produced to assess the agreement between the two methods
(Bland & Altman, 1986; Altman & Bland, 2002; Ludbrook, 2010).

Results and Discussion
Recovery
Extraction recovery was tested to evaluate the accuracy of the method. As is evident in table
1 recovery and detection in both the GC-FID and the high-throughput ESI-MS methods was
greater than 86% for most fatty acids.
An unexpected result was the low recovery of 18:0 using the MS-based method (50.961.3%) and 22:6 using both methods (66.9-85.1% for GC-FID method and 63.5-75.3% for
ESI-MS method). Interestingly, PtdEtn (18:0/22:6), was noticeably yellow in colour inside the
2.5 mL ampule (starting material) and low signal of PtdEtn (18:0/22:6) detected (See
supplementary figure S2) , suggesting oxidation had occurred and may explain these
findings. The GC-FID method measures only the fatty acids and not the whole PL molecule.
This means that only the data for the oxidized fatty acid is altered; i.e. a lower than expected
22:6 level was detected. This is in contrast to the high-throughput ESI-MS method, which
measures the intact PL. Therefore, when one fatty acid is oxidized the data from both fatty
acids is lost. In the case of oxidized PtdEtn (18:0/22:6) both 22:6 and 18:0 would be reduced
as observed. If the concentration of PtdEtn (18:0/22:6) add to the synthetic mixtures is
removed from the expected values, the recovery of 18:0 of using the ESI-MS method
increases to (70.3-99.3%) and 22:6 is improved for both methods (83.7-106.4% for the GCFID method and 81.2-94.1% for the ESI-MS method).
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Table 1:- Average amount of synthetic PL mixtures (nmol/ml) across a range of n-3 indexes recovered using the GC-FID and high-throughput
ESI-MS methods (n=3 for all mixtures).
* Synthetic PL mixtures
(%)

Fatty acids

2

Expected value

GC-FID method

nmol/ml

Mean ± SEM

16:0
18:0
18:1
18:2
20:4
22:6

941.5
58.5
444.6
363.8
151.6
40.0

4

16:0
18:0
18:1
18:2
20:4
22:6

6

8

10

The high-throughput ESI-MS method
Mean ± SEM

930.0 ± 24.3
57.8 ± 0.9
429.8 ± 15.9
344.9 ± 2.7
147.4 ± 7.5
27.8 ± 0.2

(%) recovery of synthetic
PL
98.8%
98.8%
96.7%
94.8%
97.2%
69.6%

929.9 ± 10.1
35.5 ± 0.2
406.5 ± 11.5
396.0 ± 2.6
132.8 ± 5.5
30.1 ± 0.9

(%) recovery of synthetic
PL
98.8%
60.7%
91.4%
108.9%
87.6%
75.3%

935.6
64.4
426.1
348.6
145.3
80.0

927.0 ± 17.8
64.9 ± 1.9
423.1 ± 3.3
347.8 ± 10.8
141.9 ± 4.4
56.5 ± 1.9

99.1%
100.8%
99.3%
99.8%
97.7%
70.6%

890.1 ± 13.9
36.9 ± 2.0
400.3± 7.8
341.3 ± 3.1
125.5 ± 1.9
59.9 ± 1.7

95.1%
57.3%
93.9%
97.9%
86.4%
74.8%

16:0
18:0
18:1
18:2
20:4
22:6

929.7
70.3
407.6
333.5
138.9
120.0

827.0 ± 7.8
67.9 ± 1.7
386.7 ±3.2
316.7 ± 2.2
128 ± 1.6
80.3 ± 1.2

88.9%
96.6%
94.9%
94.9%
92.4%
66.9%

893.4 ± 3.0
40 ± 0.9
401.2 ± 4.5
329.1 ± 6.2
125.4 ± 2.8
77.9 ± 0.9

96.1%
57.2%
98.4%
98.7%
90.3%
64.9%

16:0
18:0
18:1
18:2
20:4
22:6

923.8
76.2
389.1
318.3
132.6
160.0

907.4 ± 19.1
75.8 ± 3.1
384.2 ± 9.9
313.7 ± 1.6
121.0 ± 6.1
136.2 ± 9.3

98.2%
99.4%
98.7%
98.6%
91.6%
85.1%

855.3 ± 4.7
41.9 ± 0.4
374.2 ± 6.4
301.2 ± 1.7
120.1± 0.8
101.7±1.9

92.6%
54.9%
96.2%
94.6%
90.6%
63.5%

16:0
18:0
18:1
18:2
20:4
22:6

917.9
82.1
370.5
303.2
126.6
200.0

896.3 ± 3.6
83.9 ± 0.4
367.9 ± 2.6
303.6 ± 1.4
125.6 ± 8.5
149.1 ± 1.7

879.3 ± 8.6
41.8 ± 1.6
360.2 ± 5.3
294.0 ± 4.6
118.5 ± 0.5
148.4 ± 5.2

95.8%
50.9%
97.2%
96.9%
93.6%
74.2%

97.6%
102.3%
99.3%
100.1%
99.2%
74.5%
SEM, standard error of the mean. * See supplementary materials (Tables S1 to S5) for additional Synthetic PL mixtures

88

information.

Precision
Precision was assessed by estimating within-run and between-run %CV for both methods as
shown in Table 2.
The within-run %CV of each fatty acid in each synthetic PL mixture for both the GC-FID
method and the high-throughput ESI-MS methods were calculated for n=3 (Table 2). The
within-run precision for high-throughput ESI-MS method was less than 10% and this is
comparable to the GC-FID method. The high-throughput ESI-MS method also shows
comparable results for within-run precision with previously published work using gas
chromatography-flame ionization detection (GC-FID) fatty acid analysis (CV < 8% and <
14%) (Glaser et al., 2010; Lin et al., 2012) and gas chromatography/mass spectrometry
analysis GC-MS (CV <14%) (Quehenberger, Armando, & Dennis, 2011).
Measurement of between-run precision was calculated for samples of synthetic PL mixtures
(n=3/day) over one month (Table 2). The between-run %CV in high-throughput ESI-MS
method was slightly higher (≤ 15.2%) compared to the between-run coefficient of variation (≤
13.9%) observed in GC-FID method. Also, the between-run coefficient of variation observed
in the high-throughput ESI-MS method was comparable to that of the method used GC-FID
and GC-MS fatty acid analysis (CV <16% and <17%) (Lin et al., 2012; Quehenberger,
Armando, & Dennis, 2011). The QC samples intra-assay precision (within the batch) ranged
from 0.90% to 17.4% of 19 batches and the average inter-assay precision (batch-to-batch)
ranged from 6.9% to 20% of 19 batches. (See supplementary material table S9 for fatty
acids QC samples concentration data).
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Table 2: Within–run and between-run precision for the GC-FID and high-throughput ESI-MS methods.
*Synthetic
PL mixtures
(%)

2

4

6

8

10

Fatty
acids
16:0
18:0
18:1
18:2
20:4
22:6
16:0
18:0
18:1
18:2
20:4
22:6

GC-FID method
Mean nmol/ml ± SEM (within-run
Mean nmol/ml ± SEM (between-run
%CV)
%CV)
930.0 ± 24.3 (4.4)
962.1 ± 36.4 (11.9)
57.8 ± 0.9 (2.6)
59.4 ± 1.5 (7.9)
429.8 ± 15.9 (6.3)
443.3 ± 16.5 (11.8)
344.9 ± 2.7 (1.3)
362.9 ± 3.0 (2.6)
147.4 ± 7.5 (8.7)
145.0 ± 5.5 (11.9)
27.8 ± 0.2 (1.2)
27.6 ± 1.0 (11.4)
927.0 ± 17.8 (3.3)
924.8 ± 18.0 (6.2)
64.9 ± 1.9 (4.9)
65.8 ± 2.5 (12.0)
423.1 ± 3.3 (1.3)
420.7 ± 4.0 (3.0)
347.8 ± 10.8 (5.3)
352.1 ± 10.0 (8.9)
141.9 ± 4.4 (5.3)
136.7 ± 5.0 (11.6)
56.5 ± 1.9 (5.7)
55.0 ± 1.5 (8.6)

The high-throughput ESI-MS method
Mean nmol/ml ± SEM (within-run
Mean nmol/ml ± SEM (between-run
%CV)
%CV)
929.9 ± 10.1 (1.8)
831.6 ± 22.2 (8.4)
35.5 ± 0.2 (0.9)
36.5 ± 0.4 (3.5)
406.5 ± 11.5 (4.8)
375.8 ± 8.9 (7.5)
396.0 ± 2.6 (1.1)
335.8 ± 14.2 (13.4)
132.8 ± 5.5 (7.0)
127.4 ± 3.4 (8.4)
30.1 ± 0.9 (5.1)
29.1 ± 0.5 (5.4)
890.1 ± 13.9 (2.7)
843.4 ± 19.8 (7.5)
36.9 ± 2.0 (9.2)
35.9 ± 1.3 (11.4)
400.3± 7.8 (3.3)
379.8 ± 11.1 (9.2)
341.3 ± 3.1 (1.5)
327.9 ± 10.4 (10.0)
125.5 ± 1.9 (2.6)
113.4 ± 3.1 (8.6)
59.9 ± 1.7 (4.8)
57.3 ± 1.4 (7.7)

16:0
18:0
18:1
18:2
20:4
22:6

827.0 ± 7.8 (1.6)
67.9 ± 1.7 (4.3)
386.7 ±3.2 (1.4)
316.7 ± 2.2 (2.6)
128 ± 1.6 (2.1)
80.3 ± 1.2 (2.5)

835.2 ± 8.9 (3.4)
70.9 ± 2.8 (12.5)
397.5 ± 4.1 (3.3)
325.1 ± 3.7 (3.6)
130.1 ± 1.9 (4.6)
81.2 ± 3.1 (12.1)

893.4 ± 3.0 (0.6)
40.0 ± 0.9 (3.8)
401.2 ± 4.5 (1.9)
329.1 ± 6.2 (3.2)
125.4 ± 2.8 (3.8)
77.9 ± 0.9 (1.9)

905.5 ± 5.5 (1.9)
41.7 ± 2.0 (15.2)
395.1 ± 8.4 (6.7)
309.7 ± 9.5 (9.7)
119.0 ± 5.5 (14.6)
75.2 ± 1.1 (4.6)

16:0
18:0
18:1
18:2
20:4
22:6

907.4 ±19.1 (3.6)
75.8 ± 3.1 (6.9)
384.2 ± 9.9 (4.4)
313.7 ± 1.6 (0.9)
121.0 ± 6.1 (8.6)
136.2 ± 8.0 (10.0)

929.4 ± 20.2 (6.9)
76.9 ± 3.4 (13.9)
379.6 ± 10.5 (8.7)
323.2 ± 1.9 (1.9)
118.3 ± 5.0 (13.4)
132.2 ± 5.8 (13.9)

855.3 ± 4.7 (0.2)
41.9 ± 0.4 (1.6)
374.2 ± 6.4 (2.9)
301.2 ± 1.7 (0.9)
120.1± 0.8 (1.1)
101.7±1.9 (3.2)

778.9 ± 20.9 (8.5)
40.5 ± 1.9 (14.8)
334.5 ± 11.2 (10.6)
283.6 ± 6.6 (7.4)
105.8 ± 4.6 (13.7)
95.6 ± 2.5 (8.3)

16:0
18:0
18:1
18:2
20:4
22:6

896.3 ± 3.6 (0.7)
83.9 ± 0.4 (0.6)
367.9 ± 2.6 (1.2)
303.6 ± 1.4 (0.6)
125.6 ± 6.5 (8.8)
149.1 ± 1.7 (1.9)

900.9 ± 4.5 (1.6)
84.8 ± 1.2 (4.5)
364.9 ± 2.9 (2.5)
307.9 ± 1.5 (1.5)
118.2 ± 5.1 (13.6)
144.3 ± 2.4 (5.3)

879.3 ± 8.6(1.7)
41.8 ± 1.6 (6.5)
360.2 ± 5.3 (2.5)
294.0 ± 4.6 (2.7)
118.5 ± 0.5 (0.7)
148.4 ± 5.2 (5.9)

813.4 ± 21.5 (8.4)
42.6 ± 1.9 (14.0)
341.7 ± 14.9 (13.8)
261.7 ± 10.2 (12.3)
106.4 ± 4.1 (12.2)
146.2 ± 4.9 (10.6)

Coefficient of variation (%CV). SEM, standard error of the mean. Within run %CV (n=3); between run %CV (n= 3/day over one month).* See supplementary materials
(Tables S1 to S5) for additional Synthetic PL mixtures information.
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Measurement of erythrocyte fatty acids and n-3 index using two methods
There is a strong correlation (R= 0.993) between the GC-FID method and the high
throughput ESI-MS method when assessing n-3 index over a range of 2-10% (figure 1).
Erythrocytes omega-3 index (%)
GC-FID method vs the high throughput ESI-MS method

GC-FID method

10
8
6
4
2
0
0

2

4

6

8

10

The high throughput ESI-MS method
Figure 1: Correlation between the GC-FID method and the high throughput ESI-MS method
using erythrocyte samples (n=25) over an n-3 index range of 2-10%. The line of best fit is y =
1.01567x. R= 0.993.
There was good agreement between the two methods across the range of n-3 index (2-10
%) with all points plotted falling within both the upper and lower limits of agreement (95% CI)
as shown in figure 2. There was no systematic bias in the detection of n-3 index extracted
using either method. To the best of the authors’ knowledge, this is the first validation study
using Bland-Altman plot in comparing the difference between the two methods measuring
fatty acids. The reporting of correlation coefficients can be misleading as correlations
measure the strength of a relationship between two methods rather than the level of
agreement between the results yielded by two methods (Bland & Altman, 1986). As
described by Bland and Altman (1986) a significant correlation is expected if two measures
are measuring same thing. As such, studies validating a novel method against a reference
method should be interpreted with caution where validity is measured and reported by way
of correlation.
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Figure 2: Bland-Altman plot of the difference between the two methods (the high throughput
ESI-MS method minus GC-FID method) against their mean of n-3 index (%) using
erythrocytes (n=25). The line of best fit (dashed line) is y = 02 + -0.01x (R² = 0.015). {95 %
confidence interval = Mean difference ± (STD of difference * 1.96)} STD = 0.235.
The concentration of erythrocytes fatty acids as determined by the GC-FID method and the
high throughput ESI-MS method are presented in Table 3. The difference between the two
methods was less than 10% with exception for fatty acid 22:4, where the difference was
37.5%. The abundance of fatty acid 22:4 is relatively low. The amount of 22:4 measured by
the GC-FID method detects the total fatty acid amount obtained from all PL species in a
single GC peak. This is advantageous as it improves signal -to-noise and therefore
sensitivity of fatty acid with low relative abundance. Because 22:4 is of relatively low total
abundance and was bound to several different PL species, the signal obtained by ESI-MS
was further diluted. This results in a decreased signal-to-noise and therefore, some 22:4
containing PLs were below the limit of quantification and are not included in the MS totals
(but would be included in the GC analysis).
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Table 3: comparison of erythrocytes fatty acids concentrations using GC-FID method and
high throughput ESI-MS method. (nmol/ml blood) (n=25)
Fatty
GC-FID method
GC-FID method (Mean
high throughput
Difference
± SEM) corrected
acids
(Mean ± SEM)
ESI-MS method
%
(Mean ± SEM)
460.3 ± 8.6
16:0
331.8 ± 8.4
464.9 ± 7.3
N/A*
17:0
16.6 ± 0.8
18.1 ± 0.8
-8.6
263.8 ± 5.5
18:0
232.9 ± 6.2
269.3 ± 7.1
N/A*
93.5 ± 2.9
24:0
37.7 ± 2.1
85.0 ± 2.6
N/A*
16:1
4.9 ± 0.8
4.6 ± 0.7
6.3
198.0 ± 3.3
18:1
186.5 ± 4.4
207.3 ± 3.9
N/A*
122.7 ± 3.6
24:1
49.5 ± 1.8
122.7 ± 3.6
N/A*
18:2
155.1 ± 6.9
158.1 ± 6.4
-1.9
20:3
23.8 ± 1.6
22.9 ± 1.6
3.9
20:4
201.7 ± 5.2
195.7 ± 4.3
3.0
20:5
9.8 ± 1.1
9.9 ± 1.2
-1.0
22:4
37.6 ± 1.6
25.7 ± 1.9
37.5
22:5
31.5 ± 1.6
31.1 ± 1.5
1.3
22:6
67.6 ± 3.3
66.7 ± 3.2
1.3
Corrected data shown in bold, Values (V), Difference % = |V 1 − V 2| / (V 1 +V 2) / 2 × 100. (V1 GC-FID results)
& V2 ESI-MS results). N/A* (the difference % was not calculated because the data has been corrected using the
new method).

Sample derivatization is required to improve fatty acid volatility (Brondz, 2002). Nowadays,
procedures allowing simultaneous hydrolysis and methylation of bound fatty acids are
becoming more and more popular. Lepage & Roy (1986) have proposed the one-step direct
transesterification procedure suitable for fatty acid classes. The analysis of fatty acid methyl
esters (FAME) from erythrocyte membranes may be differentially affected by the method of
lipid extraction. Rodrıg
́ uez-Palmero coworkers compared direct (Lepage & Roy) and
conventional esterification (Folch) methods and found that the direct method has substantial
advantages over the conventional method in terms of reduce contamination and increased
throughput. However, the transesterification of amides from sphingomyelin (CerPCho) is less
efficient than that of esters from glycerophospholipids (Christie & Han, 2012); this results in
an underestimation of fatty acids bound to CerPCho when using the GC-FID method
described here.
To determine the transesterification efficiency of sphingomyelin using the Lepage and Roy
method CerPCho 24:1 was added to the synthetic PL mixture shown in table S5. This
mixture was then subjected to both the GC and MS methods described earlier and the
results shown in the supplementary material (Table S6). A very low recovery (45%) was
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obtained using the GC-FID method compared to 98% recovery using the high-throughput
ESI-MS method. In order to account for this underestimation a correction factor was
determined and applied as follows. Five erythrocytes samples were selected at random and
the concentration of fatty acid 24:1 obtained from the high-throughput ESI-MS method (123
nmol/ml blood) was divided by the fatty acid 24:1 concentration determined by the GC-FID
method (49.5 nmol/ml blood). This produced a correction factor of 2.48. Fatty acid 24:1 was
chosen to calculate the correction factor as it was found exclusively bound to CerPCho in
erythrocytes. To correct for fatty acids exclusive to CerPCho, i.e. 24:1 and 24:0 the GC-FID
data was simply multiplied by 2.48 (the correction factor).
For fatty acids bound to both phospholipids and CerPCho (16:0, 18:0 and 18:1) further
calculations were required to determine the corrected fatty acid concentrations. They were;
1) dividing the concentration of CerPCho bound fatty acid by the total fatty acid
concentration (both determined by ESI-MS) for 16:0, 18:0 and 18:1 in every sample to obtain
the proportion of CerPCho fatty acid, 2) multiplying the GC data by this proportion to obtain
the approximate CerPCho fatty acid concentration, 3) multiplying the calculated CerPCho
fatty acid concentration by the correction factor (2.48), and 4) adding the corrected CerPCho
fatty acid concentration to the PL fatty acid concentration. A step-by step example of this
calculation is provided in the supplementary material. The result of applying the correction
factor to 16:0, 18:0, 18:1, 24:0 and 24:1 concentrations determined by GC-FID are shown in
Table 3.
As shown in the table 4 the new method is cheaper than the GC-FID method with several
other advantages e.g. throughput is increased by almost 8 times; sample and reagent
volumes can be reduced four-fold and additional information, i.e. phospholipid class and
species information is obtained.
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Table 4: comparison between methods using GC-FID method and high throughput ESI-MS
method.
high throughput ESI-MS method
GC-FID method
Number of samples per
24 samples per day

186 samples per day

Time needed for sample

Approximately 6 hours

Approximately 6 hours to prepare

preparation

to prepare 24 samples

186 samples

Quantity of sample used

400 uL

10 uL

Data acquired

Only fatty acids

Fatty acids

day

PL classes
Quantity of solvents used
8 ml

Approximately 2 ml

$ 50

$ 20

per sample
Cost per sample

The throughput ESI-MS method does however, have limitations. First the diluting of signal
from low relative abundance fatty acids across several PL species can hinder their detection.
Second, the double bond location cannot be determined, e.g., this method is unable to
determine whether 22:5 docosapentaenoic acid is 22:5n-3 or 22:5n-6 or if 18:1 is 18:1n-9 or
18:1n-7. While several MS-based methods for determining double bond position have been
developed they are not yet amenable to high-throughput, quantitative anlysis (Hancock et al.
2017). Nevertheless, future addition of such techniques will further enhance the analysis of
FAs and the n-3 index. Additionally, pipetting of 10 uL of packed erythrocytes introduced
variation between samples (data not shown), as pipetting this volume of packed cells is
difficult. Given that sample volume is generally not limited in this process, the initial starting
volume of erythrocytes could easily be increased to further reduce variability between
sample measurements. This could possibly be achieved using the robotic system to initially
pipette a larger cell volume and perform hemolysis prior to aliquoting a small volume of the
lyzed cell mixture for extraction.
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In conclusion, the high throughput ESI-MS method described here allows the determination
of human erythrocyte fatty acid concentration and n-3 index from low sample volumes. The
method is convenient, simple, low in cost and significantly increases throughput compared to
the reference GC-FID method. Consequently, the method is well suited for application in
epidemiological studies and large clinical trials.

Acknowledgements: This research was supported by a small project grant from the Faculty
of Science, Medicine and Health, from the University of Wollongong. The authors would like
to thank the volunteers that participated in this study. We also thank to King Fahad Specialist
Hospital administration, Dammam, Saudi Arabia for sponsoring Ayedh Alqarni

96

References
Albert, C.M., Campos, H., Stampfer, M.J., Ridker, P.M., Manson, J.E., Willett, W.C., MA, J.
(2002) Blood levels of long-chain n-3 fatty acids and the risk of sudden death. New England
Journal of Medicine, 346, 1113-8.

Altman, D.G., Bland, J.M. (2002) Commentary on quantifying agreement between two
methods of measurement. Clinical Chemistry, 48, 801-802.

Arab, L. (2003) Biomarkers of fat and fatty acid intake. Journal of Nutrition, 133, 925S-932S.

Bakker, E., Ghys, A., Kester, A., Vles, J., Dubas, J., Blanco, C., Hornstra, G. (2003) Longchain polyunsaturated fatty acids at birth and cognitive function at 7y of age. European
Journal of Clinical Nutrition, 57, 89-95.

Bland, J.M., Altman, D.G. (1986) Statistical methods for assessing agreement between two
methods of clinical measurement. Lancet, 327, 307-310.

Block, R.C., Harris, W.S., Reid, K.J., Sands, S.A., Spertus, J.A. (2008) EPA and DHA in
blood cell membranes from acute coronary syndrome patients and controls. Atherosclerosis,
197, 821-828.

Brondz, I., (2002) Development of fatty acid analysis by high-performance liquid
chromatography, gas chromatography, and related techniques. Analytica Chimica Acta, 465,
1-37.

Brown, S.H., Kunnen, C.M., Duchoslav, E., Dolla, N.K., Kelso, M.J., Papas, E.B., Lazon de
la jara, P., Willcox, M.D., Blanksby, S.J., Mitchell, T.W. (2013) A comparison of patient
matched meibum and tear lipidomes. Investigative Ophthalmology & Visual Science, 54,
7417-7424.

Brugger B., Erben G., Sandhoff R., Wieland F.T., Lehmann W.D. (1997) Quantitative
analysis of biological membrane lipids at the low picomole level by nano-electrospray
ionization tandem mass spectrometry. Proceedings of the National Academy of Sciences of
the United States of America, 94, 2339-2344

97

Calon, F., Lim, G.P., Morihara, T., Yang, F., Ubeda, O., Salem, N., Frautschy, S.A., Cole,
G.M. (2005) Dietary n‐3 polyunsaturated fatty acid depletion activates caspases and
decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's
disease. European Journal of Neuroscience, 22, 617-626.

Christie, W.W., Han, X. (2012) Lipid Analysis, Separation, Identification and Lipidomic
Analysis. (Fourth edition). Woodhead Publishing.

Folch, J., Lees, M., Sloane-Stanley, G. (1957) A simple method for the isolation and
purification of total lipids from animal tissues. Journal of Biological Chemistry, 226, 497-509.

Glaser, C., Demmelmair, H., Koletzko, B. (2010) High-throughput analysis of total plasma
fatty acid composition with direct in situ transesterification. PloS one, 5, e12045.
Goozee, K., Chatterjee, P., James, I., Shen, K., Sohrabi, H.R., Asih, P.R., Dave, P., Ball, B.,
Manyan, C., Taddei, K., Chung, R., Garg, M.L., Martins, R.N. (2017) Alterations in
erythrocyte fatty acid composition in preclinical Alzheimer's disease. Scientific Reports, 7,
676.

Hancock S.E., Poad B.L.J., Batarseh A., Abbott S.K., Mitchell T.W. (2017) Advances and
unresolved challenges in the structural characterization of isomeric lipids. Analytical
Biochemistry, 524, 45-55.

Harris W.S., Von Schacky, C. (2004) The n-3 Index: A new risk factor for Death from
Coronary Artery disease? Preventive Medicine, 39, 212-220.

Harris, W.S. (2008) The n-3 index as a risk factor for coronary heart disease. The American
Journal of Clinical Nutrition, 87, 1997S-2002S.

Harris, W.S., Thomas, R.M. (2010) Biological variability of blood n-3 biomarkers. Clinical
Biochemistry, 43, 338-340.

Hibbeln, J.R., Davis, J.M., Steer, C., Emmett, P., Rogers, I., Williams, C., Golding, J. (2007)
Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in
childhood (ALSPAC study): an observational cohort study. Lancet, 369, 578-585.

98

Hibbeln, J.R., Salem, N. (1995) Dietary polyunsaturated fatty acids and depression: when
cholesterol does not satisfy. The American Journal of Clinical Nutrition, 62, 1-9.

Jackson, J.A., Riordan, H.D., Hunninghake, R., Meng, X., Sarwar, Y. (1997) Red blood cell
membrane fatty acids as a diagnostic test. Journal of Orthomolecular Medicine, 12, 20-22.

Katan, M.B., Deslypere, J.P., Van birgelen, A.P., Penders, M., Zegwaard, M. (1997) Kinetics
of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte
membranes, and adipose tissue: an 18-month controlled study. Journal of Lipid Research,
38, 2012-2022.

Lepage G, Roy C, (1986) Direct transesterification of all classes of lipids in a one-step
reaction. Journal of Lipid Research, vol. 27, pp. 114-120.

Lin, Y.H., Salem, N., Wells, E.M., Zhou, W., Loewke, J.D., Brown, J.A., Lands, W.E.,
Goldman, L.R., Hibbeln, J.R., (2012) Automated high-throughput fatty acid analysis of
umbilical cord serum and application to an epidemiological study. Lipids, 47, 527-539.

Ludbrook, J. (2010) Confidence in Altman–Bland plots: a critical review of the method of
differences. Clinical and Experimental Pharmacology and Physiology, 37, 143-149.

Marchioli, R., Barzi, F., Bomba, E., Chieffo, C., DI gregorio, D., DI mascio, R., Franzosi,
M.G., Geraci, E., Levantesi, G., Maggioni, A.P., Mantini, L., Marfisi, R.M., Mastrogiuseppe,
G., Mininni, N., Nicolosi, G.L., Santini, M., Schweiger, C., Tavazzi, L., Tognoni, G., Tucci, C.,
Valagussa, F. (2002) Early protection against sudden death by n-3 polyunsaturated fatty
acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano
per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation,
105, 1897-903.

Masood, A., Salem, N. (2008) High-throughput Analysis of Plasma Fatty Acid Methyl Esters
Employing Robotic Transesterification and Fast Gas Chromatography, Journal of Lipid
Research, vol. 43, 171-180.

Masood, A., Salem, N., Stark, K. (2005) A simplified and efficient method for the Analysis of
fatty acid methyl esters suitable for large clinical studies, Journal of Lipid Research, vol. 46,
pp 2299-2305.

99

Matyash, V., Liebisch, G., Kurzchalia, T.V., Shevchenko, A., Schwudke, D. (2008) Lipid
extraction by methyl-tert-butyl ether for high-throughput lipidomics. Journal of Lipid
Research, 49, 1137-1146.

Meyer, B.J. (2016) Australians are not Meeting the Recommended Intakes for n-3 Long
Chain Polyunsaturated Fatty Acids: Results of an Analysis from the 2011–2012 National
Nutrition and Physical Activity Survey. Nutrients, 8, 111.
Mozaffarian, D. (2008) Fish and n− 3 fatty acids for the prevention of fatal coronary heart
disease and sudden cardiac death. The American Journal of Clinical Nutrition, 87, 1991S1996S.

Nealon, J.R., Blanksby, S.J., Mitchell, T.W., Else, P.L. (2008) Systematic differences in
membrane acyl composition associated with varying body mass in mammals occur in all
phospholipid classes: an analysis of kidney and brain. The Journal of Experimental Biology,
211, 3195-3204.

Norris, S.E., Friedrich, M.G., Mitchell, T.W., Truscott, R.J.W., Else, P.L. (2015) Human
prefrontal cortex phospholipids containing docosahexaenoic acid increase during normal
adult aging, whereas those containing arachidonic acid decrease. Neurobiology of Aging, 36,
1659-1669.

Parletta, N., Zarnowiecki, D., Cho, J., Wilson, A., Procter, N., Gordon, A., Bogomolova, S.,
O'dea, K., Strachan, J., Ballestrin, M., Champion, A., Meyer, B.J. (2016) People with
schizophrenia and depression have a low n-3 index. Prostaglandins, Leukotrienes and
Essential Fatty Acids, 110, 42-47.

Phuong, P. N., Brown, S. H., Mitchell, T. W., Matuschewski, K., Mcmillan, P. J., Kirk, K.,
Dixon, M. W. & Maier, A. G. (2014) A female gametocyte-specific ABC transporter plays a
role in lipid metabolism in the malaria parasite. Nat Commun, 5, 4773.

Quehenberger, O., Armando, A.M., Dennis, E.A. (2011) High sensitivity quantitative
lipidomics analysis of fatty acids in biological samples by gas chromatography–mass
spectrometry. Biochim Biophys Acta - Molecular and Cell Biology of Lipids, 1811, 648-656.

Reed, C.F., Swisher, S.N., Marinetti, G.V., Enen, E.G. (1960) Studies of the lipids of the
erythrocyte. I. Quantitative analysis of the lipids of normal human red blood cells. Journal of
100

Laboratory and Clinical Medicine, 56, 281-289.

Ridges, L., Sunderland, R., Moerman, K., Meyer, B., Astheimer, L., Howe, P. (2001)
Cholesterol lowering benefits of soy and linseed enriched foods. Asia Pacific Journal of
Clinical Nutrition, 10, 204-211.
Rodrıg
́ uez-Palmero, M., Lopez-Sabater, M.C., Castellote-Bargallo, A.I., De la torre-Boronat,
M.C., Rivero-urgell, M. (1998) Comparison of two methods for the determination of fatty acid
profiles in plasma and erythrocytes. Journal of Chromatography A, 793, 420-425.

Rose, H.G., Oklander, M. (1965) Improved procedure for the extraction of lipids from human
erythrocytes. The Journal of Lipid Research, 6, 428-431.

Salem, N. (1989) n-3 fatty acids: molecular and biochemical aspects. In: Current Topics in
Nutrition and Disease: New Protective Roles for Selected Nutrients. (Spiller GA, ed), pp 109–
228.

Salem, N., Kim, H.Y., Yergy, J.A. (1986) Docosahexaenoic acid: membrane function and
metabolism. In: health effects of polyunsaturated fatty acids in seafoods (Simopoulos AP,
Kifer RR, Martin RE.,eds), pp 263-317.

Simopoulos, A.P. (1999) Essential fatty acids in health and chronic disease. The American
Journal of Clinical Nutrition, 70, 560s-569s.

Siscovick, D.S., Raghunathan, T.E., King, I., Weinmann, S., Wicklund, K.G., Albright, J.,
Bovbjerg, V., Arbogast, P., Smith, H., Kushi, L.H., Cobb, L.A., Copass, M.K., Psaty, B.M.,
Lemaitre, R., Retzlaff, B., Childs, M., Knopp, R.H. (1995) Dietary Intake and Cell Membrane
Levels of Long-Chain n-3 Polyunsaturated Fatty Acids and the Risk of Primary Cardiac
Arrest. The Journal of the American Medical Association, 274, 1363-1367.

Stark, K.D., Van elswyk, M.E., Higgins, M.R., Weatherford, C.A., Salem, N. (2016) Global
survey of the n-3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid in the blood
stream of healthy adults. Progress in Lipid Research, 63, 132-152.

Stewart, F., Rodie, V.A., Ramsay, J.E., Greer, I.A., Freeman, D.J., Meyer, B.J. (2007)
Longitudinal assessment of erythrocyte fatty acid composition throughout pregnancy and
post partum. Lipids, 42, 335-344.
101

Sullivan, B.L., Williams, P.G., Meyer, B.J. (2006) Biomarker validation of a long-chain n-3
polyunsaturated fatty acid food frequency questionnaire. Lipids, 41, 845-850.

Surma, M.A.; Herzog, R.; Vasilj, A.; Klose, C.; Christinat, N.; Morin-Rivron, D.; Simons, K.;
Masoodi, M.; Sampaio, J.L. (2015) An automated shotgun lipidomics platform for high
throughput, comprehensive, and quantitative analysis of blood plasma intact lipids. Eur. J.
Lipid Sci. Technol. 117, 1540–1549.

Turcot, V., Brunet, J., Daneault, C., Tardif, J. C., Des Rosiers, C. & Lettre, G.(2015)
Validation of fatty acid intakes estimated by a food frequency questionnaire using
erythrocyte fatty acid profiling in the Montreal Heart Institute Biobank. J Hum Nutr Diet, 28,
646-58.

Von schacky, C., Harris, W.S. (2007) Cardiovascular risk and the n-3 index. Journal of
Cardiovascular Medicine, 8, S46-S49.

102

Supplementary Material

A high throughput method for the analysis of erythrocyte fatty acids and the n-3 index
Authors: Ayedh Alqarni1, 2, 3, Kiara J. Mcintyre1, 2, Simon H. J. Brown2, 4, Barbara J. Meyer1, 2,
Todd W. Mitchell1, 2*
1

School of Medicine and Lipid Research Centre, University of Wollongong, Australia

2

Illawarra Health and Medical Research Institute, University of Wollongong, Australia

3

King Fahad Specialist Hospital, Dammam city, Saudi Arabia

4

School of Biological Sciences, University of Wollongong, Australia

* Corresponding author: A/Professor Todd Mitchell, School of Medicine, University of
Wollongong, Northfields Avenue, Wollongong, NSW 2522, Australia. Tel +61 (0)2 4221 5443
Fax +61 (0)2 4221 8141 Email address: toddm@uow.edu.au.

103

The amount of each phospholipid (PL) standard stock solutions added to create the
five synthetic PL mixtures.
Table S1: Amount of each synthetic PL stock solutions added to create 2% synthetic PL
mixtures.
Synthetic PL standards
PtdEtn 16:0/18:1
PtdCho 16:0/18:1
PtdCho 16:0/18:2
PtdEtn 18:0/20:4
PtdCho 16:0/20:4
PtdEtn 18:0/22:6
PtdCho 16:0/22:6

uMolar
80.8
363.8
363.8
50.5
101.1
8.0
32.0

% total phospholipids
8.1
36.4
36.4
5.1
10.1
0.8
3.2

Table S2: Amount of each synthetic PL stock solutions added to create 4% synthetic PL
mixtures.
Synthetic PL standards
PtdEtn 16:0/18:1
PtdCho 16:0/18:1
PtdCho 16:0/18:2
PtdEtn 18:0/20:4
PtdCho 16:0/20:4
PtdEtn 18:0/22:6
PtdCho 16:0/22:6

uMolar
77.5
348.6
348.6
48.4
96.8
16.0
64.0

% total phospholipids
7.7
34.9
34.9
4.8
9.7
1.6
6.4

Table S3: Amount of each synthetic PL stock solutions added to create 6% synthetic PL
mixtures.
Synthetic PL standards
PtdEtn 16:0/18:1
PtdCho 16:0/18:1
PtdCho 16:0/18:2
PtdEtn 18:0/20:4
PtdCho 16:0/20:4
PtdEtn 18:0/22:6
PtdCho 16:0/22:6
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uMolar
74.1
333.5
333.5
46.3
92.6
24.0
96.0

% total phospholipids
7.4
33.3
33.3
4.6
9.3
2.4
9.6

Table S4: Amount of each synthetic PL stock solutions added to create 8% synthetic PL
mixtures.
Synthetic PL standards
PtdEtn 16:0/18:1
PtdCho 16:0/18:1
PtdCho 16:0/18:2
PtdEtn 18:0/20:4
PtdCho 16:0/20:4
PtdEtn 18:0/22:6
PtdCho 16:0/22:6

uMolar
70.7
318.3
318.3
44.2
88.4
32.0
128.0

% total phospholipids
7.1
31.8
31.8
4.4
8.8
3.2
12.8

Table S5: Amount of each synthetic PL stock solutions added to create 10% synthetic PL
mixtures.
Synthetic PL standards
PtdEtn 16:0/18:1
PtdCho 16:0/18:1
PtdCho 16:0/18:2
PtdEtn 18:0/20:4
PtdCho 16:0/20:4
PtdEtn 18:0/22:6
PtdCho 16:0/22:6
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uMolar
67.4
303.2
303.2
42.1
84.2
40.0
160.0

% total phospholipids
6.7
30.3
30.3
4.2
8.4
4.0
16.0

Example of the correction applied to 16:0, 18:0 and 18:1 concentration determined by
GC. The example provided here is for 18:0 in a single sample. This procedure was
repeated for 16:0, 18:0 and 18:1 in every sample.
1) Determine the proportion of CerPCho 18:0 from MS data.
[CerPCho 18:0 (MS)] / [total 18:0 (MS)] = proportion of CerPCho 18:0 (MS)
(0.95 nmol/ml) / (6.91 nmol/ml) = 0.14
2) Estimate the concentration of CerPCho 18:0 obtained by GC.
0.14 X [18:0 (GC)] = [CerPCho 18:0 (GC)]
0.14 X 213.8 nmol/ml = 29.9 nmol/ml
3) Correct the concentration of CerPCho 18:0 obtained by GC
29.9 nmol/ml X correction factor = corrected [CerPCho 18:0 (GC)]
29.9 nmol/ml X 2.48 = 74.2 nmol/ml
4) Add corrected CerPCho 18:0 concentration to the PL 18:0 concentration to determine
corrected total 18:0 concentration by GC.
([18:0 (GC)] – [CerPCho 18:0 (GC)])+ corrected [CerPCho 18:0 (GC)] = corrected [18:0
(GC)]
(213.8 - 29.9) + 74.2 = 258.1
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Sphingomyelin fatty acids transesterification experiment
An experiment was conducted to examine the extraction recovery of sphingomyelin fatty
acids using two methods; namely the Lepage and Roy transesterification as used in the GCFID method and the new high throughput ESI-MS method. CerPCho 24:1 was selected and
added to the synthetic PL mixture shown in table S5. The results are shown in table S6 and
it clearly shows that 24:1 (sphingomyelin fatty acids) are not completely transesterified using
the Lepage and Roy method as there was only a 45% recovery.
Tables S6: Recovery results of Sphingomyelin fatty acids transesterification experiment
(n=3).
Fatty
acids
16:0
18:0
18:1
18:2
20:4
22:6
24:1

Added
concentration
nmol/ml
917.9
82.1#
370.5
303.2
126.3
200*
200

GC-FID method
Mean ± SEM
870.4 ± 17.3
85.4 ± 0.5
361.9 ± 6.4
278.6 ± 4.6
111.9 ± 5.4
154.6 ± 17.3
89.6 ± 6.7

(%) recovery
94.8%
104.0%
97.7%
91.9%
88.4%
77.3%
44.8%

The high-throughput ESI-MS method
Mean ± SEM
880.2 ± 11.9
45.7 ± 1.0
360.2 ± 3.7
297.7 ± 6.2
116.5 ± 1.9
150.0 ± 5.8
195.5 ± 2.4

(%) recovery
95.9%
55.7%
97.2%
98.2%
92.2%
75.0%
97.8%

Footnote of abbreviations; * due to oxidation of PtdEtn (18:0/22:6) as described the expected
concentration was 160 nmol/ml; #Due to oxidation of PtdEtn (18:0/22:6) the expect ESI-MS value was
42.1 nmol/ml.
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Table S7: Targeted ion scans used to acquired phospholipid data.
Lipid
Ion
Scan
DP
EP CE CXP
Head group scans

Mass range (Da)

PtdCho/CerPCho [M+H]+
PtdEtn
[M+H]+
PtdSer
[M+H]+

PI 184.1
NL141.0
NL 185.0

100
100
100

10
10
10

47
30
30

8
8
8

640-1000
685-950
755-965

Fatty acyl chain scans
16:1
[M-H]¯
16:0
[M-H]¯
17:0
[M-H]¯
18:2
[M-H]¯
18:1
[M-H]¯
18:0
[M-H]¯
19:0
[M-H]¯
20:5
[M-H]¯
20:4
[M-H]¯
20:3
[M-H]¯
22:6
[M-H]¯
22:5
[M-H]¯
22:4
[M-H]¯
24:0
[M-H]¯
24:1
[M-H]¯

PI 253.2
PI 255.2
PI 269.3
PI 279.2
PI 281.3
PI 283.3
PI 297.3
PI 301.2
PI 303.2
PI 305.2
PI 327.2
PI 329.2
PI 331.2
PI 365.3
PI 363.3

-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100
-100

-10
-10
-10
-10
-10
-10
-10
-10
-10
-10
-10
-10
-10
-10
-10

-55
-55
-55
-40
-55
-55
-55
-40
-40
-40
-40
-40
-40
-40
-40

-11
-11
-11
-11
-11
-11
-11
-11
-11
-11
-11
-11
-11
-11
-11

600-900
600-900
560-900
600-900
600-900
600-900
600-900
500-1000
600-1000
600-1000
700-1000
700-1000
700-1000
740-1040
740-1040

Scan rate for positive ion mode was 200 Da/s, for negative ion mode 1000 Da/s. Mass shifting was
prevented in negative ion mode by increasing number of summed scans. PI Precursor ion, NL neutral
loss, DP declustering potential, EP entrance potential, CE collision energy, CXP collision cell exit
potential.

Table S8: Justification for Cost per sample for GC-FID method and ESI-MS method.
Items
GC-FID method
ESI-MS method
Materials and consumables
$ 28.0
$ 10.0
Maintenance contributions and initial cost
Total cost per sample
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$ 22.0
$ 50.0

$ 10.0
$ 20.0

Table S9: Fatty acids concentrations (nmol/ml blood) in QC samples (n=57). Values are
shown as mean ± SEM (%CV) from 19 runs.

Fatty acids

109

16:0

Mean ± SEM (%CV)
454.3 ± 12.5 (13.4%)

17:0

17.6 ± 1.1 (13.7%)

18:0

257.7 ± 1.7 (8.3%)

24:0

83.9 ± 1.3 (19.7%)

16:1

4.4 ± 0.1 (14.9%)

18:1

206.9 ± 10.9 (13.8%)

24:1

104.0 ± 0.5 (7.5%)

18:2

146.5 ± 3.3 (13.3)

20:3

22.2 ± 0.3 (17.2%)

20:4

187.9 ± 2.3 (10.0%)

20:5

5.7 ± 0.1 (15.5%)

22:4

21.7 ± 2.2 (17.9%)

22:5

29.8 ± 1.2 (10.7%)

22:6

73.9 ± 2.5 (6.9 %)

PL species
PtdCho 16:0 -16:0
PtdCho 16:0 -16:1
PtdCho 16:0 -17:0
PtdCho 16:0 -18:0
PtdCho 16:0 -18:1
PtdCho 16:0 -18:2
PtdCho 17:0 -18:1
PtdCho 17:0 -18:2
PtdCho 18:0 -18:0
PtdCho 18:0 -18:1
PtdCho 18:0 -18:2
PtdCho 18:1 -18:1
PtdCho 18:1 -18:2
PtdCho 16:0 -20:3
PtdCho 16:0 -20:4
PtdCho 16:0 -20:5
PtdCho 18:0 -20:4
PtdCho 18:1 -20:4
PtdCho 16:0 -22:6
PtdCho 18:0 -22:6
PtdEtn 16:0 -18:1
PtdEtn 16:0 -18:2
PtdEtn 18:0 -18:0
PtdEtn 18:0 -18:1
PtdEtn 18:0 -18:2
PtdEtn 18:1 -18:1
PtdEtn 18:1 -18:2
PtdEtn 16:0 -20:3
PtdEtn 16:0 -20:4
PtdEtn 16:0 -20:5
PtdEtn 17:0 -20:4
PtdEtn 17:0 -20:5
PtdEtn 18:0 -20:4
PtdEtn 16:0 -22:4
PtdEtn 16:0 -22:5
PtdEtn 18:1 -20:4
PtdEtn 16:0 -22:6
PtdEtn 17:0 -22:5
PtdEtn 18:0 -22:6
PtdSer 18:0 -18:0
PtdSer 18:0 -18:1
PtdSer 18:0 -20:4
PtdSer 18:0 -22:5
PtdSer 18:0 -22:6
CerPCho 16:0
CerPCho 18:0
CerPCho 18:1
CerPCho 24:0
CerPCho 24:1
Fatty acids
16:0
16:1
17:0
18:0
18:1
18:2
20:3
20:4
20:5
22:4
22:5
22:6
24:0
24:1
Fatty acids
16:0
16:1
17:0
18:0
18:1
18:2
20:3
20:4
20:5
22:4
22:5
22:6
24:0
24:1

Sample #1
0.3067
0.0529
0.0223
0.0670
1.4029
2.4135
0.0577
0.0571
0.0218
0.2411
0.5075
0.1741
0.2553
0.3944
0.7541
0.0323
0.3001
0.1172
0.2240
0.0488
0.9952
0.4094
0.0107
0.2436
0.2253
0.2107
0.2692
0.0805
0.6756
0.0391
0.1052
0.1183
0.4480
0.2259
0.1216
0.3976
0.3658
0.0595
0.1188
0.0047
0.2237
1.3874
0.2739
0.4162
2.5708
0.3409
0.1172
2.5009
3.1676
Sample #1
11.5
0.1
0.4
4.9
4.7
4.1
0.5
4.2
0.2
0.2
0.5
1.2
2.5
3.2
Sample #1
458.4
2.1
16.8
196.7
187.7
165.5
19.0
167.4
7.6
9.0
18.2
46.9
100.0
126.7

Sample #2
0.4257
0.0559
0.0440
0.1240
1.9089
2.5645
0.0829
0.1042
0.0307
0.3723
0.7984
0.2029
0.3664
0.2256
0.9201
0.0865
0.4022
0.1923
0.3027
0.0681
1.6980
0.5437
0.0206
0.2933
0.2728
0.3383
0.4544
0.0813
0.9784
0.0648
0.1373
0.1675
0.5038
0.2528
0.2065
0.5620
0.4774
0.0761
0.1370
0.0056
0.1789
1.6430
0.3720
0.6404
3.6073
0.5706
0.2077
2.9584
4.1307
Sample #2
15.0
0.1
0.6
6.5
6.8
5.1
0.3
5.3
0.3
0.3
0.7
1.6
3.0
4.1
Sample #2
599.7
2.2
24.5
259.6
273.5
204.2
12.3
213.6
12.8
10.1
26.2
65.0
118.3
165.2

Sample #3
0.4061
0.0840
0.0404
0.0692
1.7042
2.4609
0.0991
0.1010
0.0192
0.4016
0.8687
0.2515
0.4422
0.2142
0.6681
0.0774
0.3045
0.1533
0.2285
0.0758
1.1877
0.4861
0.0135
0.2676
0.2325
0.3201
0.4678
0.0891
0.6669
0.0584
0.1044
0.1294
0.4570
0.1547
0.1147
0.4405
0.3093
0.0590
0.1001
0.0067
0.2599
1.6171
0.2826
0.4840
3.3175
0.4763
0.1788
2.0206
3.6350
Sample #3
12.7
0.1
0.5
6.0
6.3
5.1
0.3
4.4
0.3
0.2
0.5
1.2
2.0
3.6
Sample #3
509.7
3.4
21.3
239.0
252.2
202.4
12.1
176.5
10.6
6.2
18.3
47.9
80.8
145.4

Individual PL species
concentration
(nmol/10 uL of packed
RBCs) determined by
mass spectrometry as
described in methods.

Individual fatty acid
concentration
(nmol/10 uL of packed
RBCs) calculated
from the sum of each
individual PL species
that contains that FA.
If the PL contained 2
moles of the FA, e.g.
PtdCho 16:0-16:0 it
was added twice.

To convert FA
concentration from
nmol/10 uL of packed
RBCs to nmol/mL of
blood the FA
concentration obtained
for 10 uL of packed
RBCs was multiplied
by 40 (x 100 to obtain
mL of RBCs then x 0.4
to convert to whole
blood, assuming an
hematocrit of 40%).

Figure S1: An example of spread sheet used to calculate the fatty acids levels from PL
individual species detected from ESI-MS method.
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Figure S2:- An example of positive ion mass spectra of PtdEtn cation (m/z 141) neutral loss showing low signal of m/z 792.7 for PtdEtn (18:0/22:6).
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Testing solvents for lysing erythrocyte membranes
a) The TRIS-Aliquot method
In 2 mL glass vials, 10 μL of packed erythrocytes were added to 240 μL of TRIS-HCl.
Following this, the tubes were vortexed for two minutes before a 25 μL aliquot was taken.
The aliquot was dispensed into a new tube to which 75 μL of 200 mM ammonium acetate
and 90 μL of methanol were added prior to a further 2 minutes of vortexing. Following this,
300 μL of MTBE was added and tubes were vortexed again for 2 minutes after which they
were left to stand for 1 minutes to allow phase separation. After phase separation had
occurred, 300 μL of the upper lipid containing phase was removed and dried under nitrogen
at 37oC. The dried lipid were then reconstituted to 150 μL using 2:1 methanol: chloroform
and were stored at -20 oC until ready to be analysed. Prior to mass spectrometric analysis,
extracts were diluted using 2:1 methanol: chloroform solution containing 5 mM ammonium
acetate as spray solvent.

b) Adding ammonium acetate first
In 2 mL eppendorf tube, 10 uL of packed erythrocytes were added to 100 μL of an aqueous
mixture containing 150 mM ammonium acetate and 2 mM EDTA before being vortexed.
Following this, 100 μL of methanol was added and vortexed for 2 minutes. After that 400 μL
of MTBE was added and vortexed for 2 minutes. 400 μL of the supernatant was removed
and dried under nitrogen at 37oC and then reconstituted with 200 μL of 2:1 methanol:
chloroform solution containing 5 mM ammonium acetate. Lipid extracts were stored at -20 oC
until ready for analysis.

c) TRIS-buffered ammonium chloride
TRIS-buffered ammonium chloride was firstly optimised to PH 7.4 by the addition
hydrochloric acid. As per methods above, 10 μL of packed erythrocytes were added to 100
μL of the TRIS-buffered ammonium chloride and mixed by repeated aspirating/dispensing.
The tubes were then vortexed for 2 minutes after which 120 μL of methanol was added
112

followed by further 2 minutes of vortexing. To each tube, 400 μL of MTBE was then added
and each tube was again vortexed for 2 minutes. The upper phase was extracted, placed in
a new glass vial and dried under nitrogen at 37oC and then reconstituted with 300 μL of 2:1
methanol: chloroform and then stored at -20 oC until ready for analysis.

d) Adding methanol first
The method carried out was analogous to those previously described with some minor
adjustments to reagent order and times for vortexing. Briefly, 10 μL of packed erythrocytes
were added to 120 μL of methanol containing 0.01% BHT in eppendorf tubes and vortexed
for 10 minutes. Following this, 400 μL of MTBE was added and the tubes underwent another
10 minutes vortex before phase separation was initiated by addition 100 μL of 5 mM
ammonium acetate. Lipid extracts were stored at -20 oC until ready for analysis.

This study demonstrated that adding ammonium acetate as first reagent to packed
erythrocytes produced quality mass spectra when analysed using ESI-MS. Having the
erythrocytes suspended in aqueous mixture containing ammonium acetate and EDTA
enable the methanol to interface more readily with the packed erythrocytes than if they were
not in suspension. Further to this, the uniform solution created by suspending the packed
erythrocytes in ammonium acetate and EDTA makes their analysis considerably more
amenable to the robotic platform as the propensity of packed erythrocytes to clot is
ameliorated.
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Chapter 3
Comparison of n-3 index erythrocyte fatty acids and
molecular phospholipid species in healthy people and people
at ultra high risk of developing psychosis

This chapter has been prepared in its current form and will be submitted to Schizophrenia
Bulletin.
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Abstract
People classified as ultra high risk (UHR) of developing psychosis have reduced cellular
membrane n-3 and n-6 polyunsaturated fatty acids. We aimed to compare n-3 index, fatty
acids and molecular phospholipid species from erythrocytes of people with UHR (n =285)
with age-matched healthy controls (n =120). The molecular phospholipid and fatty acid
composition of erythrocytes for both groups were determined by mass spectrometry. Lower
proportions of polyunsaturated fatty acids were observed in the UHR group compared to
healthy controls; specifically, eicosapentaenoic acid was 29.3% lower, docosahexaenoic
acid 27.2% was lower, arachidonic acid 15.8% was lower and the n-3 index 26.9% lower in
the UHR group compared to healthy group. Conversely, the proportion of nervonic acid was
64.4% higher in the UHR group compared to healthy controls. At a lipid class level, the UHR
group had higher concentrations of sphingomyelin 16% and lower concentrations
phosphatidylethanolamine 46% compared to healthy group. Of the 49 individual molecular
phospholipid components studied here, twenty seven phospholipid species were lower in the
UHR group. In conclusion, there are clear differences in the proportions of erythrocyte fatty
acids and phospholipids between UHR and healthy controls and UHR had higher
concentrations of SM and lower concentrations of PE. These differences may represent a
promising prodromal risk biomarker in the UHR population to aid clinical diagnosis.
Keywords: - Sphingomyelin, phosphatidylserine, phosphatidylethanolamine,
phosphatidylcholine, phospholipids.
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Introduction
Psychosis is a term used to describe a number of psychological symptoms that impact on a
person’s perception of reality or understanding, and affects approximately 1% of the
population.1,2 It is severely disabling and has a major socioeconomic impact.3 In the past two
decades criteria were introduced for identifying people in the prodromal phase that have an
ultra high risk (UHR) of developing psychosis.4-8 People classified as UHR of developing
psychosis are usually young people who experience brief limited psychotic symptoms,
attenuated psychotic symptoms or possess a key risk factor (e.g. first degree relative with
psychosis and schizotypal personality disorder) in addition to a decline in psychosocial
functioning.4,9 A recent meta-analysis of UHR found that the proportion of people who
transitioned to psychosis increased with time, i.e. 18% by 6 months, 22% by 1 year, 29% by
2 years and 36 by 3 years.10 These values are consistent with evidence that some UHR
patients develop psychosis after the first 24 months following presentation when the
transition risk is thought to be maximal.11,12
Polyunsaturated fatty acid (PUFA) deficiency may underlie the physiological and clinical
phenomena observed in some neuropsychiatric diseases, particularly in schizophrenia.13 It
has been reported that people at UHR of psychosis14 and patients with schizophrenia15-18
have low levels of n-3 and n-6 PUFA. This is supported by a meta-analysis that compared
the erythrocyte fatty acids composition of 429 schizophrenia patients and 444 healthy
controls.19 This study found that the schizophrenia patients had lower levels of erythrocyte
docosahexaenoic acid (DHA, 22:6), docosapentaenoic acid (DPA, 22:5), eicosapentaenoic
acid (EPA, 20:5) and arachidonic acid (AA, 20:4). Several studies have also found a low
(≤4%) n-3 index (the sum of EPA and DHA levels in erythrocytes membranes expressed as
percent of total fatty acids)20, 21 in individuals at UHR of developing psychosis14 and other
psychotic disorders.22, 23, 24
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The PUFA content, specifically DHA, of erythrocyte membranes reflects their content in the
brain r=0.8625 and therefore, erythrocyte membrane DHA represents an ideal target in
psychotic patients. Erythrocytes also have less inter-individual variability compared to
plasma26; it reflects dietary intake that has occurred during the past 120 days27, 28 and
maintains stability at -80C for several years29,30 and is therefore an ideal tissue/sample to
investigate.
Currently, little is known about the molecular phospholipid species and associated fatty acids
in people at UHR of psychosis and which of these lipid species are altered compared to
healthy people. The aim of this study was to quantify and compare the erythrocyte fatty
acids, n-3 index and molecular phospholipid species from people at UHR of developing
psychosis to aged matched healthy controls.
Material & methods
Ethics
This study was approved by the human research ethics committees at the University of
Wollongong (HE 16/018) and the University of Melbourne (2008.628).

UHR participants
The NEURAPRO-E study is a double-blind, placebo-controlled, randomized clinical trial to
determine whether treatment with n-3 LCPUFA in combination with a high-quality
psychosocial intervention (cognitive behavioural case management [CBCM]) is more
effective than placebo plus CBCM. UHR participants were recruited between March 1, 2010
and September 30, 2014 from Melbourne, Sydney, Hong Kong, Vienna, Basel, Winterthur,
Copenhagen, Amsterdam, Singapore and Jena.29, 30 Inclusion and exclusion criteria for these
participants have been reported previously. 29, 30 20 mL of blood collected into vacutainers
coated with EDTA as antioxidant at baseline and the 6-month time point. The packed
erythrocytes were processed (centrifuged and aliquoted according to the guidelines in the
Neurapro-E Pathology Manual) frozen erythrocyte samples were transported to the
University of Wollongong on dry ice and kept at -80°C until the time of analyses. There is
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evidence that shows the samples stable for 3.5 years at -80°C31. The UHR samples
collected 2014 and samples run completed by 2017 which is within 3.5 years.
Healthy control participants, screening questionnaire and blood sampling
125 healthy control participants were recruited between October 2016 and March 2017 from
the University of Wollongong staff, their children and undergraduate students to achieve
similar age range to the UHR participants, namely 13-40. All participants were assigned a
study number and data regarding their sex, age, weight, height and smoking were recorded.
Inclusion criteria of the healthy control group were age between 13-40 years, no psychiatric
history, no family history of psychiatric illness and no drug use. The healthy subjects were
screened using the 16-item Version of the Prodromal Questionnaire PQ-16.32 A score of 6
or more indicates a risk of psychosis and was used as an exclusion criterion.33 Five
participants were excluded from this study due to their ages being over 40 years old and no
participants were excluded due to psychiatric symptoms or history.
After an 8 hour overnight fast, blood samples were collected into vacutainers coated with
ethylenediaminetetraacetic acid (EDTA) as antioxidant and to prevent clotting. The blood
samples were subjected to centrifugation at 3000 rpm at 4 oC for 10 minutes. The
supernatant of plasma and white blood cells were removed and the packed erythrocytes
were aliquots of 1.5 ml and stored at -80 oC until required for analysis.
Materials
High performance liquid chromatography (HPLC) grade or higher methyl tert-butyl ether
(MTBE), chloroform and methanol were purchased from VWR International (QLD, Australia).
Butylated hydroxytoluene (BHT), and ethylenediaminetetraacetic acid (EDTA) were
purchased from Sigma Aldrich (NSW, Australia). Analytical grade ammonium acetate was
obtained from Crown Scientific (New South Wales, Australia). Phospholipid internal
standards were purchased from Avanti Polar Lipids through Auspep (Victoria, Australia) and
consisted of dinonadecanoyl phosphatidylcholine (PC 19:0/19:0); diheptadecanoyl
phosphatidylethanolamine (PE17:0/17:0); diheptadecanoyl phosphatidylserine (PS
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17:0/17:0); N-lauroyl-D-erythro-sphinganylphosphorylcholine (SM d18:0/12:0).
Twin-tec PCR plates and 96-well plates were purchased from Eppendorf (POCD scientific,
Australia). Two types of disposable conductive CO-RE tips (without filter) in 50 uL and 300
uL sizes were used and purchased from Hamilton Robotics (Reno NV, USA).
Lipid extraction
Both healthy control & UHR of psychosis erythrocyte samples were extracted using the
automated extraction method described previously.34 In brief, 290 uL an aqueous mixture
containing 2 mM EDTA and 150 mM Ammonium acetate was added to the wells of a 2.0 mL
96-well plate on ice. A 10 μL aliquot of packed erythrocytes was added to the wells and the
plate mixed using a vortex at 800 rpm for 10 minutes. Robotic procedures were then started
with all reagents, solvents and plates loaded onto the automated liquid handling station
(Hamilton, Nevada, USA). A 300 μL aliquot of an internal standard mixture in methanol [500
uM (PC 19:0/19:0); 166.7 uM (PE 17:0/17:0); 100 uM (PS 17:0/17:0); 500 uM (SM
18:0/12:0)] was added to the wells prior to mixing and standing for 10 minutes. 1 mL of
MTBE was added to the wells and mixed for 30 minutes before the mixture was allowed to
stand for 15 minutes to allow phase separation. Following this, 500 μL of the MTBE top
phase was removed to the extraction plate (containing the extracted phospholipids) and 40
μL of extract was transferred to another 96-well plate and diluted with 760 μL of a 2:1 (v:v)
methanol/chloroform solution containing 5 mM Ammonium acetate. A 40 μL aliquot of the
diluted extract was transferred to another 96-well plate which was sealed with aluminium foil
prior to analysis by mass spectrometry.
Electrospray ionization mass spectrometry (ESI-MS)
Mass spectrometry was performed utilizing a hybrid triple quadrupole linear ion trap mass
spectrometer (QTRAP 5500 AB Sciex, MA, USA) with an automated chip-based
nanoelectrospray source (Triversa NanoMate, Advion Biosciences, New York, USA) as
previously described.34, 35, 36 A 10 uL aliquot of lipid extract diluted in methanol: chloroform
(2:1 v/v) containing 5mM ammonium acetate (approximately 10 uM) was infused into the
nano-electrospray ion source. Spray parameters were a voltage of 1.2 kV for positive ion
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acquisition and 1.1 kV for negative ion acquisition and a nitrogen gas pressure of 0.40 psi. 35,
36

Lipids were identified using precursor ion and neutral loss scans as previously

described.35, 36
Ionized lipids identified with a minimum signal-to-noise ratio of 10 were included in the
analysis. Identification and quantification was accomplished using LipidView software
(version 1.2, Sciex, MA, USA) this included smoothing, identification, removal of isotope
contribution from lower mass species, and correction for isotope distribution, as described.35,
36

Quantification was performed using LipidView software by comparing the spectral peak

area of individual lipids to their class specific internal standards following isotope correction.
Statistical analysis
Microsoft™ Excel software (Microsoft Corp., California, USA) was used for the basic
statistical analyses including mean, median, interquartile range (IQR), standard deviation
and standard error of the mean. All variables were not normally distributed thus the MannWhitney U-test was used to estimate the significance of these variables between UHR and
healthy groups. Categorical data were analyzed using chi-square. Correction for multiple
comparisons was performed using the Bonferroni method; P values measuring < 0.0008 was
considered to be statistically significant. Statistical analyses were completed using SPSS
software (version 19.0 SPSS. Inc).
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Results
Baseline characteristics of UHR and healthy controls
Of the 304 participants that started the Neurapro-E study30, 285 participants completed the
study and 19 participants were either not eligible or lost to follow-up. The control group
consisted of 120 age matched healthy participants. The baseline characteristics of each
group are presented in table 1.
Table 1. Characteristics of UHR group and healthy control.
UHR group

Healthy group

General characteristics

(n=285)

(n=120)

P value

Age median (IQR-1, IQR-3)

18 (16 , 22)

17 (16 , 20)

0.195

Sex male n (%)

129 (50.4%)

61 (51%)

0.305

Body mass index Kg/m2 (IQR-1, IQR-3)

23 (20 , 26.7)*

21.7 (19.8 , 25.2)

0.012

Smoking n (%)

110 (38.6%)

25 (20.8%)

0.001

* BMI is for 252 of the 285 participants. “Ultra high risk (UHR) of developing psychosis; Interquartile

range (IQR)”.

Fatty acids and n-3 index
The fatty acid composition of erythrocytes and the n-3 index of UHR and healthy controls are
shown in table 2. A number of fatty acids, i.e. 17:0, 18:0, 18:2, 20:4, 20:5, 22:4; 22:5 and
22:6 were lower in the UHR group compared to healthy controls. The n-3 index was also
lower in the UHR group than the healthy controls. In contrast, UHR participants had higher
percentages of 16:0, 18:1, 24:0 and 24:1 than controls.
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Table 2. Individual erythrocyte fatty acid composition from healthy (n=120) and people at
UHR of developing psychosis (n= 285) (results are express as % of total fatty acids).
Fatty acids

Healthy group

UHR group

Median (First, Third quartile)

Median (First, Third quartile)

% difference

P-value

from healthy
16:0

31.37 (30.49 , 32.39)

32.31 (30.65 , 34.24)

2.9%↑

<0.0001

16:1

0.20 (0.13 , 0.31)

0.21 (0.14 , 0.29)

5.0%

0.936

17:0

1.35 (1.24 , 1.52)

1.28 (1.18 , 1.40)

5.2%↓

<0.0001

18:0

14.38 (13.77 , 14.89)

12.99 (11.98, 13.94)

9.7%↓

<0.0001

18:1

15.49 (14.43 , 16.63)

16.62 (15.51 , 17.73)

7.3%↑

<0.0001

18:2

12.89 (11.63 , 14.04)

12.04 (10.49 , 13.53)

6.6%↓

<0.0001

20:3

0.86 (0.63 , 1.09)

0.81 (0.65 , 0.98)

5.8%

0.884

20:4

10.95 (10.11 , 11.64)

9.22 (7.52 , 10.11)

15.8%↓

<0.0001

20:5

0.75 (0.63 , 0.88)

0.53 (0.45 , 0.63)

29.3%↓

<0.0001

22:4

0.37 (0.30 , 0.47)

0.31 (0.14 , 0.45)

16.2%↓

<0.0001

22:5

1.16 (1.03 , 1.31)

1.05 (0.83 , 1.31)

9.5%↓

<0.0001

22:6

3.34 (2.83 , 3.92)

2.43 (1.94 , 2.91)

27.2%↓

<0.0001

24:0

2.19 (1.41 , 3.94)

3.95 (2.98 , 5.15)

80.4%↑

<0.0001

24:1

3.40 (2.26 , 6.16)

5.59 ( 4.27 , 7.27)

64.4%↑

<0.0001

n-3 index

4.09 (3.59 , 4.65)

2.99 (2.49 , 3.54)

26.9%↓

<0.0001

P-values were calculated by using Mann-Whitney U-test; statistical significance shown in bold. ↑
(Increase). ↓ (decrease). “Ultra high risk (UHR) of developing psychosis”.
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Classes
As shown in figure1, the erythrocyte membranes of the UHR group and the healthy controls
showed similar proportions of phosphatidylcholine (PC) and phosphatidylserine (PS), but a
lower percentage of phosphatidylethanolamine (PE) and a higher percentage of
sphingomyelin (SM). Investigating the concentrations (nmol/10ul erythrocyte) for these four
classes shows similar results with lower PE (3.57±0.26 vs. 6.63±0.45, p<0.0001) and higher
SM (6.36±0.57 vs. 5.50±0.32, p<0.0001) concentrations in the UHR group compared to
healthy controls. No differences in the concentrations of PC (7.48±0.69 vs. 8.95±0.37,
p=0.266) or PS (1.60±0.37 vs. 2.75±0.18, p=0.175) were found between UHR and healthy
controls.
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A) Healthy group

*Total SM
23 ± 0.8

Total PC
42 ± 0.2

Total PS
10 ± 0.3
*Total PE
25 ± 0.1

B) Ultra-high risk of psychosis group

*Total SM
32 ± 1.0

Total PS
9 ± 0.5

Total PC
41 ± 0.2

*Total PE
18 ± 0.1

Figure 1. Percentage of the four major phospholipid classes within the human erythrocyte
membranes of healthy controls (A) and UHR (B). Values are mean ± SEM for the entire
cohort (n=120 for healthy group & 285 for UHR group). “PC, phosphatidylcholine; PE,
phosphatidylethanolamine; PS, phosphatidylserine; SM, Sphingomyelin”. (* Statistical
significance).
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Molecular phospholipids
Phosphatidylcholine (PC)
A comparison of the individual PC molecules from erythrocytes from UHR and healthy
controls expressed as percentage of the total phospholipids is shown in table 3. Although
there was no difference in total PC concentration twelve of the twenty PC species were
different between the two groups.
Of the two major PC species in human erythrocytes in both UHR and healthy controls, there
was a lower proportion of PC (16:0_18:2) and higher proportion of PC (16:0_18:1) in UHR
compared to the healthy controls. The other less abundant PC species such as PC
(16:0_20:4), PC (16:0_20:5), (16:0_22:6), PC (18:0_22:6), PC (18:0_20:4), PC (18:1_18:2),
PC (18:1_20:4) were lower in UHR compared to healthy controls. Conversely, PC
(16:0_16:0), PC (16:0_17:0), PC (18:0_18:1) conributed a lower proportion of total
phospholipids in healthy compared to UHR groups (see table 3). It should be noted however,
that these PCs contribute less than 4% of total phospholipid.
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Table 3. Individual species of phosphatidylcholine content of erythrocyte membranes from
healthy (n=120) and people at UHR of developing psychosis (n= 285) (results are express
as % of total phospholipids)
Healthy group

UHR group

Median (First, Third quartile)

Median (First, Third quartile)

% difference

P-value

from healthy
PC 16:0_16:0

1.72 (1.59 , 1.96)

2.10 (1.81 , 2.77 )

22.0%↑

<0.0001

PC 16:0_16:1

0.35 (0.23 , 0.55)

0.35 (0.24 , 0.49)

0.0%

0.717

PC 16:0_17:0

0.11 (0.08 , 0.16)

0.24 (0.12 , 0.30)

118.0% ↑

<0.0001

PC 16:0_18:0

0.39 (0.29 , 0.48)

0.42 (0.31 , 0.56)

7.7%

0.0114

PC 16:0_18:1

8.60 (7.35 , 9.62)

9.84 (8.42 , 11.44)

14.4%↑

<0.0001

PC 16:0_18:2

11.90 (10.18 , 13.47)

11.00 (8.81 , 13.64)

7.6%↓

<0.0001

PC 16:0_20:3

1.08 (0.76 , 1.44)

0.96 (0.70 , 1.31)

11.1%

0.033

PC 16:0_20:4

3.31 (2.85 , 3.82)

2.82 (2.08 , 3.47)

14.8%↓

<0.0001

PC 16:0_20:5

0.38 (0.30 , 0.52)

0.25 (0.17 , 0.33)

34.2%↓

<0.0001

PC 16:0_22:6

1.26 (0.98 , 1.53)

0.84 (0.62 , 1.04)

33.3%↓

<0.0001

PC 17:0_18:1

0.43 (0.37 , 0.48)

0.42 (0.36 , 0.48)

2.3%

0.264

PC 17:0_18:2

0.45 (0.39 , 0.54)

0.46 (0.35 , 0.57)

2.2%

0.405

PC 18:0_18:0

0.12 (0.07 , 0.30)

0.10 (0.06 , 0.15)

16.7%

0.010

PC 18:0_18:1

1.81(1.60 , 2.07)

2.09(1.72 , 2.43)

15.5%↑

<0.0001

PC 18:0_18:2

3.90 (3.29 , 4.55)

3.64 (2.93 , 4.42)

6.7%

0.002

PC 18:0_20:4

1.51 (1.30 , 1.77)

1.39 (1.08 , 1.68)

7.9%↓

<0.0001

PC 18:1_18:1

0.87 (0.67 , 1.13)

1.12 (0.77 , 1.49)

28.7%

0.005

PC 18:1_18:2

1.53 (1.15 , 1.80)

1.35 (0.97 , 1.64)

11.8%↓

<0.0001

PC 18:1_20:4

0.79 (0.64 , 0.94)

0.60 (0.47 , 0.71)

24.1%↓

<0.0001

P-values were calculated by using Mann-Whitney U-test; statistical significance shown in bold. ↑
(Increase). ↓ (decrease). “Ultra high risk (UHR) of developing psychosis; PC, phosphatidylcholine”.
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Phosphatidylethanolamine (PE)
Table 4 compares the PE measured in UHR and healthy erythrocytes. The lower abundance
of total PE in the UHR group is reflected in the molecular PE species with all but PE
(16:0_20:3) and PE (18:0_18:0) being a lower percentage of total phospholipids.
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Table 4. Individual species of phosphatidylethanolamine content of erythrocyte membranes
from healthy (n=120) and people at UHR of developing psychosis (n= 285) (results are
express as % of total phospholipids)
Healthy group

UHR group

Median (First, Third quartile)

Median (First, Third

% difference

quartile)

from healthy

P-value

PE 16:0_18:1

5.37 (4.60 , 5.95)

4.16 (3.79 , 4.64)

22.5%↓

<0.0001

PE 16:0_18:2

2.08 (1.76 , 2.51)

1.60 (1.38 , 1.86)

23.1%↓

<0.0001

PE 16:0_20:3

0.29 (0.21 , 0.48)

0.30 (0.20 , 0.51)

3.4%

0.685

PE 16:0_20:4

3.15 (2.68 , 3.72)

2.43 (2.12 , 2.73)

22.9%↓

<0.0001

PE 16:0_20:5

0.30 (0.22 , 0.44)

0.18 (0.13 , 0.23)

40.0%↓

<0.0001

PE 16:0_22:4

0.63 (0.53 , 0.81)

0.53 (0.23 , 0.74)

15.9%↓

<0.0001

PE 16:0_22:5

0.61 (0.46 , 0.78)

0.40 (0.22 , 0.55)

34.4%↓

<0.0001

PE 16:0_22:6

1.54 (1.28 , 2.05)

1.00 (0.76 , 1.23)

35.1%↓

<0.0001

PE 17:0_20:4

0.48 (0.41 , 0.55)

0.39 (0.31 , 0.46)

18.8%↓

<0.0001

PE 17:0_20:5

0.59 (0.51 , 0.67)

0.45 (0.39 , 0.52)

23.7%↓

<0.0001

PE 17:0_22:5

0.26 (0.22 , 0.32)

0.21 (0.17 , 0.25)

19.2%↓

<0.0001

PE 18:0_18:0

0.09 (0.05 , 0.16)

0.08 (0.06 , 0.11)

11.1%

0.015

PE 18:0_18:1

1.15 (0.98 , 1.30)

0.96 (0.84 , 1.07)

16.5%↓

<0.0001

PE 18:0_18:2

0.90 (0.77 , 1.12)

0.75 (0.65 , 0.88)

16.7%↓

<0.0001

PE 18:0_20:4

1.90 (1.62 , 2.22)

1.19 (0.59 , 1.67)

37.4%↓

<0.0001

PE 18:0_22:6

0.48 (0.40 , 0.61)

0.32 (0.23 , 0.39)

33.3%↓

<0.0001

PE 18:1_18:1

1.10 (0.86 , 1.51)

0.84 (0.66 , 1.05)

23.6%↓

<0.0001

PE 18:1_18:2

1.66 (1.25 , 1.99)

1.18 (0.85 , 1.50)

28.9%↓

<0.0001

PE 18:1_20:4

1.79 (1.48 , 2.17)

1.40 (1.07 , 1.67)

21.8%↓

<0.0001

P-values were calculated by using Mann-Whitney U-test; statistical significance shown in bold. ↑
(Increase). ↓ (decrease). “Ultra high risk (UHR) of developing psychosis; PE, phosphatidylethanolamine”.
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Phosphatidylserine (PS)
The PS species detected in this study and their percentage of the total phospholipids is
shown in table 5. Only five PS species were quantified, with an increased percentage of PS
(18:0_18:0) and a lower percentage of PS (18:0_20:4) and PS (18:0_22:6) in the UHR group
compared to the healthy group.
Table 5. Individual species of phosphatidylserine content of erythrocyte membranes from
healthy (n=120) and people at UHR of developing psychosis (n= 285) (results are express
as % of total phospholipids)
Healthy group

UHR group

Median (First, Third quartile)

Median (First, Third quartile)

% difference

P-value

from healthy
PS 18:0_18:0

0.03 (0.01 , 0.07)

0.11 (0.10 , 0.14)

266.7%↑

<0.0001

PS 18:0_18:1

1.06 (0.92 , 1.23)

1.00 (0.82 , 1.20)

5.6%

0.080

PS 18:0_20:4

5.82 (5.29 , 6.29)

5.16 (3.85 , 6.12)

11.3%↓

<0.0001

PS 18:0_22:5

1.13 (1.00 , 1.27)

1.17 (0.94 , 1.36)

3.5%

0.329

PS 18:0_22:6

2.07 (1.59 , 2.43)

1.61 (1.19 , 2.00)

22.2%↓

<0.0001

P-values were calculated by using Mann-Whitney U-test; statistical significance shown in bold. ↑
(Increase). ↓ (decrease). “Ultra high risk (UHR) of developing psychosis; PS, phosphatidylserine”.

130

Sphingomyelin (SM)
Erythrocytes SM results are shown in table 6. The higher percentage of total SM observed in
the UHR group (figure 1) is reflected in the higher contribution of SM 16:0, SM 18:0, SM 24:0
and SM 24:1 to total phospholipids. The lowest SM species measured (SM 18:1) contributed
a similar proportion of total phospholipids to both groups.
Table 6. Individual species of sphingomyelins content of erythrocyte membranes from
healthy (n=120) and people at UHR of developing psychosis (n= 285) (results are express
as % of total phospholipids)
Healthy group

UHR group

Median (First, Third quartile)

Median (First, Third quartile)

% difference

P-value

from healthy
SM 16:0

9.17 (7.62 , 11.32)

10.63 (9.18 , 13.45)

15.9%↑

<0.0001

SM 18:0

1.12 (0.93 , 1.67)

1.60 (1.32 , 2.23)

42.9%↑

<0.0001

SM 18:1

0.53 (0.43 , 0.65)

0.55 (0.45 , 0.79)

3.8%

0.010

SM 24:0

3.88 (2.57 , 6.62)

6.77 (5.23 , 8.42)

74.5%↑

<0.0001

SM 24:1

6.05 (4.12 , 10.18)

9.63 (7.44 , 11.79)

59.2%↑

<0.0001

P-values were calculated by using Mann-Whitney U-test; statistical significance shown in bold. ↑
(Increase). ↓ (decrease). “Ultra high risk (UHR) of developing psychosis; SM, Sphingomyelin
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Discussion
To the authors knowledge this is the first study to compare the molecular phospholipid
composition of human erythrocytes from individual at UHR of developing psychosis with that
from age-matched healthy individuals.
A striking finding of this study was the large difference in the level of phospholipid classes
between the UHR patients and healthy controls. In particular, the UHR group had an
approximately 46% lower concentration of PE and 16% higher concentration of SM in their
erythrocyte membranes. Interestingly, both Keshavan et al. 37 and Ponizovsky et al.38 report
similar lower levels of PE and increased levels of SM in the erythrocytes of schizophrenia
patients compared to healthy individuals. In fact, reduced PE levels in erythrocytes of
schizophrenia patients is a common finding37-44 and has also been observed in fibroblasts45
and postmortem brain tissue.46 There are however, two studies that did not detect
differences in erythrocyte phospholipid classes in patients with schizophrenia47 and in
hippocampus of individuals with schizophrenia and with bipolar disorder 48 the possible
reason for there was no differences observed in these two studies might come from
diagnostic or biological differences between populations or laboratory methodologies.

Previous findings in schizophrenic patients suggest there are two possible mechanisms that
lead to a decrease in the erythrocyte levels of PE. First, decreased phosphomonoesters
including phosphoethanolamine (precursors of membrane phospholipids) in the brains of
schizophrenic patients49, 50 suggests a decrease in PE synthesis. Second, elevated levels of
phospholipase A2 (PLA2) in erythrocytes of schizophrenia and UHR patients23, 51-56 and
phosphodiesters, particularly glycerophosphoethanolamine (breakdown products of
membrane phospholipids) in the brains of schizophrenic patients50 suggests an increase in
the breakdown of PE. Elevated levels of SM may represent compensatory changes in the
metabolism of phospholipids. The inverse relationship between PE and SM is compatible
with this possibility.
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Of the 49 individual molecular phospholipids reported here (Tables 3, 4, 5 and 6), twenty
seven were lower in proportion and nine were higher in proportion in the UHR group
compared to healthy controls. All twenty seven phospholipids that were lower in the UHR
group were glycerophospholipids and most contained PUFA. Of the phospholipids that were
higher in the UHR group all were choline containing (PC and SM), with the exception of PS
(18:0_18:0) that contributes approximately 0.1% or less of total erythrocyte phospholipids.
The abnormality in phospholipid composition in UHR may be related to alterations in lipid
metabolism as commonly observed in schizophrenia patients.16, 57, 58, 59 Evidence from brain
studies using 32P Magnetic Resonance Spectroscopy (MRS) suggests there is a decreased
synthesis of membrane phospholipids and an altered molecular composition of synaptic
vesicles in the prefrontal cortex adolescents at genetic risk for schizophrenia.60
The large differences in erythrocyte fatty acids composition is another striking finding in the
present study. The long chain PUFA, in particular AA, EPA and DHA were much lower in
UHR subjects compared to healthy subjects. While similar differences have been reported in
schizophrenia 15-19, 59 and UHR14 patients previously we can now confirm that these
differences are not the result of changes to specific molecular phospholipids as all fifteen
phospholipids containing these fatty acids were found to be lower in UHR subjects. PUFA
reductions in schizophrenia patients may in part be due to increased levels of oxidative
stress; increased breakdown or decreased incorporation of these fatty acids into
erythrocytes membrane15 disturbances in PUFA metabolism occur during the early stages of
schizophrenia61 and also those at UHR of psychosis in general.62
Another interesting finding is the elevated level of nervonic acid (NA) in the UHR group.
Again, this has been reported in schizophrenia patients previously.63 Unlike the differences
observed in PUFA however, the difference observed in NA in the current study is due to
changes in a single molecular phospholipid, i.e. SM 24:1. NA is an abundant
monounsaturated fatty acid present in the brain and the nervous system and helps to
maintain white matter integrity.64, 65 The higher levels of NA and SM may partly explain
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effects on white matter integrity observed in schizophrenia.64, 66
The n-3 index was 2.99% in the UHR group vs. 4.09% in the healthy group. This result is in
agreement with earlier observations that found a low n-3 index (3.1%) in UHR subjects.67
Additionally, low n-3 index has been reported in people diagnosed with depression and
schizophrenia68 and adolescents at UHR for bipolar disorder.24 This suggests that low n-3
index is common in individuals with psychological disorders and may be present prior to
illness onset.
The alterations of erythrocyte phospholipids and fatty acids in UHR of psychosis may be
expected to result in changes to their aggregability. Erythrocyte aggregability, i.e., their
ability to form multicellular aggregates, plays a major role in blood flow. Erythrocytes in the
presence of plasma proteins, most importantly fibrinogen, may aggregate to form rouleaux
formations.69,70 Currently, no studies have been conducted in people with the UHR
population investigate to this phenomenon; however, limited studies have reported increased
erythrocyte aggregation among schizophrenic patients with mainly negative symptoms.71,72,73
This suggests that the relationship between negative symptoms and erythrocyte aggregation
was not due to extracellular factors, but rather to changes in the cell membrane. Erythrocyte
aggregation can contribute to circulatory slowdown, especially in the microcirculation74,
which may exacerbate cerebral white matter deficiencies in different brain regions.

There is evidence to suggest that food components such as antioxidants, n-3 PUFA and B
vitamins can influence mental health and modulate brain function.75 Disturbances in the
metabolism of n-3 and n-6 PUFA are commonly seen in patients with schizophrenia, but it
remains unclear whether poor dietary habits play a role in the development of disease in
susceptible individuals. Interestingly, it has been recently reported that UHR individuals have
a significantly lower consumption of n-3 PUFA than healthy individuals.76, 77 A low level of n-3
PUFA in the brain is associated with reduced neuronal membrane fluidity78, which affects
glutamatergic, dopaminergic and serotonergic neurotransmission79, 80, 81 and increases the
vulnerability of neurons to oxidative stress.82 Taken together these deficits can lead to
134

schizophrenia in susceptible individuals.13
The strengths of this study include a large sample in a group of people with UHR of
psychosis and it utilized a new analytical technique for high throughput of erythrocyte
samples for the assessment of phospholipid species, fatty acids and the n-3 index.34 A
limitation in this study was that the healthy control group was from a single geographical
location compared to people at UHR of psychosis which included people from different cities
around the world and the confounders were not considered in this study. Also, the analytical
method is not able to assign the correct position of the double bond in the carbon chain of
the fatty acids e.g., this method is unable to determine whether 22:5 docosapentaenoic acid
is 22:5n-3 or 22:5n-6 or if 18:1 is 18:1n-9 or 18:1n-7. Despite this limitation, the current study
findings indicate that those in the UHR group have markedly different molecular
phospholipids, fatty acids and n-3 index profile in comparison to healthy control individuals.

In conclusion, the present investigation has identified large differences in n-3 index, fatty
acids and phospholipids between healthy and UHR of psychosis groups. UHR of psychosis
group had higher concentrations of SM and lower concentrations of PE. These differences
may represent a promising prodromal risk biomarker in UHR to assist clinical diagnosis and
warrant further investigation in future studies.
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Chapter 4
Supplementation with the n-3 long chain polyunsaturated fatty
acids: changes in the concentrations of n-3 index, fatty acids
and molecular phospholipids of people with ultra high risk of
developing psychosis
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Abstract
n-3 long chain polyunsaturated fatty acids (n-3 LCPUFA) are necessary for optimum mental
health, with recent studies showing low n-3 LCPUFA in people with ultra-high risk (UHR) of
developing psychosis. The aim of this study was to evaluate the effect of n-3
supplementation on erythrocyte membranes of UHR participants. 225 UHR participants
completed the 6 month intervention and 114 were randomized to fish oil capsules containing
840mg of EPA and 560mg of DHA, and 111 were randomized to placebo capsules
containing paraffin oil. Blood samples were taken at baseline and post intervention. Mass
spectrometry was used to analyse the molecular phospholipids and fatty acid composition of
erythrocytes for both groups. The n-3 index was significantly increased form 3.0% to 4.12%
after 6 months of receiving n-3 capsules. Fish oil capsules significantly increased the 20:5,
22:6 and most of 22:5 containing species of PC, PE and PS by 11.8%-50.0% and
significantly decreased 18:2, 20:3, 20:4, 22:4 containing species of PC, PE and PS by 7.4%42.9%. The SM 16:0, SM 18:0 and SM 18:1, however, significantly increased by 25.9%,
31.3% and 27.3% respectively after 6 months of receiving placebo capsules. n-3
supplementation increased n-3 index and PUFA in phospholipid molecular species but one
limitation is the lack of compliance of the groups with taking their daily supplementation.

Keywords: - Sphingomyelin, phosphatidylserine, phosphatidylethanolamine,
phosphatidylcholine, phospholipids.
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Introduction
Several studies have investigated the health benefits of consuming n-3 long chain
polyunsaturated fatty acids (n-3 LCPUFA) predominantly focusing on their protective effects
against such diseases as inflammatory diseases (e.g., arthritis) (Gillies et al., 2012),
cardiovascular diseases (Marik & Varon, 2009), Alzheimer’s disease (van Gelder et al.,
2007) and depression (Hibbeln & Salem, 1995; Hibbeln, 2009; Parletta et al., 2017).

Lower levels of PUFA are frequently observed in the erythrocyte membranes of patients with
schizophrenia compared to healthy people (Carver et al., 2001; Khan et al., 2002;
Arvindakshan et al., 2003; Peet et al., 2004; Parletta et al., 2016). PUFA deficiencies in
neuronal membranes can be the result of the decreased incorporation or increased release
of PUFA within membrane phospholipids (Pawelczyk et al., 2015). Both processes were
found to be defective in schizophrenia patients (Pawelczyk et al., 2015).

Supplementation with n-3 LCPUFA can prevent a transition to psychosis in people at UHR of
developing psychosis (Amminger et al., 2010, 2015). Study results showed 4.9% (2 out of
41) of patients treated with n-3 LCPUFA (700 mg of EPA and 480 mg of DHA) transitioned to
psychosis compared to 27.5% (11 out of 40) of individuals treated with placebo supplements
in addition to their standard care (Amminger et al., 2010). No severe functional impairment
was found in the majority of the individuals from the n-3 group, and in addition, they no
longer experienced attenuated psychotic symptoms at follow-up (Median, 6.7 years)
(Amminger et al., 2010; 2015). This indicates that supplementation with n-3 LCPUFA could
possibly reduce the risk of a transition to psychosis in those at ultra-high risk. High
erythrocyte PUFA levels in schizophrenia patients are associated with reduced psychotic
symptoms, better function, and improved myelin integrity (Amminger et al., 2012, 2015;
Zhang et al., 2011; Peters et al., 2013). Research studies have shown that n-3 LCPUFA
have neuroprotective and anti-inflammatory properties (Pandya et al., 2013; Smesny et al.,
2014), n-3 LCPUFA supplementation inhibits activity of phospholipase A2, reducing the
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release of arachidonic acid and the production of inflammatory eicosanoids and cytokines
(Szefel et al., 2015). Nevertheless, n-3 LCPUFA therapeutic effects are complex and not
fully understood.
The PUFA content of erythrocyte membranes reflects the distribution in the brain (Kuratko &
Salem, 2009) and therefore is an ideal sample to study. Erythrocyte PUFA have advantages
over plasma PUFA since there is less inter-individual variability compared to plasma PUFA,
more stable biomarker (Arab, 2003; Harris & Thomas, 2010) and reflects the last few months
of food intake (Sullivan et al., 2006).
Previous research investigating supplementation with n-3 LCPUFA in people with UHR
compared to placebo supplementation identified increased erythrocyte n-3 LCPUFA levels
and reduced transition to psychosis (Amminger et al., 2010). Nevertheless, this study was
limited in the number of participants and lacks information on erythrocyte molecular
phospholipid species. The aim of the present study was to investigate the effect of n-3
LCPUFA supplementation on the n-3 index, fatty acids and molecular phospholipids species
in erythrocytes samples from people diagnosed with UHR of developing psychosis
compared to placebo supplementation.

Material & methods
Ethics and Subjects recruitment
The NEURAPRO-E study is a double-blind, placebo-controlled, randomized clinical trial of n3 LCPUFA supplementation for participants at UHR of developing psychosis (McGorry et al.,
2017). The participants at UHR of developing psychosis were diagnosed and recruited
between March 2010 and September 2014 from different cities around the world (Melbourne,
Sydney, Hong Kong, Vienna, Basel, Winterthur, Copenhagen, Amsterdam, Singapore and
Jena) as described in previously published reports (Markulev et al., 2015; Mcgorry et al.,
2017). Study characteristics such as exclusion and inclusion criteria have previously been
described by study collaborators (Markulev et al., 2015; Mcgorry et al., 2017) and are shown
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in appendix (B). This study was approved by the human research ethics committee at the
University of Melbourne (2008.628). The trial is registered as ACTRN 12608000475347 with
The Australian New Zealand Clinical Trials Registry.
Study intervention and randomization
This trial was a double-blind, randomized placebo- controlled trial. Participants were
randomized at entry to one of two treatment groups: n-3 PUFAs plus CBCM or placebo plus
CBCM. There was equal allocation to the two treatment groups. The randomization was
stratified by site and total score <21 or ≥21 on the Montgomery Asberg Depression Rating
Scale (MADRS) (Montgomery, 1979) as both depression and antidepressants may impact
on prodromal symptoms and illness progression.
As previously described by (McGorry et al., 2017), participants were treated for a 6 month
period with a daily dose of gelatin capsules containing either n-3 LCPUFA or the placebo
control. Bottles of capsules were distributed to participants with each capsule containing
either (a) 2600 to 3000 mg of concentrated marine fish oil (active intervention: 560mg of
(DHA) 22:6n-3 and 840mg of (EPA) 20:5n-3, equivalent to approximately 1400 mg of n-3
LCPUFA per day) or (b) 2600 to 3000 mg of paraffin oil (placebo control). Paraffin oil was
specifically chosen as placebo because it does not contain PUFAs and has no impact on n-3
PUFA metabolism. Placebo capsules were carefully matched in appearance and flavour with
the active treatment to preserve blinding. The placebo capsules also contained the same
amount of vitamin E as the fish oil capsules, and approximately 1% fish oil to mimic taste.
This dose was similar to that described in a previous study (Amminger et al., 2010) and
higher than dose recommended for people who diagnosed with cardiovascular disease 1000
mg/day of n-3 LCPUFA (NHFA, 2008).
Materials
High performance liquid chromatography (HPLC) grade or higher of chloroform, methyl tertbutyl ether (MTBE) and methanol were purchased from VWR International (QLD, Australia).
Phospholipid internal standards were purchased from Avanti Polar Lipids (Victoria, Australia)
through Auspep and consisted of dinonadecanoyl phosphatidylcholine (PC 19:0/19:0);
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diheptadecanoyl phosphatidylethanolamine (PE17:0/17:0); diheptadecanoyl
phosphatidylserine (PS 17:0/17:0); N-lauroyl-D-erythro-sphinganylphosphorylcholine (SM
d18:0/12:0). Ethylenediaminetetraacetic acid (EDTA) and butylated hydroxytoluene (BHT)
were purchased from Sigma Aldrich (NSW, Australia). Analytical grade ammonium acetate
was purchased from Crown Scientific (New South Wales, Australia). 96-well plates and twintec PCR plates were purchased from Eppendorf (POCD scientific, Australia). Two types of
disposable conductive CO-RE tips (without filter) in 50 uL and 300 uL sizes were used and
purchased from Hamilton Robotics (Reno NV, USA).
Lipid extraction
Erythrocyte samples were extracted using an automated extraction method described
previously (Alqarni et al., 2018), In brief, 290 uL of aqueous ammonium acetate 150 mM with
2 mM EDTA was added to the wells of a 2.0 mL, 96-well plate cooled on ice. A 10 μL aliquot
of packed erythrocyte samples was added to the wells before the plate was mixed using a
vortex at 800 rpm for 10 minutes. Solvents, sample plates and reagents were loaded onto
the liquid handling workstation (Hamilton, Nevada, USA) where the following steps were
performed. First, a 300 μL aliquot of an internal standard mixture in methanol [500 uM (PC
19:0/19:0); 166.7 uM (PE 17:0/17:0); 100 uM (PS 17:0/17:0); 500 uM (SM 18:0/12:0)] was
added to the wells prior to mixing and standing for 10 minutes. Next, 1000 uL of MTBE was
added to the samples and mixed for 30 minutes before the mixture was allowed to stand for
15 minutes to allow phase separation. Following this, 500 μL of the MTBE top phase was
removed to the extraction plate (containing the extracted phospholipids) and 40 μL of extract
was transferred to another 96-well plate and diluted with 760 μL of a 2:1 (v:v)
methanol/chloroform solution containing 5 mM ammonium acetate. A 40 μL aliquot of the
diluted extract was transferred to another 96-well plate which was sealed with aluminium foil
prior to analysis by mass spectrometry.
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Electrospray ionization mass spectrometry ESI-MS
Mass spectra were acquired using a chip based nanoelectrospray ionization source
(Triversa NanoMate, Advion Biosciences, New York, USA) coupled to a hybrid linear ion
trap-triple quadruple mass spectrometer (QTRAP 5500 AB Sciex, MA, USA) as previously
described (Alqarni et al., 2018; Brown et al., 2013; Norris et al., 2015). A 10 uL aliquot of
lipid extract diluted in methanol: chloroform (2:1 v/v) containing 5mM ammonium acetate
(approximately 10 uM) was infused into the nano-electrospray ion source. The delivery gas
was nitrogen at a pressure of 0.40 psi and spray voltage of 1.1 kV and 1.2 kV for negative
and positive ion acquisition, respectively (Brown et al., 2013; Norris et al., 2015).
Lipids were identified using precursor ion and neutral loss scans as previously described
(Brown et al., 2013; Norris et al., 2015).
Data were analyzed using LipidView software (version 1.2, Sciex, MA, USA), this included
identification, smoothing, correction for isotope distribution, and removal of isotope
contribution from lower mass species (Brown et al., 2013; Norris et al., 2015). Ionized lipids
identified with a minimum signal-to-noise ratio of 10 were included in the analysis.
Quantification was achieved using LipidView software by comparing the spectral peak area
of individual lipids to their class specific internal standards after isotope correction.

Statistical analysis
Statistical analyses were carried out using SPSS software (version 19.0 SPSS. Inc), and
results presented as median and interquartile range (IQR). All variables were not normally
distributed thus the Wilcoxon signed-rank test (for paired samples) and the Mann-Whitney U
test (for unpaired samples) were used to compare means. Categorical data were analyzed
using chi-square and Mann-Whitney U test was used to calculate the significance of
continuous variables. For multiple comparisons the P-values were corrected using the
Bonferroni method and therefore P < 0.0008 was considered to be statistically significant.
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Results
Characteristics of participants
A total of 304 participants at UHR of developing psychosis were randomized to either n-3
LCPUFA or placebo group in this study (McGorry et al., 2017). Seventy-nine participants
were lost to follow-up during the study and 225 completed the 6-month period (McGorry et
al., 2017). The participant characteristics for each group are presented in table 1. As shown
in table 1 there were no differences in participant characteristics between n-3 LCPUFA or
placebo groups at baseline.
Table 1: Characteristics of the study participants at UHR of developing psychosis at
baseline after randomisation to the n-3 LCPUFA and placebo groups.
n-3 LCPUFA group
Placebo group
P
General characteristics

(n=114)

(n=111)
value

Age median (IQR-1, IQR-3)

17 (16,22)

17 (16,21)

Sex male n (%)

59 (51.8%)

43 (38.7%)

Body mass index Kg/m2 (IQR-1, IQR-3)

23 (20 , 26.5)*

23 ( 20.5 , 27.1)*

Smoking n (%)

40 (35.1%)

43 (38.7%)

0.564
0.050
0.961
0.570

* 22 participants BMI information missed (10 from placebo group and 12 from n-3 LCPUFA group).

Pre versus post n-3 LCPUFA and placebo supplementation.
Table 2 shows the fatty acid results from the n-3 LCPUFA and placebo groups. Out of the 14
fatty acids measured four fatty acids (18:2, 20:3, 20:4, 22:4) were decreased and three fatty
acids (20:5, 22:5, 22:6) were increased in n-3 LCPUFA supplementation group after 6
months of supplementation. Additionally, the n-3 index increased by 37.3% in the n-3
LCPUFA supplementation group while no change was observed in the placebo group after 6
months of supplementation with paraffin oil (Table 2).
As shown in table 3, no change from baseline was observed in total erythrocyte PC, PE or
PS after 6 months of supplementation with either n-3 LCPUFA or placebo. Interestingly, total
sphingomyelin (SM) increased by 22.9% after 6 months of supplementation with placebo.
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The individual phospholipid molecules PC, PE, PS and SM expressed as nmol/10ul
erythrocytes are shown in table 4. Out of a total of 20 PC species, seven species (PC
16:0_18:1, PC 16:0_18:2, PC 17:0_18:2, PC 18:0_18:2, PC 16:0_20:3, PC 16:0_20:4 and
18:0_20:4) decreased by 12.8%, 13.7%, 22.2%, 20.3%, 20.3%, 22.6%, 29.6%, respectively
and three species (PC 16:0_20:5, PC 16:0_22:6 and PC 18:0_22:6) increased by 50.0%,
11.8%, 40.0%, respectively in the n-3 LCPUFA supplementation group while the placebo
group showed no difference post dose. Similar changes were seen with both PE and PS
species. Eight PE species (PE 16:0_18:2, PE 18:1_18:2, PE 16:0_20:3, PE 16:0_20:4, PE
17:0_20:4, PE 18:0_20:4, PE 16:0_22:4, PE 18:1_20:4) decreased by 9.1%, 24.0%, 28.6%,
10.4%, 25.0%, 7.4%, 33.3%, 10.7%, respectively and four PE species (PE 16:0_20:5, PE
16:0_22:5, PE 16:0_22:6, PE 18:0_22:6) increased by 50.0%, 12.5%, 36.8%, 33.3%,
respectively in the n-3 LCPUFA supplementation group. PS 18:0_20:4 decreased by 14.4%
and PS 18:0_22:6 increased by 31.3% after 6 months of n-3 LCPUFA supplementation. No
changes were observed post placebo dose for PC, PE and PS species (Table 4). SM
species did not shows any significant changes in n-3 LCPUFA group however, three SM
species (SM 16:0, SM 18:0, SM 18:1) significantly increased by 25.9%, 31.3%, 27.3%
respectively after 6 months of supplementation with placebo.
After 6 months of n-3 LCPUFA supplementation PC n-3 LCPUFA increased by 43.0% from
3.30% to 4.72% of total PC and similar increase was observed in PE n-3 LCPUFA by 32.6%
from 10.08% to 13.37% of total PE and PS n-3 LCPUFA by 33.4% from 17.58% to 23.46%
of total PS. n-3 LCPUFA supplementation led to increase in n-3 species and decrease in n-6
species.
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Table 2: Erythrocyte fatty acids of UHR of developing psychosis groups (n-3 LCPUFA and placebo).
n-3 LCPUFA group (n=114)
Fatty
acids

Placebo group (n=111)

Median (IQR)
Pre
supplementation

Median (IQR)
Post
supplementation

P
value

%
changes

Median (IQR)
Pre
supplementation

Median (IQR)
Post
supplementation

P
value

%
changes

16:0

423.45 (405.30 , 450.21)

434.41 (422.30 , 458.93)

0.567

2.60%

430.53 (407.11 , 455.77)

433.43(411.26 , 462.62)

0.248

0.67%

16:1

2.86 (2.05 , 4.05)

2.39 (1.57 , 3.65)

0.035

16.40%

2.57 (1.76 , 3.66)

2.66 (1.88 , 3.92)

0.380

3.50%

17:0

17.03 ( 15.69 , 18.68)

16.72 (14.90 , 18.80)

0.474

1.80%

16.52 (15.18 , 17.86)

16.69 (15.24 , 19.33)

0.056

1.02%

18:0

171.29 (159.57 , 184.72)

175.44 (162.85 , 184.71)

0.072

2.40%

171.16 (155.07 , 182.49)

175.03 (160.93 , 188.73)

0.016

2.26%

18:1

218.76 (203.09 , 233.48)

222.87 (207.79 , 240.75)

0.069

1.87%

218.13 (203.97 , 230.74)

220.17 (206.49 , 234.19)

0.780

0.94%

18:2

155.89 (139.60 , 177.04)

152.25 ( 127.79 , 165.71)

<0.0001

2.33%↓

159.03 (135.74 , 177.09)

146.83 (136.24 , 170.22)

0.133

7.67%

20:3

10.56 ( 8.81 , 12.38 )

8.25 (6.81 , 10.41)

<0.0001

21.88%↓

11.01 (8.46 , 13.00)

8.61 (7.26 , 11.26)

0.003

21.79%

20:4

121.38(98.56 , 131.89)

111.26 (101.95 , 122.60)

<0.0001

8.33%↓

123.07 (98.09 , 135.53)

123.23 (106.04 , 134.10)

0.783

0.13%

20:5

7.31 (6.32 , 8.30)

9.60 (7.15 , 14.84)

<0.0001

31.32%↑

6.72 (5.60 , 8.36)

7.47 (6.17 , 9.90)

0.005

11.16%

22:4

4.35 (2.33 , 5.95 )

3.85 (1.39 , 4.87)

<0.0001

11.49%↓

4.22 (1.82 , 5.85)

4.19 (1.42 , 5.74)

0.568

0.71%

22:5

13.99 (11.43 , 17.03)

16.76 (13.45 , 19.55)

<0.0001

19.79%↑

13.28 (10.47 , 17.11)

14.51 (11.68 , 16.36)

0.635

9.26%

22:6

32.41 (26.18 , 40.04)

45.95 (31.07 , 53.83)

<0.0001

41.77%↑

33.14 (26.34 , 38.45)

36.44 (27.95 , 43.13)

0.396

9.95%

24:0

54.07 (39.69 , 68.46)

60.31 (42.45 , 70.63)

0.131

11.54%

51.79 (39.53 , 68.81)

57.62 (44.67 , 81.08)

0.017

11.25%

24:1

73.62 (55.84 , 97.07)

83.52 (64.43 , 105.04)

0.045

13.45%

74.31 (56.42 , 97.66)

85.41 (63.81 , 111.83)

0.011

14.94%

n-3 index

3.00 (2.48 , 3.59)

4.12 (2.89 , 5.09)

<0.0001

37.3%↑

3.02 (2.49 , 3.56)

3.21 (2.34 , 4.11)

0.200

6.30%

Statistical significance shown in (bold). Not significant (n.s). ↑ (Increase). ↓ (decrease). ↔ (No change). Data expressed as nmol/ml blood, Median (IQR).
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Table 3: Different PL classes distribution in erythrocyte membranes pre and post supplementation with (n-3 LCPUFA and placebo) in UHR of
developing psychosis groups.
n-3 LCPUFA group (n=114)
Phospholipid
Classes

Placebo group (n=111)

Median (IQR)
Pre
supplementation

Median (IQR)
Post
supplementation

P
value

%
changes

Median (IQR)
Pre
supplementation

Median (IQR)
Post
supplementation

P
value

%
changes

PC

8.33 ( 6.47 , 9.46)

6.93 (6.18 , 8.20)

0.259

16.8%

8.06 (6.48 , 9.22)

7.59 (6.75 , 8.89)

0.499

5.8%

PE

3.74 (3.39 , 4.22)

3.79 (3.27 , 4.14)

0.302

1.3%

3.49 (3.16 , 4.15)

4.11 (3.34 , 4.68)

0.001

17.8%

PS

1.87 (1.57 , 2.05)

1.83 (1.62 , 2.02)

0.824

2.1%

1.81 (1.53 , 2.02)

1.96 (1.68 , 2.14)

0.099

8.3%

SM

5.74 (4.84 , 7.44)

6.31 (5.19 , 7.25)

0.228

9.9%

5.66 (4.88 , 7.29)

6.96 (5.62 , 8.22)

<0.0001

22.9%↑

Statistical significance shown in (bold). Not significant (n.s). ↑ (Increase). ↓ (decrease). ↔ (No change). Data expressed as nmol/10ul erythrocytes.
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Table 4: Erythrocyte PL species of UHR of developing psychosis groups (n-3 LCPUFA and placebo).
n-3 LCPUFA group (n=114)
Phospholipids

Placebo group (n=111)

Median (IQR)
Pre
supplementation

Median (IQR)
Post
supplementation

P
value

%
changes

Median (IQR)
Pre
supplementation

Median (IQR)
Post
supplementation

P
value

%
changes

PC 16:0_16:0

0.42 (0.35 , 0.55)

0.38 (0.34 , 0.47)

0.153

9.5%

0.41 (0.36 , 0.52)

0.42 (0.35 , 0.51)

0.964

2.4%

PC 16:0_16:1

0.07 (0.05 , 0.10)

0.06 (0.04 , 0.09)

0.047

14.3%

0.07 (0.04 , 0.09)

0.07 (0.05 , 0.09)

0.534

↔

PC 16:0_17:0

0.05 (0.03 , 0.06)

0.05 (0.03 , 0.06)

0.943

↔

0.04 (0.02 , 0.06)

0.05 (0.03 , 0.06)

0.006

25.0%

PC 16:0_18:0

0.08 ( 0.06 , 0.11)

0.07 (0.06 , 0.10)

0.200

12.5%

0.08 (0.06 , 0.11)

0.08 (0.06 , 0.10)

0.995

↔

PC 16:0_18:1

1.96 (1.64 , 2.29)

1.71 (1.45 , 2.05)

<0.0001

12.8%↓

1.93 (1.67 , 2.18)

1.90 (1.61 , 2.20)

0.911

1.6%

PC 16:0_18:2

2.11 (1.70 , 2.63)

1.82 (1.52 , 2.22)

<0.0001

13.7%↓

2.21 (1.67 , 2.67)

1.95 (1.71 , 2.42)

0.548

11.8%

PC 16:0_20:3

0.21 (0.14 , 0.26)

0.12 (0.09 , 0.16)

<0.0001

42.9%↓

0.19 (0.14 , 0.27)

0.15 (0.12 , 0.23)

0.021

21.0%

PC 16:0_20:4

0.53 (0.41 , 0.69)

0.41 (0.31 , 0.53)

<0.0001

22.6%↓

0.56 (0.42 , 0.69)

0.48 (0.36 , 0.63)

0.003

14.3%

PC 16:0_20:5

0.04 (0.03 , 0.07)

0.06 (0.04 , 0.10)

<0.0001

50.0%↑

0.05 (0.03 , 0.07)

0.04 (0.03 , 0.06)

0.139

20.0%

PC 16:0_22:6

0.17 (0.12 , 0.19)

0.19 (0.13 , 0.25)

<0.0001

11.8%↑

0.17 (0.12 , 0.22)

0.15 (0.11 , 0.20)

0.101

11.8%

PC 17:0_18:1

0.08 (0.07 , 0.09)

0.07 (0.06 , 0.08)

0.002

12.5%

0.07 (0.06 , 0.09)

0.08 (0.07 , 0.09)

0.081

14.3%

PC 17:0_18:2

0.09 (0.07 , 0.11)

0.07 (0.06 , 0.09)

<0.0001

22.2%↓

0.09 (0.07 , 0.12)

0.08 (0.07 , 0.10)

0.962

11.1%

PC 18:0_18:0

0.02 (0.01 , 0.03)

0.02 (0.01 , 0.03)

0.473

↔

0.02 (0.01 , 0.03)

0.02 (0.01 , 0.04)

0.616

↔

PC 18:0_18:1

0.41 (0.33 , 0.48)

0.36 (0.29 , 0.44)

0.002

12.2%

0.40 (0.34 , 0.48)

0.39 (0.33 , 0.48)

0.873

2.5%

PC 18:0_18:2

0.74 (0.60 , 0.88)

0.59 (0.47 , 0.75)

<0.0001

20.3%↓

0.70 (0.57 , 0.85)

0.65 (0.54 , 0.82)

0.432

7.1%

PC 18:0_20:4

0.27 (0.21 , 0.34)

0.19 (0.15 , 0.24)

<0.0001

29.6%↓

0.27 (0.21 , 0.32)

0.25 (0.18 , 0.29)

0.003

7.4%

PC 18:0_22:6

0.05 (0.03 , 0.07)

0.07 (0.04 , 0.09)

<0.0001

40.0%↑

0.05 (0.03 , 0.07)

0.04 (0.03 , 0.07)

0.161

20.0%

PC 18:1_18:1

0.21 (0.16 , 0.29)

0.20 (0.14 , 0.26)

0.379

4.8%

0.22 (0.15 , 0.29)

0.23 (0.17 , 0.27)

0.542

4.5%

PC 18:1_18:2

0.25 (0.20 , 0.33)

0.23 (0.18 , 0.32)

0.695

8%

0.25 (0.18 , 0.33)

0.25 (0.19 , 0.34)

0.179

↔

PC 18:1_20:4

0.12 (0.09 , 0.15)

0.11 (0.08 , 0.14)

0.378

8.3%

0.12 (0.09 , 0.14)

0.10 (0.07 , 0.13)

0.004

16.6%
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Table 4: (continued)

n-3 LCPUFA group (n=114)
Phospholipids

Placebo group (n=111)

Median (IQR)
Pre
supplementation

Median (IQR)
Post
supplementation

P
value

%
changes

Median (IQR)
Pre
supplementation

Median (IQR)
Post
supplementation

P
value

%
changes

PE 16:0_18:1

0.84 (0.76 , 0.95)

0.85 ( 0.76 , 0.91)

0.243

1.2%

0.82 (0.74 , 0.93)

0.89 (0.80 , 0.95)

0.120

8.5%

PE 16:0_18:2

0.33 (0.28 , 0.39)

0.30 (0.24 , 0.34)

<0.0001

9.1%↓

0.29 (0.26 , 0.35)

0.34 (0.28 , 0.39)

0.210

17.2%

PE 16:0_20:3

0.07 (0.04 , 0.11)

0.05 (0.04 , 0.09)

<0.0001

28.6%↓

0.06 (0.04 , 0.12)

0.06 (0.04 , 0.10)

0.862

↔

PE 16:0_20:4

0.48 (0.43 , 0.55)

0.43 (0.37 , 0.47)

<0.0001

10.4%↓

0.48 (0.41 , 0.55)

0.51 (0.38 , 0.57)

0.743

6.3%

PE 16:0_20:5

0.04 (0.03 , 0.04)

0.06 (0.04 , 0.10)

<0.0001

50.0%↑

0.03 (0.02 , 0.04)

0.04 (0.03 , 0.07)

0.652

33.3%

PE 16:0_22:4

0.12 (0.05 , 0.16)

0.08 (0.03 , 0.12)

<0.0001

33.3%↓

0.09 (0.04 , 0.15)

0.10 (0.03 , 0.14)

0.713

11.1%

PE 16:0_22:5

0.08 (0.05 , 0.12)

0.09 (0.06 , 0.14)

<0.0001

12.5%↑

0.07 (0.04 , 0.10)

0.08 (0.05 , 0.12)

0.021

14.3%

PE 16:0_22:6

0.19 (0.16 , 0.25)

0.26 (0.18 , 0.35)

<0.0001

36.8%↑

0.19 (0.14 , 0.24)

0.25 (0.16 , 0.37)

0.010

31.7%

PE 17:0_20:4

0.08 (0.06 , 0.09)

0.06 (0.04 , 0.08)

<0.0001

25.0%↓

0.07 (0.06 , 0.09)

0.08 (0.06 , 0.09)

0.296

14.3%

PE 17:0_20:5

0.09 (0.08 , 0.10)

0.08 (0.06 , 0.14)

0.915

11.1%

0.08 (0.07 , 0.11)

0.09 (0.08 , 0.14)

0.195

12.5%

PE 17:0_22:5

0.04 (0.03 , 0.05)

0.04 ( 0.03 , 0.05)

0.055

↔

0.03 (0.03 , 0.05)

0.04 (0.03 , 0.06)

0.199

33.3%

PE 18:0_18:0

0.02 (0.01 , 0.02)

0.02 (0.01 , 0.05)

0.758

↔

0.01 (0.01 , 0.02)

0.01 (0.01 ,0.03)

0.920

↔

PE 18:0_18:1

0.19 (0.17 , 0.22)

0.20 (0.17 , 0.22)

0.738

5.3%

0.19 (0.16 , 0.21)

0.22 (0.18 , 0.24)

0.007

15.8%

PE 18:0_18:2

0.17 (0.14 , 0.19)

0.14 (0.12 , 0.17)

0.005

17.6%

0.15 (0.12 , 0.17)

0.17 (0.13 , 0.18)

0.054

13.3%

PE 18:0_20:4

0.27 (0.11 , 0.35)

0.25 (0.12 , 0.30)

<0.0001

7.4%↓

0.19 (0.11 , 0.33)

0.27 (0.12 , 0.36)

0.074

42.1%

PE 18:0_22:6

0.06 (0.05 , 0.08)

0.08 (0.06 , 0.09)

<0.0001

33.3%↑

0.06 (0.04 , 0.08)

0.07 (0.05 , 0.09)

0.245

16.7%

PE 18:1_18:1

0.17 (0.13 , 0.20)

0.16 (0.13 , 0.19)

0.224

5.90%

0.16 (0.13 , 0.21)

0.17 (0.13 , 0.21)

0.816

6.3%

PE 18:1_18:2

0.25 (0.17 , 0.30)

0.19 (0.13 , 0.26)

<0.0001

24.0%↓

0.22 (0.16 , 0.28)

0.24 (0.16 , 0.29)

0.168

9.1%

PE 18:1_20:4

0.28 (0.23 , 0.33)

0.25 (0.16 , 0.29)

<0.0001

10.7%↓

0.27 (0.18 , 0.33)

0.29 (0.17 , 0.35)

0.739

7.4%

PS 18:0_18:0

0.02 (0.02 , 0.03)

0.02 (0.02 , 0.03)

0.499

↔

0.02 (0.02 , 0.03)

0.02 (0.02 , 0.03)

0.256

↔
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Table 4: (continued)

n-3 LCPUFA group (n=114)
Phospholipids

Placebo group (n=111)

Median (IQR)
Pre
supplementation

Median (IQR)
Post
supplementation

P
value

%
changes

Median (IQR)
Pre
supplementation

Median (IQR)
Post
supplementation

P
value

%
changes

PS 18:0_18:1

0.20 (0.16 , 0.24)

0.22 (0.19 , 0.27)

0.001

10.0%

0.20 (0.16 , 0.24)

0.23 (0.19 , 0.28)

0.010

15.0%

PS 18:0_20:4

1.04 (0.69 , 1.19)

0.89 (0.75 , 1.02)

<0.0001

14.4%↓

0.97 (0.57 , 1.21)

1.08 (0.87 , 1.25)

0.100

11.3%

PS 18:0_22:5

0.24 (0.19 , 0.27)

0.24 (0.20 , 0.28)

0.861

↔

0.23 (0.17 , 0.27)

0.23 (0.19 , 0.26)

0.519

↔

PS 18:0_22:6

0.32 (0.23 , 0.40)

0.42 (0.28 , 0.50)

<0.0001

31.3%↑

0.33 (0.24 , 0.39)

0.32 (0.23 , 0.41)

3.0%

SM 16:0

2.19 (1.85 , 2.75)

2.49 (2.11 , 2.82)

0.038

13.7%

2.08 (1.83 , 2.67 )

2.62 (2.23 , 3.07)

0.446
<0.0001

25.9%↑

0.42 (0.33 , 0.52)

<0.0001

31.3%↑
27.3%↑

SM 18:0

0.32 (0.26 , 0.44)

0.38 (0.29 , 0.44)

0.159

18.8%

0.32 (0.25 , 0.45 )

SM 18:1

0.11 (0.09 , 0.16)

0.13 (0.09 , 0.15)

0.195

18.2%

0.11 (0.09 , 0.16)

0.14 (0.11 , 0.18)

<0.0001

SM 24:0

1.39 (1.06 , 1.73)

1.39 (1.02 , 1.65)

0.900

↔

1.31 (0.95 , 1.72)

1.48 (1.16 , 2.02)

0.015

12.9%

SM 24:1

1.91 (1.49 , 2.36)

1.96 (1.55 , 2.39)

0.629

2.6%

1.89 (1.41 , 2.37)

2.20 (1.73 , 2.79)

0.018

16.4%

Statistical significance shown in (bold). Not significant (n.s). ↑ (Increase). ↓ (decrease). ↔ (No change). Data expressed as nmol/10ul erythrocytes
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Effect of n-3 LCPUFA supplementation
After 6 months of supplementation, 20:5 (2.64 vs. 1.01, p<0.0001), 22:6 (13.72 vs. 1.74,
p<0.0001) and the n-3 index (1.12 vs. 0.19, p<0.0001) were higher in the n-3 LCPUFA group
compared to the placebo group (Table 5).

There were no differences in phospholipid class totals between the two groups after the 6
month of intervention period (Table 6), however there were concentration differences in 8 out
of 49 molecular species (Table 7) PC 16:0_20:3 (-0.06 vs. -0.02, p<0.0001), PE 16:0_20:4 (0.07 vs. 0.02, p<0.0001) and PE 17:0_20:4 (-0.02 vs. 0.002, p<0.0001) were lower in n-3
LCPUFA group and PC 16:0_20:5 (0.01 vs. -0.004, p<0.0001), PC 16:0_22:6 (0.01 vs. 0.02, p<0.0001), PC 18:0_22:6 (0.01 vs. -0.004, p<0.0001), PE 16:0_20:5 (0.02 vs. 0.01,
p<0.0001), PS 18:0_22:6(0.06 vs. -0.01, p<0.0001) were higher in n-3 LCPUFA group
compared to placebo group.
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Table 5: Comparison the effects of n-3 LCPUFA vs. placebo on fatty acids in UHR of
developing psychosis groups.
Fatty acids

n-3 LCPUFA group (n=114)

Placebo group (n=111)

P value

16:0

Change

15.18 (-10.57 , 33.61)

Change

8.25 (-23.82 , 28.94)

0.122

16:1

Change

-0.47

(-1.73 , 0.84)

Change

0.06 (-0.96 , 1.33)

0.034

17:0

Change

-0.56

(-2.94 , 2.46)

Change

0.74 (-2.05 , 3.07)

0.050

18:0

Change

4.06

(-11.26 , 22.26)

Change

9.11 (-8.93 , 23.26)

0.469

18:1

Change

5.02

(-13.44 , 25.13)

Change

2.37 (-20.19 , 20.21)

0.332

18:2

Change

-7.58

(-25.61 , 9.87)

Change -5.54 (-27.98 , 18.49)

0.590

20:3

Change

-2.18

(-4.86 , 0.40)

Change -1.20 (-4.08 , 1.81)

0.151

20:4

Change

-6.30

(-23.07 , 14.69)

Change -1.48 (-17.24 , 21.47)

0.151

20:5

Change

2.64

(-0.05 , 6.98)

Change 1.01

22:4

Change

-1.05

(-2.99 , 1.09)

Change -0.44 (-2.06 , 2.35)

0.063

22:5

Change

1.86

(-4.74 , 6.13)

Change

0.74 (-4.41 , 4.30)

0.327

22:6

Change

13.72 (-3.16 , 23.97)

Change

1.74 (-8.63 , 13.09)

<0.0001

24:0

Change

3.68

(-14.02 , 23.48)

Change

9.29 (-10.50 , 24.29)

0.465

24:1

Change

6.69

(-18.04 , 33.04)

Change

9.50 (-10.14 , 31.22)

0.642

n-3 index

Change

1.12

(-0.20 , 2.24)

Change

0.19 (-0.55 , 1.27)

(-1.66 , 4.78)

<0.0001

<0.0001

Statistical significance shown in (bold). Not significant (n.s). Data expressed as nmol/ml blood, Median (IQR).

Table 6: Comparison the effect of n-3 LCPUFA vs. placebo supplementation on molecular
PL classes in UHR of developing psychosis groups.
Phospholipid
Classes
PC

Change

-0.89 (-2.14 , 0.11)

Change

0.29 (-1.52, 1.14)

0.001

PE

Change

-0.03 (-0.73, 0.51)

Change

0.33 (-0.25 , 0.98)

0.002

PS

Change

-0.03 (-0.31 , 0.29)

Change

0.12 (-0.32 , 0.49)

0.129

SM

Change

0.36 (-0.84 , 1.21)

Change

0.87 (-0.07 , 2.43)

0.008

n-3 LCPUFA group (n=114)

Placebo group (n=111)

Statistical significance shown in (bold). Data expressed as nmol/10ul erythrocytes, Median (IQR).
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P value

Table 7: Comparison the effect of n-3 LCPUFA vs. placebo on molecular PL species in UHR
of developing psychosis groups.
Phospholipids

n-3 LCPUFA group (n=114)

Placebo group (n=111)

P
value

PC 16:0_16:0

Change

-0.01

(-0.09 , 0.08)

Change

0.02

(-0.10 , 0.09)

0.341

PC 16:0_16:1

Change

-0.01

(-0.04 , 0.02)

Change

0.001 (-0.25 , 0.03)

0.063

PC 16:0_17:0

Change

0.0002 (-0.02 , 0.01)

Change

0.01

0.031

PC 16:0_18:0

Change

-0.01

(-0.3 , 0.01)

Change

-0.0001 (-0.02 , 0.03)

0.362

PC 16:0_18:1

Change

-0.22

(-0.48 , 0.15)

Change

0.03

(-0.34 , 0.39)

0.011

PC 16:0_18:2

Change

-0.16

(-0.71 , 0.10)

Change

-0.07

(-0.47 , 0.26)

0.002

PC 16:0_20:3

Change

-0.06

(-0.13 , -0.01)

Change

-0.02

(-0.07 , 0.04)

<0.0001

PC 16:0_20:4

Change

-0.11

(-0.25 , -0.01)

Change

-0.09

(-0.18 , 0.05)

0.120

PC 16:0_20:5

Change

0.01

(-0.01 , 0.05)

Change

-0.004 (-0.02 , 0.01)

<0.0001

PC 16:0_22:6

Change

0.01

(-0.04 , 0.09)

Change

-0.02

(-0.06 , 0.02)

<0.0001

PC 17:0_18:1

Change

-0.01

(-0.02 , 0.01)

Change

0.01

(-0.01 , 0.02)

0.001

PC 17:0_18:2

Change

-0.01

(-0.04 , 0.01)

Change

-0.001 (-0.02 , 0.02)

0.013

PC 18:0_18:0

Change

0.001

(-0.01 , 0.01)

Change

0.001 (-0.01 , 0.01)

0.389

PC 18:0_18:1

Change

-0.04

(-0.14 , 0.03)

Change

0.01

(-0.07 , 0.06)

0.026

PC 18:0_18:2

Change

-0.11

(-0.33 , 0.03)

Change

-0.03

(-0.16 , 0.11)

0.007

PC 18:0_20:4

Change

-0.07

(-0.14 , -0.002)

Change

-0.03

(-0.09 , 0.04)

0.012

PC 18:0_22:6

Change

0.01

(-0.02 , 0.03)

Change

-0.004

(-0.02 , 0.01)

<0.0001

PC 18:1_18:1

Change

-0.01

(-0.08 , 0.07)

Change

0.01

(-0.07 , 0.09)

0.342

PC 18:1_18:2

Change

-0.01

(-0.07 , 0.07)

Change

0.01

(-0.05 , 0.09)

0.146

PC 18:1_20:4

Change

-0.01

(-0.05 , 0.03)

Change

-0.01

(-0.04 , 0.02)

0.232

PE 16:0_18:1

Change

-0.02

(-0.08 , 0.05)

Change

0.05

(-0.04 , 0.13)

0.049

PE 16:0_18:2

Change

-0.03

(-0.09 , 0.003)

Change

0.02

(-0.03 , 0.09)

0.001

PE 16:0_20:3

Change

-0.02

(-0.05 , 0.02)

Change

-0.001

(-0.38 , 0.04)

0.244

PE 16:0_20:4

Change

-0.07

(-0.15 , -0.001)

Change

0.02

(-0.07 , 0.09)

<0.0001

PE 16:0_20:5

Change

0.02

(-0.002 , 0.07)

Change

0.01

(-0.01 , 0.03)

<0.0001

PE 16:0_22:4

Change

-0.03

(-0.10 , 0.01)

Change

-0.01

(-0.08 , 0.05)

0.002

PE 16:0_22:5

Change

0.01

(-0.04 , 0.07)

Change

0.01

(-0.04 , 0.06)

0.542

PE16:0_22:6

Change

0.05

(-0.02 , 0.18)

Change

0.04

(-0.03 , 0.16)

0.747

PE 17:0_20:4

Change

-0.02

(-0.03 , 0.002)

Change

0.002

(-0.01 , 0.02)

<0.0001

PE 17:0_20:5

Change

-0.01

(-0.03 , 0.03)

Change

0.01

(-0.02 , 0.07)

0.007

PE 17:0_22:5

Change

-0.002 (-0.01 , 0.01)

Change

0.002

(-0.01 , 0.02)

0.025

PE 18:0_18:0

Change

0.002 (-0.01 , 0.03)

Change

0.003

(-0.003 , 0.02)

0.582
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(-0.004 , 0.02)

Table 7: (continued)
Phospholipids

n-3 LCPUFA group (n=114)

Placebo group (n=111)

P
value

PE 18:0_18:1

Change

-0.002

(-0.02 , 0.02)

Change

0.01

(-0.01 , 0.05)

0.005

PE 18:0_18:2

Change

-0.02

(-0.06 , 0.02)

Change

0.004 (-0.03 , 0.05)

0.001

PE 18:0_20:4

Change

-0.02

(-0.13 , 0.09)

Change

0.05

(-0.07 , 0.15)

0.057

PE 18:0_22:6

Change

0.01

(-0.01 , 0.04)

Change

0.01

(-0.01 , 0.04)

0.743

PE 18:1_18:1

Change

-0.01

(-0.05 , 0.02)

Change

0.002 (-0.03 , 0.04)

0.317

PE 18:1_18:2

Change

-0.04

(-0.11 , 0.04)

Change

0.01

(-0.07 , 0.08)

0.001

PE 18:1_20:4

Change

-0.04

(-0.12 , 0.02)

Change

0.01

(-0.11 , 0.10)

0.008

PS 18:0_18:0

Change

-0.001

(-0.01 , 0.01)

Change

0.001 (-0.01 , 0.01)

0.895

PS 18:0_18:1

Change

0.01

(-0.03 , 0.11)

Change

0.03

(-0.02 , 0.09)

0.581

PS 18:0_20:4

Change

-0.13

(-0.27 , 0.08)

Change

0.03

(-0.16 , 0.29)

0.019

PS 18:0_22:5

Change

-0.001

(-0.05 , 0.04)

Change

0.001 (-0.06 , 0.05)

0.654

PS 18:0_22:6

Change

0.06

(-0.04 , 0.18)

Change

-0.01

(-0.09 , 0.07)

<0.0001

SM 16:0

Change

0.15

(-0.17 , 0.50)

Change

0.41

(0.03 , 0.81)

0.004

SM 18:0

Change

0.02

(-0.03 , 0.09)

Change

0.07

(0.01 , 0.15)

0.009

SM 18:1

Change

0.01

(-0.02 , 0.03)

Change

0.02

(0.003 , 0.04)

0.087

SM 24:0

Change

-0.03

(-0.35 , 0.32)

Change

0.23

(-0.09 , 0.52)

0.011

SM 24:1

Change

-0.42

(-0.41 , 0.57)

Change

0.26

(-0.15 , 0.77)

0.044

Statistical significance shown in (bold). Data expressed as nmol/10ul erythrocytes, Median (IQR).
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Discussion
It is known that phospholipids are the major component of the lipid bilayer of the cell
membrane, molecular species composition affect cell membrane fluidity, function, and the
activity of membrane bound proteins (Alberts et al., 2002). To the authors knowledge this is
the first study on erythrocyte phospholipid molecular species and the effect of a 6-month
intervention of n-3 LCPUFA supplementation compared to placebo supplementation in
people at UHR of psychosis.
Supplementation with n-3 LCPUFA resulted in an increase in n-3 index, all n-3 LCPUFA and
in all phospholipid molecular species containing n-3 LCPUFA in people at UHR of psychosis,
and this is largely replacing n-6 LCPUFA. This is in line with previous observations with
using cod liver oil containing 3000 mg of n-3 fatty acids and daily supplement of fatty fish
containing 3000 mg of n-3 fatty acids in healthy subjects (Popp-snijders et al., 1984; 1986).
The increases in the n-3 LCPUFA (EPA and DHA) with corresponding decreases in n-6
LCPUFA vary depending on the dose and period of supplementation (Blonk et al., 1990;
Katan et al., 1997; Sanders & Roshanai, 1983). The changes in the incorporation observed
in PC, PE and PS n-3 LCPUFA are probably due to the different pathways of renewal of
erythrocyte phospholipids (Popp-snijders et al., 1984), phospholipids on the inside of the
erythrocyte membrane are renewed via acylation of lysophospholipids (Renooij et al., 1974,
1976), whereas phospholipids on the outside are renewed by exchange of phospholipids
between red cell membrane and plasma lipoproteins (Reed, 1968).
Despite the changes observed in individual phospholipid molecular species, there were no
effects of n-3 LCPUFA supplementation on erythrocyte phospholipid PC, PE, PS and SM
totals seen in this study. Similar observation have been reported in healthy populations
(Popp-snijders et al., 1984; 1986). In contrast SM levels increased during the 6 months
supplementation with placebo capsules. We previously observed an increased in erythrocyte
SM concentration in subjects at UHR of psychosis compared to controls (chapter 3). The
data here may indicate that n-3 LCPUFA supplementation helps to maintain and limit the
increase of the SM levels.
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The fish oil supplements in the current study contained 840 mg + 560 mg of EPA and DHA.
EPA increased by as much as 29.0% and DHA increased by 39.2% following fish oil
supplementation. A recent study on a UHR population found that EPA increased by 200%
while DHA only increased by 43.1% following 12 weeks of daily supplementation with 700
mg EPA and 480 mg DHA (Smesny et al., 2014) (Figure 1). This controversial result could
be due to the participants’ lack of compliance. Previous studies have also shown that the
uptake of DHA into erythrocyte membranes is more variable than that of EPA (Katan et al.,
1997; Cao et al., 2006; Pipingas et al., 2014).

% of changes

250
200
200
150
100
50

43.1

39.2

29

0
EPA

DHA

(a) Current study (840 mg of EPA) (560 mg of DHA)
(b) Smesny et al., 2014 (700 mg of EPA) (480 mg of DHA)

Figure 1: Comparison of % of changes of EPA and DHA between two studies on n-3
LCPUFA supplementation in people at UHR of developing psychosis. (a) Current study n-3
LCPUFA supplementation containing 840 mg of EPA and 560 mg of DHA for 6 months
period. (b) Previous study (Smesny et al., 2014) n-3 LCPUFA supplementation contain 700
mg of EPA and 480 mg of DHA for 3 months period.
The increase in n-3 index after 6 months of n-3 LCPUFA supplementation from 3.0% to
4.10% was much lower than that observed in previous studies that administered EPA+DHA
for up to 12 months (Katan et al., 1997; Cao et al., 2006; Browning et al., 2012; Flock et al.,
2013) (Figure 2). An n-3 index increase from 4.3% to 9.5% with 1800 mg/day of (EPA 60%
+DHA 40%) over a period of 5 months (Flock et al., 2013), and a similar n-3 index increase
of 5.9% to 11.4% was observed in older healthy adults supplemented with 1900 mg/day of
(EPA 46% +DHA 54%) for a year (Browning et al., 2012). In comparison, healthy men
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supplemented with approximately 2000 mg/day of (EPA 85% +DHA 15%) for a year saw
increase in the n-3 index by from 5.5% to 9.5% (Katan et al., 1997); furthermore, an n-3
index increase from 4.3% to 7.8% with 2200 mg/day of (EPA 60% +DHA 40%) over a period
of 2 months was also observed (Cao et al., 2006) (Figure 2). These studies suggest that, in
addition to duration of intake and dose, the relative proportions of EPA and DHA may affect
the n-3 index response.
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5.5
4.3
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2.2
2.0

1.1
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(a) Current
study

(b) Smesny et
al., 2014
pre dose

(c) Flock et al., (d) Browning et (e) Cao et al.,
2013
al., 2012
2006
post dose

(f) Katan et al.,
1997

% of change

Figure 2: Comparison of the n-3 index measured in different studies with different doses (a)
1400 mg/day of n-3 LCPUFA for 6 months period. (b) 1200 mg/day of n-3 LCPUFA for 3
months period. (c) 1800 mg/day of n-3 LCPUFA for 5 months period. (d) 1900 mg/day of n-3
LCPUFA for 12 months period. (e) 2200 mg/day of n-3 LCPUFA for 2 months period. (f)
2000 mg/day of n-3 LCPUFA for 12 months period.
There is one study that investigated 1200 mg/day of (EPA 59.3% +DHA 40.7%) in people
with UHR of developing psychosis and this resulted in n-3 index increase of 3.2% to 5.4%
over a period of 3 months (Smesny et al., 2014). The current study used a similar dose but
double the duration and resulted in a much lower increase in n-3 index. In the current study
the commitment to intake capsules every day only 43.1% in the n-3 LCPUFA group and
41.1% in the placebo (McGorry et al., 2017) compared to 81.4% adherence to daily intake in
the n-3 group and 75.4% in the placebo group in a previous study (Amminger et al., 2010).
This suggest that participants’ lack of compliance contributed to the lower than expected
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increase in the n-3 index. In this study, a similar number of participants at UHR of developing
psychosis transitioned to psychosis from both the n-3 treated (17 out of 153) and placebo
groups (15 out of 151) (McGorry et al., 2017). The possible reasons for this lower transition
rate 11.5% from the n-3 and 11.2% from placebo groups could be due to the high level of
antidepressant treatment received by both groups and the sample may have been
insufficiently enriched for risk of transition (McGorry et al., 2017).
Whilst dietary intake of n-3 LCPUFA is associated with erythrocyte levels of n-3 LCPUFA,
dietary intake was not measured in this study for the following reasons. Firstly dietary intake
methodology is not as robust as measuring the levels of n-3LCPUFA in erythrocyte
membranes (Meyer et al., 2013). Secondly, dietary intake of n-3 LCPUFA is reported to be
low (Meyer, 2016) and the intake levels are approximately 4 fold lower than the
supplemental levels of 1.4g per day. Therefore measuring levels of n-3 LCPUFA in
erythrocyte membranes is superior to measuring dietary intake on n-3 LCPUFA.
There is emerging evidence that suggests there is a relationship between an n-3 index of
less than 4% and risk for major depressive disorder (MDD) in adults (Baghai et al., 2011)
and possibly healthy adolescents (Grant et al., 2013), and also in adolescents at ultra-high
risk for bipolar disorder (Mcnamara et al., 2016). However, it should be noted that the
research available in these areas is limited as this is only the second study investigating n-3
index in people at UHR of psychosis (Smesny et al., 2014).
In conclusion, daily supplementation for 6 months with 1400 mg/day of n-3 LCPUFA led to
higher n-3 incorporation into erythrocytes. The increase was lower than previously reported
likely due to low commitment to intake of daily capsules by both groups.

In spite of this, we

found that n-3 LCPUFA is incorporated into phospholipid molecular species of all classes at
the expense of n-6 LCPUFA. As a result the total concentrations of these phospholipid
classes were not altered.
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Chapter 5
Is there an erythrocyte biomarker that can predict people with
UHR to develop psychosis?
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Abstract
People at ultra-high risk (UHR) of developing psychosis have approximately 30% chance of
developing the illness within three years. The aim of this study was to identify potential
biomarkers such as n-3 index, fatty acids and/or molecular phospholipid species that may be
a predictor of psychosis for people at UHR of developing psychosis. 304 people with UHR of
developing psychosis were enrolled for the NEURAPRO-E study and 285 people completed
this study. From 285 people 29 people developed psychoses (UHR-T, Transition) and 256
did not developed psychosis (UHR-NT, non-transition) in 12 months. There were no
differences in the n-3 index, fatty acids or molecular phospholipid species observed between
those that did and did not transition to psychosis. In conclusion, none of the assessed n-3
index, fatty acids and molecular phospholipid species predict transition to psychosis in those
at UHR of developing psychosis.

Keywords: - Sphingomyelin, phosphatidylserine, phosphatidylethanolamine,
phosphatidylcholine, phospholipids.
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Introduction
Ultra-High Risk (UHR) is a term used to identify individuals considered to be at ‘ultra high
risk of developing psychosis’ (Yung et al., 1996). The concept of clinical UHR of developing
psychosis has been developed to facilitate early detection and intervention and is defined by
a cluster of subthreshold psychotic symptoms affecting perception e.g., hallucinations and
thinking e.g., magical thinking or odd beliefs; or trait risk factors, such as a family history of
psychosis, accompanied by impairment in day-to-day function (Yung et al., 2005). Recent
meta-analysis shows that less than 30% of people at UHR of developing psychosis will have
transitioned to psychosis 3 years after identification (Fusar-Poli et al., 2012A).

Previous work has identified biological and clinical predictors for transition from UHR to
psychosis. Clinical features such as impaired premorbid psychosocial functioning, a history
of substance use, traumatic experiences, duration of symptoms, gender and age are all
associated with an increased transition risk (Nelson et al., 2013; Yung et al., 2004; Strobl et
al., 2012; Dragt et al., 2011). Dynamic clinical factors include psychotic symptoms and the
extent of baseline mood (Yung et al., 2005; Thompson et al., 2013). Additionally, specific
patterns of cognitive function, in particular deficits in emotional processing, memory and
verbal fluency (Fusar-Poli et al., 2012B; Allott et al., 2014) as well as impaired general
function are associated with a higher transition risk to psychosis (Strobl et al., 2012;
Velthorst et al., 2013). Biological predictors include abnormalities of functional and structural
electrophysiology, e.g. significant smaller duration mismatch negativity amplitudes (dMMN)
in people at risk of mental state than healthy controls and frontal delta activity was correlated
with negative symptoms in UHR patients who later transitioned to psychosis (Sumiyoshi et
al., 2013; Lavoie et al., 2012), pituitary gland enlargement (Garner et al., 2005) and genetic
markers such as neuregulin 1 (NRG1) (Bousman et al., 2013).

Low erythrocyte levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are
associated with increase the risk for mental illness in adults (Freeman et al., 2012). n-3 index
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is defined as the sum of EPA and DHA levels in erythrocytes membranes expressed as
percent of total fatty acids (Harris & Von Schacky, 2004; Harris, 2008). Recently, several
studies have also found low n-3 index (≤4%) in individuals at UHR of developing psychosis
(Rice et al., 2015) and patients diagnosed with different psychotic disorders such as major
depressive disorder (MDD) (Baghai et al., 2011), bipolar disorder (McNamara et al., 2016),
schizophrenia and depression (Parletta et al., 2016).
In order to ameliorate, prevent or delay the onset of a psychotic disorder, efforts have been
made to identify people at high clinical risk of developing a psychotic disorder. We previously
observed marked differences in erythrocyte n-3 index, fatty acids and molecular
phospholipids species in people with UHR of developing psychosis compared to age
matched healthy controls (chapter 3). Specifically, in people with UHR of developing
psychosis; i) the n-3 index was 26.9% lower, ii) Phosphatidylethanolamine (PE) was reduced
by 46%, sphingomyelin (SM) was increased by 16%, and iii) various molecular phospholipids
species were either primarily lower or higher. The aim of this study was to identify a potential
biomarker (n-3 index, any fatty acids and/or any molecular phospholipid species) to predict
transition to psychosis for people at UHR of developing psychosis.

Material & methods
Ethics and Subjects recruitment
The NEURAPRO-E study is a double-blind, placebo-controlled, randomized clinical trial of n3 fatty acids therapy for participants at UHR developing psychosis (McGorry et al., 2017).
The subjects diagnosed with UHR of developing psychosis were recruited between March
2010 and September 2014 (Markulev et al, 2015; McGorry et al., 2017). Inclusion and
exclusion criteria for these participants has been reported previously (Markulev et al, 2015;
McGorry et al., 2017) and are shown in appendix (B). This study was approved by the
human research ethics committees at the University of Melbourne (2008.628).
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Materials
High performance liquid chromatography (HPLC) grade or higher of methanol, methyl tertbutyl ether (MTBE) and chloroform were purchased from VWR International (QLD,
Australia). Analytical grade ammonium acetate was obtained from Crown Scientific (New
South Wales, Australia). Ethylenediaminetetraacetic acid (EDTA), butylated hydroxytoluene
(BHT) were all purchased from Sigma Aldrich (NSW, Australia). Phospholipid internal
standards were purchased from Avanti Polar Lipids through Auspep (Victoria, Australia) and
consisted of [dinonadecanoyl phosphatidylcholine (PC 19:0/19:0); diheptadecanoyl
phosphatidylethanolamine (PE17:0/17:0); diheptadecanoyl phosphatidylserine (PS
17:0/17:0); N-lauroyl-D-erythro-sphinganylphosphorylcholine (SM d18:0/12:0)]. Two types of
disposable conductive CO-RE tips (without filter) in 50 uL and 300 uL sizes were used and
purchased from Hamilton Robotics (Reno NV, USA). 96-well plates and Twin-tec PCR plates
were purchased from Eppendorf (POCD scientific, Australia).

Lipid extraction
Erythrocyte samples were extracted using the automated extraction method described
previously (Alqarni et al., 2018), 290 uL of an aqueous mixture containing 2 mM EDTA and
150 mM ammonium acetate was added to the wells of a 2.0 mL 96-well plate on ice. 10 μL
of packed erythrocyte samples was added to the wells, the plate were mixed using a vortex
at 800 rpm for 10 minutes. Robotic procedures were then started with all reagents, solvents
and plates loaded onto the automated liquid handling station (Hamilton, Nevada, USA). A
300 μL aliquot of an internal standard mixture in methanol [500 uM (PC 19:0/19:0); 166.7 uM
(PE 17:0/17:0); 100 uM (PS 17:0/17:0); 500 uM (SM 18:0/12:0)] was added to the wells prior
to mixing and standing for 10 minutes. 1 mL of MTBE was added to the wells and mixed for
30 minutes before the mixture was allowed to stand for 15 minutes to allow phase
separation. Following this, 500 μL of the MTBE top phase was removed to the extraction
plate (containing the extracted phospholipids) and 40 μL of extract was transferred to
another 96-well plate and diluted with 760 μL of a 2:1 (v:v) methanol/chloroform solution
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containing 5 mM ammonium acetate mixture. A 40 μL aliquot of the diluted extract was
transferred to another 96-well plate which was sealed with aluminium foil prior to analysis by
mass spectrometry.

Electrospray ionization mass spectrometry ESI-MS
Nanoelectrospray ionization mass spectrometry was performed using a hybrid triple
quadrupole linear ion trap mass spectrometer (QTRAP 5500 AB Sciex, MA, USA) with an
automated chip-based nanoelectrospray source (Triversa NanoMate, Advion Biosciences,
New York, USA) as previously described (Brown et al., 2013; Norris et al., 2015). A 10 uL
aliquot of lipid extract diluted in methanol: chloroform (2:1 v/v) containing 5 mM ammonium
acetate (approximately 10 uM) was infused into the nano-electrospray ion source. Spray
parameters were a voltage of 1.2 kV for positive ion acquisition and 1.1 kV for negative ion
acquisition and a nitrogen gas pressure of 0.40 psi (Brown et al., 2013; Norris et al., 2015).
Lipids were identified using precursor ion and neutral loss scans as previously described
(Brown et al., 2013; Norris et al., 2015).
Ionized lipids identified with a minimum signal-to-noise ratio of 10 were included in the
analysis. Identification and quantification was accomplished using lipidview software (version
1.2, Sciex, MA, USA) this included smoothing, identification, removal of isotope contribution
from lower mass species, and correction for isotope distribution, as described (Brown et al.,
2013; Norris et al., 2015). Quantification was performed using LipidView software (AB
SCIEX) by comparing the spectral peak area of individual lipids to their class specific internal
standards following isotope correction.
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Statistical analysis
Simple logistic regression was used to evaluate the association between erythrocyte n-3
index, fatty acids and molecular phospholipids species between Transition (UHR-T) and
non-transition (UHR-NT). Given that there were no differences between confounder factors
age, sex, BMI and smoking this was performed as unadjusted model. Categorical data were
analyzed using chi-square and Mann-Whitney U test was used to calculate the significance
of continuous variables. P-values were corrected for multiple comparisons using the
Bonferroni method with P < 0.0008 considered statistically significant. The statistical
analyses were completed using SPSS software (version 19.0 SPSS. Inc).
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Results
Participants Characteristics
304 people at UHR of developing psychosis were recruited for NEURAPRO-E study
(McGorry et al., 2017) and 285 people completed this study. From 285 people 29 people
developed psychoses (UHR-T, Transition) and 256 did not developed psychosis (UHR-NT,
non-transition) in 12 months. The participants baseline characteristics of each group are
presented in table 1 and there were no significant differences between (UHR-T, Transition)
and (UHR-NT, non-transition) groups.
Table 1: Baseline characteristics of study population (UHR-NT, non-transition) vs. (UHR-T,
Transition).
UHR-NT
UHR-T
General characteristics

(n=256)

(n=29)

P value

Age median (IQR-1, IQR-3)

18 (16,21)

17 (16,20)

0.803

Sex male n (%)

118 (46.1%)

11 (37.9%)

0.403

Body mass index Kg/m2 (IQR-1, IQR-3)

23 (20.2 , 26.8)*

22 (19.7 , 26.5)*

0.539

Smoking n (%)

99 (38.7%)

11 (37.9%)

0.938

* 31 participants BMI information missed (29 from UHR-NT group and 2 from UHR-T group).

Identification of n-3 index and fatty acids associated with ultra-high-risk of developing
psychosis
Logistic regressions were performed for n3 index and all fatty acids. The n-3 index did not
shown any association with transition to psychosis. Similarly From 14 fatty acids none were
associated with transition to psychosis (Figures 1 and Supplementary table S1).
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Figure 1: A logistic regression was performed to identify fatty acids and the n-3 index
associated with UHR-T (n=29) vs. UHR-NT cases (n=256). Circle show odds ratio, lines are
95% confidence intervals. Fatty acids with odds ratio > 1.0 has increased likelihood of
transition to psychosis. Fatty acids with odds ratio < 1.0 has reduced likelihood of transition
to psychosis. No significant results has been shown, P<0.0008 considered statistically
significant.
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Identification of molecular phospholipid species associated with ultra-high-risk of
developing psychosis

None of the 4 major phospholipid classes phosphatidylcholine (PC),
phosphatidylethanolamine (PE), phosphatidylserine (PS) and sphingomyelin (SM) were
associated with transition to psychosis (Figure 2 and Supplementary table S2). Also, none of
the 49 phospholipid species showed any association with transition to psychosis in those at
ultra-high risk (Figures 3, 4, 5, 6 and Supplementary table S3).

Figure 2: A logistic regression was performed to identify phospholipid classes (PC, PE, PS,
SM) associated with UHR-T (n=29) vs. UHR-NT cases (n=256). Circle show odds ratio, lines
are 95% confidence intervals. Species with odds ratio > 1.0 has increased likelihood of
transition to psychosis. Species with odds ratio < 1.0 has reduced likelihood of transition to
psychosis. No significant results has been shown, P<0.0008 considered statistically
significant.
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Figure 3: A logistic regression was performed to identify molecular phospholipid species
(PC) associated with UHR-T (n=29) vs. UHR-NT cases (n=256). Circle show odds ratio,
lines are 95% confidence intervals. Species with odds ratio > 1.0 has increased likelihood of
transition to psychosis. Species with odds ratio < 1.0 has reduced likelihood of transition to
psychosis. No significant results has been shown, P<0.0008 considered statistically
significant.
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Figure 4: A logistic regression was performed to identify molecular phospholipid species
(PE) associated with UHR-T (n=29) vs. UHR-NT cases (n=256). Circle show odds ratio, lines
are 95% confidence intervals. Species with odds ratio > 1.0 has increased likelihood of
transition to psychosis. Species with odds ratio < 1.0 has reduced likelihood of transition to
psychosis. No significant results has been shown, P<0.0008 considered statistically
significant.
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Figure 5: A logistic regression was performed to identify molecular phospholipid species
(PS) associated with UHR-T (n=29) vs. UHR-NT cases (n=256). Circle show odds ratio, lines
are 95% confidence intervals. Species with odds ratio > 1.0 has increased likelihood of
transition to psychosis. Species with odds ratio < 1.0 has reduced likelihood of transition to
psychosis. No significant results has been shown, P<0.0008 considered statistically
significant.
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Figure 6: A logistic regression was performed to identify molecular phospholipid species
(SM) associated with UHR-T (n=29) vs. UHR-NT cases (n=256). Circle show odds ratio,
lines are 95% confidence intervals. Species with odds ratio > 1.0 has increased likelihood of
transition to psychosis. Species with odds ratio < 1.0 has reduced likelihood of transition to
psychosis. No significant results has been shown, P<0.0008 considered statistically
significant.
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Discussion
In this large study of people at UHR of developing psychosis, no measures of
erythrocyte lipids were associated with the transition to psychosis. Noteworthy is the
fact that, the power of study was reduced because of low number of UHR transitioned
into psychosis (UHR-T, Transition (n=29)).
While we were not able to find any association between n-3 index, fatty acids or
molecular phospholipid species and transition to psychosis previous studies have
identified clinical features, such as poor life functioning, subthreshold positive
symptoms (Yung et al., 2003; Cannon et al., 2008; Ruhrmann et al., 2010) and severity
of negative symptoms (Yung et al., 2003; Piskulic et al., 2012; Velthorst et al., 2009) as
well as neuroimaging markers such as pituitary volumes and insula (Garner et al.,
2005; Takahashi et al., 2009) whole-brain neuroanatomical abnormalities (Koutsouleris
et al., 2009) and thickness of anterior cingulate cortex and corpus callosum (Fornito et
al., 2008; Walterfang et al., 2008) as predictive markers of transition to psychosis in
those at ultra-high risk. Additionally, genetic variation in two neuregulin 1 (NRG1)
haplotype-tagging single nucleotide polymorphisms (htSNPs) (rs12155594 and
rs4281084) provides a promising factor for differentiating between (UHR-NT) and
(UHR-T) individuals, the risk of transitioning to psychosis increased by 1.5 fold in
people who carried rs12155594 and/or rs4281084 allele (Bousman et al., 2013).

Previously, we have observed differences in erythrocyte n-3 index, fatty acids and
molecular phospholipid species between individuals at UHR of developing psychosis
and healthy subjects (Chapter 3). Specifically, total PE was reduced by 46% as was a
16% increase in the concentration of SM (Chapter 3). Furthermore, the n-3 index was
low in people with UHR of developing psychosis compared to healthy (McNamara,
2011; Rice et al., 2015). This suggests that the n-3 index, fatty acids and molecular
phospholipids deficiencies may be present prior to illness onset and may be useful as a
potential risk biomarker for the high-risk state not for psychosis (Figure 7).
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Interestingly, three SM species (SM 16:0, SM 24:0 and SM 24:1) shows close to
significant and these species with odds ratio has high likelihood of transition to
psychosis, this suggest that SM may be an important biomarker to investigate and this
cohort worth following up and investigate with more (UHR-T, Transition), whether SM is
a predictor.

Healthy vs. UHR of psychosis







Low n-3 index in UHR of
psychosis.
Low fatty acids in UHR of
psychosis
Various molecular
phospholipids species were
either primarily lower or
higher in UHR of psychosis.
High SM and low PE in UHR
of psychosis.

UHR-NT vs. UHR-T



No differences were found
between (UHR-NT) and
(UHR-T) across the n-3
index, fatty acids and all
molecular phospholipids
species.

Figure 7: Timeline for the findings between healthy vs. UHR of psychosis and between
UHR-NT (non-transition) vs. UHR-T, (Transition).

In conclusion, the data from this study suggest that neither the n-3 index, fatty acids or
molecular phospholipid species predict transition to psychosis in people at ultra-high
risk.
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Table S1: Erythrocytes fatty acids and n-3 index associated with ultra high risk of developing psychosis UHR-NT (256) UHR-T (29) (results are
express as % of total fatty acids).
Median (IQR) UHR-NT

OR (95% CI)
P value
UHR-NT, non-transition cases (n=256)
vs.
UHR-T, Transition (n=29)
16:0
32.38 (30.64 , 34.24)
31.81 (31.04 , 34.92)
1.02 (0.86 , 1.19)
0.849
16:1
0.21 (0.14 , 0.29)
0.22 ( 0.15 , 0.29)
0.31 (0.01 , 8.58)
0.489
17:0
1.27 (1.17 , 1.39)
1.33 (1.21 , 1.41)
1.81 (0.33 , 9.89)
0.491
18:0
13.07 (11.99 , 13.99)
12.48 (11.82 , 13.59)
0.85(0.65 , 1.11)
0.239
18:1
16.61 (15.62 , 17.67)
16.75 (15.28 , 17.93)
1.00 (0.84 , 1.20)
0.954
18:2
12.30 (10.58 , 13.57)
11.06 (9.91 , 12.11)
0.83 (0.69 , 1.00)
0.059
20:3
0.81 (0.66 , 0.98)
0.78 (0.58 , 0.92)
0.44 (0.10 , 1.92)
0.171
20:4
9.22 (7.78 , 10.08)
8.84 (5.99 , 10.28)
0.91 (0.79 , 1.05)
0.234
20:5
0.53 (0.45 , 0.63)
0.51 (0.44 , 0.63)
0.70 (0.08 , 5.82)
0.746
22:4
0.30 (0.14 , 0.46)
0.31 (0.09 , 0.43)
0.30 (0.05 , 1.82)
0.192
22:5
1.04 (0.83 , 1.31)
1.09 (0.72 , 1.21)
0.93 (0.57 , 1.52)
0.778
22:6
2.44 (1.96 , 2.88)
2.32 (1.72 , 2.97)
0.98 (0.66 , 1.45)
0.940
24:0
3.93 (2.95 , 5.01)
5.31 (3.31 , 6.04 )
1.14 (0.97 , 1.35)
0.100
24:1
5.49 (4.21 , 7.18)
7.00 (4.99 , 8.59)
1.11 (0.99 , 1.24)
0.065
n-3 index
3.00 (2.47 , 3.52)
2.77 (2.24 , 3.65)
0.97 (0.69 , 1.38)
0.904
A logistic regression was performed to identify fatty acids and n-3 index associated with UHR-T, Transition (n=29) vs. UHR-NT, non-transition cases (n=256). Odds
ratio and 95% confidence intervals are shown. OR= Odds Ratio, (95% CI) = 95% of confidence interval. p<0.0008 considered statistically significant.
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Median (IQR) UHR-T

Table S2: Erythrocytes molecular phospholipids classes associated with ultra high risk of developing psychosis UHR-NT (256) UHR-T (29)
(results are express as % of total phospholipids).

Phospholipids

Median (IQR) UHR-NT

Median (IQR) UHR-T

OR (95% CI)
UHR-NT, non-transition cases (n=256)
vs.
UHR-T, Transition (n=29)

P value

PC
41.67 (33.50 , 47.63)
34.80 (30.59 , 42.06)
1.04 (0.99 , 1.08)
0.070
PE
18.48 (16.48 , 20.83)
18.62 (14.32 , 21.37)
1.00 (0.92 , 1.10)
0.927
PS
9.45 (7.96 , 10.28)
8.59 (6.67 , 9.92)
1.09 (0.94 , 1.27)
0.230
SM
28.45 (24.55 , 35.79)
36.63 (25.59 , 42.23)
1.03 (0.99 , 1.07)
0.045
A logistic regression was performed to identify molecular phospholipids classes associated with UHR-T, Transition (n=29) vs. UHR-NT, non-transition cases (n=256).
Odds ratio and 95% confidence intervals are shown. OR= Odds Ratio, (95% CI) = 95% of confidence interval. p<0.0008 considered statistically significant.
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Table S3: Erythrocytes molecular phospholipids species associated with ultra high risk of developing psychosis UHR-NT (256) UHR-T (29)
(results are express as % of total phospholipids).
Phospholipids

Median (IQR) UHR-NT

Median (IQR) UHR-T

OR (95% CI)
UHR-NT, non-transition cases (n=256)
vs.
UHR-T, Transition (n=29)

P value

PC 16:0_16:0
PC 16:0_16:1
PC 16:0_17:0
PC 16:0_18:0
PC 16:0_18:1
PC 16:0_18:2
PC 16:0_20:3
PC 16:0_20:4
PC 16:0_20:5
PC 16:0_22:6
PC 17:0_18:1
PC 17:0_18:2
PC 18:0_18:0
PC 18:0_18:1
PC 18:0_18:2
PC 18:0_20:4
PC 18:0_22:6
PC 18:1_18:1
PC 18:1_18:2
PC 18:1_20:4
PE 16:0_18:1
PE 16:0_18:2
PE 18:0_18:0
PE 16:0_20:3
PE 16:0_20:4
PE 16:0_20:5
PE 16:0_22:4
PE 16:0_22:5
PE 16:0_22:6
PE 17:0_20:4

2.11 (1.83 , 2.77)
0.35 (0.24 , 0.51)
0.23 (0.11 , 0.30)
0.43 (0.31 , 0.56)
9.84 (8.58 , 11.41)
11.31 (8.94 , 13.79)
0.97 (0.72 , 1.34)
2.87 (2.18 , 3.47)
0.25 (0.18 , 0.33)
0.85 (0.63 , 1.06)
0.42 (0.36 , 0.48)
0.46 (0.36 , 0.57)
0.10 (0.06 , 0.14)
2.09 (1.73 , 2.45)
3.73 (2.94 , 4.45)
1.39 (1.11 , 1.71)
0.25 (0.19 , 0.33)
1.14 (0.78 , 1.52)
1.39 (0.98 , 1.66)
0.62 (0.48 , 0.71)
4.16 (3.78 , 4.64)
1.60 (1.37 , 1.87)
0.07 (0.06 , 0.11)
0.28 (0.19 , 0.51)
2.43 (2.13 , 2.74)
0.18 (0.13 , 0.23)
0.53 (0.24 , 0.75)
0.39 (0.23 , 0.55)
0.99 (0.76 , 1.23)
0.39 (0.32 , 0.45)

1.88 (1.63 , 2.28)
0.34 (0.25 , 0.44)
0.27 (0.17 , 0.32)
0.36 (0.27 , 0.47)
9.37 (7.64 , 11.57)
9.59 (7.43 , 11.52)
0.79 (0.58 , 1.20)
2.17 (1.74 , 2.92)
0.20 (0.15 , 0.32)
0.78 (0.46 , 0.92)
0.41 (0.36 , 0.47)
0.44 (0.33 , 0.52)
0.14 (0.06 , 0.37)
1.96 (1.53 , 2.12)
3.16 (2.88 , 3.79)
1.15 (0.95 , 1.52)
0.21 (0.13 , 0.30)
1.05 (0.77 , 1.25)
1.11 (0.94 , 1.38)
0.54 (0.39 , 0.67)
4.13 (3.89 , 4.52)
1.68 (1.44 , 1.78)
0.07 (0.06 , 0.11)
0.32 (0.25 , 0.44)
2.46 (1.89 , 2.69)
0.19 (0.14 , 0.24)
0.54 (0.16 , 0.71)
0.43 (0.22 , 0.55)
0.99 (0.74 , 1.14)
0.38 (0.28 , 0.48)

0.64 (0.35 , 1.19)
0.39 (0.05 , 2.79)
0.13 (0.02 , 2.33)
0.18 (0.02 , 1.50 )
0.93 (0.79 , 1.10)
0.88 (0.78 , 1.00)
0.54(0.21 , 1.35)
0.67 (0.47 , 0.95)
0.06 (0.02 , 1.59)
0.51 (0.18 , 1.47)
0.94 (0.11 , 7.90)
0.55 (0.06 , 5.19)
2.17 (0.95 , 4.95)
0.54 (0.28 , 1.04)
0.73 (0.52 , 1.02)
0.55 (0.27 , 1.11)
0.06 (0.02 , 1.65)
1.03 (0.73 , 1.47)
0.46 (0.19 , 1.12)
0.20 (0.04 , 1.03)
1.06 (0.66 , 1.71)
1.01 (0.48 , 2.09)
2.09 (0.29 , 4.17)
0.78 (0.21 , 2.95)
0.88 (0.53 , 1.46)
1.47 (0.04 , 4.63)
0.45 (0.15, 1.34)
0.78 (0.18 , 3.45)
1.00 (0.43 , 2.36)
0.70 (0.03 , 15.03)

0.160
0.349
0.255
0.113
0.406
0.057
0.186
0.024
0.093
0.215
0.957
0.606
0.063
0.063
0.071
0.095
0.095
0.849
0.087
0.054
0.798
0.988
0.119
0.717
0.625
0.212
0.153
0.741
0.994
0.820

199

Table S3: Cont.
Phospholipids

Median (IQR) UHR-NT

Median (IQR) UHR-T

OR (95% CI)
UHR-NT, non-transition cases (n=256)
vs.
UHR-T, Transition (n=29)

P value

PE 17:0_20:5
0.44 (0.39 , 0.51)
0.43 (0.35 , 0.49)
0.78 (0.07 , 8.82)
0.842
PE 17:0_22:5
0.21 (0.17 , 0.25)
0.22 (0.15 , 0.24)
0.72 (0.01 , 4.09)
0.897
PE 18:0_18:1
0.96 (0.84 , 1.07)
0.95 (0.83 , 1.04)
1.02 (0.16 , 6.41)
0.986
PE 18:0_18:2
0.76 (0.65 , 0.89)
0.75 (0.67 , 0.83)
0.73 (0.12 , 4.18)
0.726
PE 18:0_20:4
1.12 (0.59 , 1.66)
1.37 (0.61 , 1.77)
1.31 (0.73 , 2.34)
0.368
PE 18:0_22:6
0.32 (0.24 , 0.39)
0.29 (0.19 , 0.40)
0.37 (0.02 , 7.24)
0.509
PE 18:1_18:1
0.84 (0.66 , 1.05)
0.89 (0.68 , 1.02)
1.18 (0.36 , 3.89)
0.785
PE 18:1_18:2
1.18 (0.85 , 1.50)
1.15 (0.93 , 1.42)
1.01 (0.47 , 2.17)
0.987
PE 18:1_20:4
1.40 (1.09 , 1.66)
1.34 (1.03 , 1.68)
0.89 (0.44 , 1.82)
0.760
PS 18:0_18:0
0.11 (0.09 , 0.14)
0.12 (0.09 , 0.15)
1.64 (0.21 , 4.08)
0.805
PS 18:0_18:1
1.01 (0.85 , 1.20)
0.92 (0.74 , 1.17)
0.66(0.27 , 1.65)
0.377
PS 18:0_20:4
5.22 (3.88 , 6.13)
4.95 (1.53 , 5.92)
0.90 (0.76 , 1.07)
0.237
PS 18:0_22:5
1.18 (0.95 , 1.36)
1.12 (0.87 , 1.24)
0.94 (0.67 , 1.33)
0.740
PS 18:0_22:6
1.63 (1.20 , 1.99)
1.33 (1.04 , 2.04)
1.05 (0.77 , 1.45)
0.749
SM 16:0
10.56 (9.12 , 13.10)
12.96 (9.87 , 14.66)
1.11 (1.01 , 1.22)
0.035
SM 18:0
1.58 (1.32 , 2.19)
2.03 (1.32 , 2.37)
1.49 (0.89 , 2.49)
0.124
SM 18:1
0.55 (0.45 , 0.77)
0.69 (0.49 , 0.89)
0.94 (0.15 , 2.84)
0.105
SM 24:0
6.73 (5.15 , 8.09)
8.55 (5.77 , 9.59)
1.12 (0.97 , 1.25)
0.068
SM 24:1
9.47 (7.37 , 11.56)
11.36 (8.70 , 13.53)
1.09 (0.99 , 1.19)
0.058
A logistic regression was performed to identify molecular phospholipids classes associated with UHR-T, Transition (n=29) vs. UHR-NT, non-transition cases (n=256).
Odds ratio and 95% confidence intervals are shown. OR= Odds Ratio, (95% CI) = 95% of confidence interval. p<0.0008 considered statistically significant.
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Chapter 6
Summary and conclusion
Consumption of n-3 LCPUFA is associated with higher n-3 LCPUFA status in the circulation,
which has in turn been associated with a number of health benefits in humans. Several
studies have investigated the n-3 LCPUFA (EPA + DHA) ‘status’ of psychiatric patients.
These studies have found that patients with bipolar disorder (Mcnamara et al., 2010; Chiu et
al., 2003; Ranjekar et al., 2003), schizophrenia (Ranjekar et al., 2003; Evans et al., 2003;
Khan et al., 2002; Reddy et al., 2004; Parletta et al., 2016), ADHD (Chen et al., 2004; Colter
et al., 2008; Stevens et al., 1995; Young et al., 2004) and major depressive disorder (MDD)
(Assies et al., 2010; Edwards et al., 1998; Maes et al., 1996; Peet et al., 1998; Riemer et al.,
2010; Mcnamara et al., 2010) and depression (Parletta et al., 2016) exhibit significant deficits
in EPA+DHA levels compared with demographically similar healthy subjects. In order to
move the field of oemga-3 research in mental health forward, large clinical trials are
warranted that also measure the levels of omeag-3 at baseline and post-intervention. In
order to be able to conduct such large trials, a high throughput method of assessing n-3, as
well as other fatty acids and phospholipid species is warranted.
The developed and validated high throughput method using an automated methyl tert-butyl
ether extraction followed by electrospray ionization mass spectrometry ESI-MS method used
in Chapter 2 allows for the determination of human erythrocyte fatty acid concentration
and the n-3 index from low sample volumes as well as for the identification of molecular
phospholipids. The new method is simple, convenient, low in cost, allow us to extract large
number of samples (96 samples/run) in a short time and provides additional information on
molecular phospholipid concentrations. The Lepage & Roy method has a number of
disadvantages such as it uses manual sample preparation and is time consuming (6 hours to
prepare only 24 samples/day), requires a relatively large amount of sample (400ul of
erythrocytes) and cannot generate molecular phospholipid data. Analysis of fatty acids by
GC also requires sample derivatization to improve fatty acid volatility. This creates further
problems such as the ineffecienct derivatization of SM fatty acids. As derivatization is not
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required by the new method such issues are avoided. The limitation of this new high
throughput method is that the MS cannot differentiate between n-3 DPA and n-6 DPA due to
their same molecular mass. A resolution for this limitation is warranted.

The methods developed in Chapter 2 enabled us to apply this high throughput method to a
large clinical trial in the following Chapters 3, 4 & 5. A comparison between the UHR
individuals and healthy controls in Chapter 3 found that lower proportions of PUFA were
observed in the UHR group. Specifically, EPA was 29.3% lower, DHA was 27.2% lower and
AA was 15.8% lower compared to the healthy group. Conversely, the proportion of nervonic
acid was 64.4% higher in the UHR group compared to healthy controls. The n-3 index was
also 26.9% lower in the UHR group. At a lipid class level, the UHR group had higher levels
of SM and lower levels PE compared to healthy group which have both already been
observed previously in schizophrenic patients (Ponizovsky et al., 2001; Keshavan et al.,
1994; Hitzemann and Garver, 1982). Low n-3 index have repeatedly been observed in UHR
patients compared to healthy population (McNamara, 2011; Rice et al., 2015) this might give
possibility in transition of n-3 index from cardiac health to psychotic health. Previous studies
have reported metabolism disturbances and deficiencies of PUFA erythrocyte membranes
which are commonly seen in patients with schizophrenia (Reddy et al., 2004; Peet et al.,
1998; Khan et al., 2002) and which might have happened with the UHR population before
their transition to psychosis. Interestingly, it has been recently reported healthy controls have
significantly higher consumption of n-3 PUFA than UHR participants who converted and did
not convert to psychosis (Pawelczyk et al., 2015; 2016), this suggests that PUFA
consumption may play a role in the conversion to psychosis in UHR individuals and can
improve mental health (e.g. depression) (Parletta et al., 2017).

The randomized controlled trial of n-3 fatty acids supplementation in people at UHR of
developing psychosis over 6 months (Chapter 4) resulted in increased concentration of PC,
PE, and PS species containing n-3 fatty acids e.g., 20:5, 22:6 and 22:5, ranging from
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11.8%-50.0% and reduce n-6 species e.g., 18:2, 20:3, 20:4, 22:4 ranging from 7.4%-42.9%.
Interestingly, SM species did not change in the n-3 LCPUFA supplementation group
however, three out of five SM species significantly increased after 6 months of
supplementation with placebo. The response of n-3 index to n-3 supplementation (from 3.0%
to 4.10%) was much lower than previous studies that administered EPA+DHA for up to 12
months (Katan et al., 1997; Cao et al., 2006; Browning et al., 2012; Flock et al., 2013). This
is likely a consequence of low compliance (< 44%) in both groups and a high level of
antidepressant treatment received by both groups (McGorry et al., 2017).

Even though numerous differences were seen between UHR and healthy groups (Chapter
3), there were no difference seen between people at high risk who developed psychosis and
did not develop psychosis (Chapter 5). Therefore, the n-3 index, fatty acids and molecular
phospholipid species do not predict transition to psychosis in people at UHR. This suggests
that the alterations in erythrocyte (and possibly the brain) lipids occurs prior to UHR and the
erythrocyte samples could help to determine UHR of developing psychosis but not used to
determine psychosis.
In conclusion, this thesis has presented an optimized method that allows the identification
and quantification of the n-3 index, fatty acids and molecular phospholipid species
in erythrocytes; using an automated extraction and ESI-MS analysis. A significant outcome
of this thesis was identifying that people at UHR of developing psychosis have different
levels of the n-3 index, fatty acids and molecular phospholipid species compared to healthy
subjects, also, none of the assessed n-3 index, fatty acids and molecular phospholipid
species predict transition to psychosis in those at ultra-high risk. To the best of my
knowledge, the work presented in this thesis is the most comprehensive examination to date
of erythrocyte membrane lipid composition of people at UHR of psychosis.

The data from this thesis supports a number of directions and recommendations for
improving understanding of why there are low levels of n-3 index, fatty acids and molecular
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phospholipid species in UHR group compared to healthy group. Future research that aims to
study UHR populations should consider the following points:
1) Investigations of erythrocytes morphology should be undertaken to see if there are
any differences in the cell shapes between the healthy and UHR groups.
2) Very low compliance of supplementation intake was found in current randomized
controlled trial so the future studies investigating n-3 fatty acids supplementation for
UHR of developing psychosis should improve the participants’ compliance with taking
their supplementation.
3) In addition to having a UHR of developing psychosis population screened for this
study, future studies might consider low and mid risk of developing psychosis
populations to try and elucidate when the lipid changes actually occur between being
“healthy” and being at “UHR of developing psychosis.
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Appendices
(A) Flow chart of the ultra-high-risk of developing psychosis participant distribution.

Randomized (n= 304)

Received placebo as randomized
(n= 151)

Received n-3 as randomized
(n= 153)

Lost to follow-up (n= 40)

Lost to follow-up (n= 39)

Completed (n= 111)

Completed (n= 114)

Transitioned (n= 15)

Transitioned (n= 17)

(B) Inclusion and exclusion criteria for UHR of developing psychosis subjects.
Individuals who were referred to the treatment service meeting standardized ‘at-risk’
criteria were approached about participating in this clinical trial. The symptomatic
inclusion criteria were based on the guidelines developed by the Melbourne group,
consisting of a subset of three groups considered ‘at-risk’ that were assessed using the
Comprehensive Assessment of At-Risk Metal State (CAARMS). The Inclusion criteria
used focused on (i) the ability to give informed consent; (ii) subjects who were between
the ages of 13 and 40 years (depending on site) at presentation; and (iii) subjects who
met the criteria of one of the ‘at-risk’ groups (Table 1).
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Table 1:- Inclusion criteria for ultra-high-risk of developing psychosis subjects (Markulev et
al., 2015).
Group

Criteria
Family history of psychosis in first-degree relative OR
schizotypal personality disorder (as defined by DSM-IV) in
identified patient.

1: Vulnerability group
(trait and state risk

Impact: A 30% drop in the social and occupational functioning

factors)

assessment scale (SOFAS) score as compared to previous
functional level, sustained for one month within the past year;
OR a SOFAS score of 50 or less for at least the past 12
months.
(2a) Subthreshold intensity:
Intensity: Global Rating Scale Score of 3–5 on Unusual
Thought Content subscale, 3–5 on Non-Bizarre Ideas subscale,
3–4 on Perceptual Abnormalities subscale and/or 4–5 on
Disorganized Speech subscales of the CAARMS.
Frequency: Frequency Scale Score of 3–6 on Unusual Thought
Content, Non-Bizarre Ideas, Perceptual Abnormalities and/or
Disorganized Speech subscales of the CAARMS.

2: Group with attenuated

Duration: symptoms have been present for at least a week.

positive psychotic
symptoms

Recency: symptoms that presented themselves within the past
year.
Impact: A drop of 30% in SOFAS score from the prior level of
functioning, sustained for one month within the past year OR a
SOFAS score of 50 or less for at least the past 12 months.
(2b) Subthreshold frequency:
Intensity: A Global Rating Scale Score of 6 on the Unusual
Thought Content subscale, 6 on the Non-Bizarre Ideas
subscale, 5–6 on the Perceptual Abnormalities subscale and/or
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Group

Criteria
6 on the Disorganized Speech subscales of the CAARMS.
Frequency: A Frequency Scale Score of 3 exhibited on the
Unusual Thought Content, Non-Bizarre Ideas, Perceptual
Abnormalities and/or on the Disorganized Speech subscales of
the CAARMS.
Recency: symptoms have been present within the past year.
Impact: A 30% drop in the SOFAS score compared to the prior
level of functioning, sustained for a month within the past year;
OR a SOFAS score of 50 or less for at least the past 12
months.
Intensity: A Global Rating Scale Score of 6 on the Unusual
Thought Content subscale, 6 on the Non-Bizarre Ideas
subscale, 5 or 6 on the Perceptual Abnormalities subscale
and/or 6 on Disorganized Speech subscales of the CAARMS.
Frequency: Frequency Scale Score of 4–6 regarding Unusual
Thought Content, Non-Bizarre Ideas, Perceptual Abnormalities

3: Those with Brief limited and/or Disorganized Speech subscales.
intermittent psychotic
symptoms

Duration: symptoms have been present for less than a week
and they remit spontaneously on every occasion.
Recency: symptoms have been present within the past year.
Impact: A 30% drop in the SOFAS score from the prior level of
functioning, sustained for one month within the past year OR a
SOFAS score of 50 or less for a minimum of the past 12
months or longer.

The criteria used to determine exclusion are if an individual has/is: (i) a past history of a
treated or untreated psychotic episode of one week or longer; (ii) an organic brain disease
such as epilepsy or an inflammatory brain disease; (iii) thyroid function test results which are
>10% above or below normal range limits, or abnormal coagulation profile parameters; (iv)
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any physical illness with psychotropic effect, if not stabilized; (v) currently treated with any
mood stabilizer, or uses ketamine for recreational use; (vi) past neuroleptic exposure that is
equivalent to a total lifetime haloperidol dose of >50 mg ; (vii) been diagnosed with a serious
developmental disorder such as Asperger's syndrome; (viii) a premorbid IQ that is measured
at < 70 and a documented history of developmental delay or an intellectual disability; (ix)
current signs of acute suicidality/self-harm or experiencing episodes of
aggression/dangerous behaviour (indicated by a CAARMS severity score of 6 on items 7.3
and/or 5.4); (x) currently pregnant; (xi) experiencing current attenuated symptoms that can
be explained entirely by acute intoxication (e.g. current attenuated symptoms which can be
fully explained by lysergic acid diethylamide [LSD] use); and (xii) more than 4 weeks of
regular n-3 supplementation (>2 capsules of standard strength that provide >600 mg
combined EPA/ DHA) within the last 6 months.

Exit/discontinuation criteria were also used to describe patients in the study who: (i)
voluntarily discontinued their participation, without prejudice to further treatment; (ii) concern
for safety issues as judged by the investigator; (iii) were severely non-compliant to protocol
as judged by the investigator; (iv) incorrectly enrolled (e.g., the enrolled patient does not
meet the required inclusion /exclusion criteria); (v) is lost to follow up; (vi) meet the exit
criteria because of a ‘transition to psychosis’ or they develop mania (first-episode mania
criteria); and (vii) develop of exclusion criteria (e.g. such as pregnancy).
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(C) Ethics approval letters.
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214
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(D) Questionnaire for healthy subjects.
AIM
The aim of this survey is to determine if you are eligible for this research project.
Thank you for your cooperation.
1
What is your age?

5

2
What is your gender?
____________________________________________________________________________
3
What is your weight?
_____________________________________________________________________________
4
What is your height?
Do you smoke cigarettes? If yes how many cigarettes per day?
Yes
1

6

Have you ever been prescribed medication for mental health problems?

7
Have you ever had counseling for mental health problems (5 or more
appointments)?

8

9

No

2

Yes

1

No

2

Yes

1

No

2

Do you take any prescription or non-prescription medicine, including Yes
herbal/any medicine?
No

1

Do you have any other medical conditions?

Yes

1

No

2

2

If yes explain_____________________________________________

Please answer the questions below by ticking either True or False. If you have ticked True, please tick
“No”, “Mild”, “Moderate” or “Severe” to ‘How much distress did you experience?’
If TRUE: how much distress did you experience?
No
1
2

3

4

5
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I feel uninterested in the things
I used to enjoy
I often seem to live through
events exactly as they
happened before
I sometimes smell or taste
things that other people can’t
smell or taste.
I often hear unusual sounds like
banging, clicking, hissing,
clapping or ringing in my ears.
I have been confused at times
whether something I

o

True

o

False

o

True

o

False

o

True

o

False

o

True

o

False

o

True

o

False

Mild

Moderate

Severe

6

7

8
9

10

11

12

13

14
15

16

experienced was real or
imaginary.
When I look at a person, or
look at myself in a mirror, I
have seen the face change right
before my eyes.
I get extremely anxious when
meeting people for the first
time.
I have seen things that other
people apparently can’t see.
My thoughts are sometimes so
strong that I can almost hear
them.
I sometimes see special
meanings in advertisements,
shop windows, or in the way
things are arranged around me.
Sometimes I have felt that I’m
not in control of my own ideas
or thoughts.
Sometimes I feel suddenly
distracted by distant sounds
that I am not normally aware of
I have heard things other
people can’t hear like voices of
people whispering or talking.
I often feel that others have it
in for me.
I have had the sense that some
person or force is around me,
even though I could not see
anyone.
I feel that parts of my body
have changed in some way, or
that parts of my body are
working differently than
before.

o

True

o

False

o

True

o

False

o

True

o

False

o

True

o

False

o

True

o

False

o

True

o

False

o

True

o

False

o

True

o

False

o

True

o

False

o

True

o

False

o

True

o

False

Please return this questionnaire
If you have any questions concerning this survey, please feel free to contact the researcher:

Ayedh Alqarni
School of Medicine
University of Wollongong
Wollongong, NSW
Australia
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Email: asa043@uowmail.edu.au
Tel:

